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Abstract 
Background: Many preterm infants require mechanical ventilation via an 
endotracheal tube for the treatment of neonatal respiratory distress (RDS). A 
side effect of mechanical ventilation is lung injury. VTV aims to reduce lung 
injury by controlling the tidal volumes delivered to the infant by the ventilator. 
Many VTV modes are widely in use but have not been compared using clinically 
relevant outcomes.  
Aim: This was the first trial to compare two modes of VTV in preterm infants 
with RDS. We aimed to compare volume-controlled ventilation (VCV) with 
volume guarantee (VG) using clinically relevant outcomes.  
Hypothesis: We hypothesised that, in preterm infants with RDS, the time taken 
to be ready for extubation would be shorter in the VG group compared with 
VCV. The initial sample size calculation indicated that 102 infants were needed 
to show a 33% reduction in the time taken to be ready for extubation with a 
significance level of 0.05 and a power of 80%.   
Methods: This single centre, randomised controlled pilot trial was undertaken in 
a tertiary neonatal unit from July 2013 – December 2015. Infants were stratified 
into two groups according to gestational age at birth (<28 weeks’ gestation and 
28 – 33+6 weeks’ gestation). The primary outcome was the duration of time 
from starting the trial mode until being ready for extubation. Readiness for 
extubation was defined using pre-determined ‘success’ criteria. Secondary 
outcomes included important clinical outcomes. After four months the consent 
method was changed from prospective to deferred parental consent. 
A trial oversight review of data from the first 50 infants identified that the primary 
outcome data were not likely to be normally distributed. The statistical analysis 
plan was therefore updated prior to any data analysis. We planned to present 
data as descriptive summary statistics including survival probabilities, hazard 
ratios (HRs) and odds ratios (ORs). In addition, using early phase trials 
statistical methods, a difference of 15% between groups in the numbers of 
infants reaching the ‘success’ criteria at 48 hours would indicate a potentially 
significant difference between groups. 
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An ancillary study was undertaken using mechanistic data downloaded from 
ventilators to validate one of the ‘success’ criteria (mean airway pressure).  
Results: One hundred and thirteen infants were enrolled. One infant was 
subsequently withdrawn due to a diagnosis consistent with exclusion criteria. 
The median time to ‘success’ criteria was 23 hours (95% CI 10.78 – 35.22 
hours) in the VG group and 36 hours (95% CI 18.03 – 53.97) in the VCV group. 
The HR was 0.93 (95% CI 0.63 – 1.37). Thirty four infants in the VG group and 
33 infants in the VCV group had met the ‘success’ criteria by 48 hours. 
Subgroup analyses showed that, in infants born at 28 – 33+6 weeks’ gestation, 
the median time to reach the primary outcome faster in the VG group. The 
pneumothorax rates and duration of ventilation were lower in the VG group. The 
use of deferred consent appeared to be more acceptable to parents and led to 
an improvement in the recruitment rate. 
The ancillary study showed very good correlation between the mean airway 
pressure values recorded manually once every hour and the values 
downloaded with every breath. This validated the use of manual recordings of 
mean airway pressure as part of the primary outcome. 
Conclusions: There was a clinical important difference between VG and VCV 
in the time taken for infants to be ready for extubation. This difference favoured 
VG but a larger trial is needed to show a definitive result. This trial also 
highlights current gaps in knowledge regarding short-term clinical outcomes and 
the use of VTV modes in different subgroups of infants. Deferred consent 
appears to be acceptable to parents of newborn infants but qualitative research 
is needed to explore this further.  
This thesis describes The VoluVent Trial (ISRCTN 04448562), the first clinical 
trial to compare two types of volume-targeted ventilation (VTV) in preterm 
infants. One of the known side effects of mechanical ventilation is lung injury. 
VTV aims to minimise ventilator-associated lung injury and different types of 
VTV are used widely. However, there is no evidence to confirm whether one 
type of VTV is better than another for preterm infants. 
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Chapter 1 Introduction 
Survival rates for preterm infants have improved over time (Costeloe et al., 
2012, Younge et al., 2017). Extremely small and preterm infants are now 
surviving due to improvements in antenatal, perinatal and neonatal care (Walsh 
et al, 2011). However preterm infants are born with organs that are under-
developed. Their organ systems are often not able to function adequately 
without the support of nursing, medical and parental care combined with 
mechanical devices and technology. This is known as neonatal intensive care. 
Preterm infants may require days, weeks and even months of neonatal 
intensive care in order to grow and develop to a point where they can survive 
without this level of care. 
One such organ system in preterm infants is the respiratory system. In basic 
terms, this consists of the upper and lower airways, the lung tissue 
(parenchyma), and the supporting muscles, bones and connective tissue. The 
respiratory system is integrally linked to all of the other organ systems, including 
the heart and circulation, the gastrointestinal system, the immune system and 
the brain and nervous system. A preterm infant’s survival depends on the 
adequate and inter-dependent functioning of all of these organ systems.  
In order to support a preterm infant’s respiratory system mechanical ventilation 
via an endotracheal (breathing) tube may be needed. This involves the 
placement of the endotracheal tube (ETT) into the trachea (windpipe) and then 
connection of the ETT to a ventilator. The ventilator can support the infant’s 
spontaneous breathing or can provide artificial respiration if the infant is not 
breathing. Although this is often a life-saving treatment, one side effect of 
mechanical ventilation is injury to the lungs. Therefore there is a balance to 
strike between using mechanical ventilation to sustain life whilst minimising the 
duration of its use in order to minimise lung injury. 
This thesis focuses on a randomised controlled trial comparing two types 
(modes) of ventilation that are used with the aim of minimising lung injury in 
preterm infants. Although these modes are used widely (Klingenberg et al., 
2011a) this is the first trial to compare two such modes in preterm infants using 
outcomes that reflect potential lung injury. 
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Introduction: Chapter 1 introduces the thesis and the trial which was called 
The VoluVent Trial (ISRCTN registry number 04448562). It frames the trial in its 
context as a research study of complex emergency interventions in a neonatal 
intensive care unit. 
Background: Chapter 2 discusses the rationale for the trial. It describes lung 
disease associated with prematurity, ventilator-associated lung injury, and the 
published literature on volume-targeted ventilation (VTV) in newborn infants. 
Three large reviews of published literature (McCallion et al., 2005; Wheeler et 
al., 2010; Klingenberg et al., 2017) have shown better clinical outcomes in 
infants who received VTV compared with pressure-limited ventilation. However, 
there are no published studies comparing different types of VTV in preterm 
infants. This trial was, therefore, undertaken to address this gap in knowledge. 
Method: Chapter 3 describes the methods used to undertake this randomised 
controlled pilot trial. The trial compared two modes of VTV, volume-controlled 
ventilation (VCV) and volume guarantee (VG), in preterm infants with 
respiratory distress syndrome. This involved the design of a rigorous but 
pragmatic trial aimed at achieving meaningful results whilst ensuring it could be 
carried out in a busy intensive care unit. A process evaluation was also planned 
for certain aspects of the trial. The challenges posed by the initial methodology, 
including the consent process and the sample size, are explained in this 
chapter. The detailed statistical analysis plan is described, the full version of 
which is included in the Appendices. 
Results: Chapter 4 describes the results of The VoluVent Trial in detail. Initial 
recruitment problems were encountered. However a change to the consent 
process improved recruitment and appeared to be more appropriate for parents 
of newborn infants receiving emergency treatments. The primary and secondary 
outcome data and the serious adverse events were analysed according to the 
statistical analysis plan and are presented in this chapter. Covariates and 
compliance with the protocol are also described. This trial showed a clinically 
relevant difference between VCV and VG in the primary outcome measure. Its 
findings highlight areas for further research. 
Ancillary study: Chapter 5 describes an ancillary study undertaken during the 
trial as part of the process evaluation. The airway pressures were downloaded 
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‘in real time’ from the ventilators of infants in The VoluVent Trial. These values 
were compared with the manually recorded mean airway pressure values that 
formed part of the trial’s primary outcome measure. This chapter describes the 
planned methodology, the statistical analysis plan, the results of this study, and 
its strengths and limitations. 
Consent during research into emergency interventions: Implementing the 
most appropriate consent process for an intensive care trial was an important 
challenge encountered during The VoluVent Trial. Chapter 6 discusses the 
lessons learnt from the trial about the ethical and practical challenges in 
seeking informed consent during neonatal research. It focuses particularly on 
consent for research into emergency interventions in infants and children. 
Recent literature regarding consent in such settings is discussed and the 
current gaps in knowledge are outlined.  
Discussion: Chapter 7 discusses the results of The VoluVent Trial and its 
ancillary study. It describes the strengths and limitations of the trial and the 
lessons learnt from the process evaluation. This chapter discusses the 
contribution made by The VoluVent Trial to current scientific knowledge. The 
unique data gained from the trial and the recommendations for future research 
have already been recognised internationally and will provide the basis for a 
larger trial. The remaining gaps in knowledge and recommendations as to how 
some of these might be addressed in future are also discussed. 
Conclusion: Chapter 8 provides a summary of this thesis, bringing together the 
themes of the use of VTV in preterm infants and how best to investigate its use 
in an intensive care setting. 
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Chapter 2 Literature review 
2.1 Introduction 
Lung injury in preterm infants is multifactorial in origin. The causative factors 
often co-exist and may exacerbate each other (Attar et al., 2002). Some of 
these factors, particularly the inflammatory factors, occur before delivery (Jobe 
et al., 1998). Preterm birth results in the abrupt cessation of fetal lung 
development and this underlies the lung disease associated with prematurity 
(Jobe et al., 2000). The ensuing clinical management strategies required to 
treat preterm lung disease can also contribute to its sequelae if they are not 
used judiciously (Jobe, 2011).  
One manifestation of respiratory failure in newborn infants is respiratory distress 
syndrome (RDS) (Donn et al., 2017b). Respiratory failure, including RDS, can 
lead to the requirement for mechanical ventilation. Mechanical ventilation is a 
treatment associated with lung injury and closely inter-linked with the other 
causes of lung injury in preterm infants, such as oxygen (Jobe et al., 2017). The 
consequence of lung injury in preterm infants is bronchopulmonary dysplasia 
(BPD), a condition that can have significant long-term clinical and financial 
effects for the infant and their family (Gibson et al., 2015).  
Therefore, preventing or limiting lung injury in preterm infants is important. 
Mechanical ventilation can be a necessary and life-saving treatment for 
neonates with respiratory failure for whom non-invasive respiratory support is 
not adequate or appropriate. (Sinha SK et al., 2011). There is much published 
literature on neonatal ventilation and comparisons of ventilatory techniques. 
Results of recent reviews favour the use of volume-targeted ventilation (VTV) 
for preterm infants with RDS (Wheeler et al., 2011; Peng et al., 2014; 
Klingenberg et al., 2017). VTV is now used widely (Klingenberg et al., 2011). 
The authors of the two most recent Cochrane reviews (Wheeler et al., 2010, 
Klingenberg et al., 2017) made recommendations for further research, including 
the recommendation that different volume-targeting strategies should be 
compared. This review summarises the evidence behind the use of VTV in 
newborn infants. The clinical outcomes that have been studied and the effects 
of different volume-targeted modes on these outcomes will be discussed, as 
well as the current gaps in knowledge. 
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2.2 Pulmonary mechanics 
The “pulmonary injury sequence” associated with lung injury in preterm infants 
was described by Attar and Donn (Attar et al., 2002). This is demonstrated as a 
timeline in Figure 2-1. 
 
Figure 2-1 The “pulmonary injury sequence” (taken from Attar et al., 2002) 
The development of alveoli, the units of lung responsible for gas exchange, is 
known as alveolarisation (Joza et al., 2015). Alveolarisation can start as early 
as 28 weeks’ post-conception and continues for months or even years into 
postnatal life. In fact, much of the process of alveolarisation occurs after 36 
weeks of gestation (Jobe., 2011), highlighting the fact that very or extremely 
preterm infants have very little pulmonary architecture at the time of birth. 
Preterm birth halts fetal lung development. Lung injury then follows due to the 
imposition of factors demonstrated in Figure 2-1. This leads to interrupted 
alveolarisation by which postnatal lung development is delayed or deviated 
down a different developmental pathway (Jobe, 2011).  
Antenatal insults such as exposure to infection or pro-inflammatory cytokines 
before birth can precipitate lung injury in the newborn. Infants who have been 
exposed to such mediators in utero and then require respiratory interventions 
after birth may then experience a cumulative effect of injury mediators (Jobe, 
1999). 
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2.3 Respiratory failure in preterm newborn infants 
2.3.1 Causes of respiratory failure 
Respiratory failure can occur in infants of any gestation. It is much more 
common in preterm infants due to the arrested alveolarisation described above. 
Some causes are similar in preterm and term infants whilst others tend to occur 
in one group rather than the other. This review focuses on respiratory failure in 
preterm infants. 
2.3.2 Respiratory distress syndrome  
Respiratory distress syndrome (RDS) is a common cause of respiratory failure 
in preterm infants (Hamvas, 2011). It occurs in approximately 80% of infants 
born at 24 weeks’ of gestation (extremely preterm) and even 5% of infants born 
at 36 weeks’ gestation (late preterm) (Donn et al., 2017b).  
The underlying causes of RDS are multifactorial. Preterm infants are 
predisposed to RDS due to a combination of:  
• immaturity of lungs, pulmonary vasculature, respiratory muscles and 
nervous system (Spitzer et al., 2011),  
• surfactant immaturity and deficiency (Jobe, 2006), 
• reduced pulmonary compliance and increased chest wall and airway 
compliance (Spitzer et al, 2011), 
• increased diffusion distance for gas exchange (Jobe, 2006). 
2.3.3 Clinical features of RDS 
RDS is characterised by a combination of clinical, biochemical and radiological 
features as shown in Table 2-1 (Donn et al., 2017b). The features listed in 
Table 2-1 may also be seen in other conditions such as sepsis, congenital 
pneumonia and hypothermia (Hamvas, 2011). In practice, the smallest and 
most preterm infants may not show many of those features. This may be 
because they have received mechanical ventilation and exogenous surfactant 
replacement shortly after birth that may conceal the classical features of RDS 
An important feature of RDS is the timing of onset. It occurs within the first few 
hours after birth and usually peaks in severity at 48 to 72 hours of age 
(Hamvas, 2011). RDS can be fatal but most infants start to recover by 72 hours 
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of age. Therefore, respiratory signs in an infant that first occur after the first 48 
hours of life are likely to be due to other underlying pathologies. 
Clinical signs Radiological features Biochemical analysis 
Tachypnoea  Diffuse reticulogranular 
pattern (‘groundglass’ 
appearance) of lung 
fields 
Respiratory acidosis 
Grunting Bilateral, homogenous 
opacification 
 
Nasal flaring Air bronchograms  
Increased use of 
accessory muscles 
Indistinct outlines of 
diaphragm and cardiac 
borders  
 
Cyanosis   
Reduced oxygen 
saturations 
  
Apnoea   
Table 2-1 Clinical, radiological and biochemical features of RDS 
RDS can affect infants of all gestational ages but is more common in preterm 
infants (Hamvas, 2011). The more preterm an infant is the more likely he or she 
is to have a diagnosis of RDS (Donn et al., 2017b). As described above, 
extremely preterm infants often do not have many clinical or radiological signs 
due to the use of surfactant. Therefore they do not necessarily display the 
typical features of RDS and are sometimes referred to as having ‘respiratory 
insufficiency of the newborn’ (Greenough et al., 2008; Hamvas, 2011).   
2.4 Ventilator-associated lung injury (VALI) 
Lung injury related to mechanical ventilation is often referred to as ‘ventilator-
induced lung injury’ (VILI). However, the medium-term clinical manifestation of 
lung injury related to mechanical ventilation in human infants is 
bronchopulmonary dysplasia (BPD). As shown in Figure 2-1 the causes of BPD 
are complex and multifactorial in nature (Attar et al., 2002). Therefore, the term 
‘ventilator-associated lung injury’ (VALI) is now increasingly used (Jarreau, 
2015) when referring to human infants. VILI is used in relation to lung injury in 
animal models caused by mechanical ventilation (Rimensberger, 2015). 
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There are several reported mechanisms of lung injury in newborn infants 
(Parker et al., 1993; Jarreau, 2015). As described below, these mechanisms are 
categorised according to different components of ventilation (pressure, volume 
etc). However, like the components of mechanical ventilation, the mechanisms 
are inter-linked. Parker et al. (Parker et al., 1993) summarised these 
mechanisms in detail, describing the injurious effects of high peak airway 
pressures and large tidal volumes on the pulmonary endothelium and 
epithelium, interstitium and vasculature.  
2.4.1 Barotrauma  
Barotrauma results from excessive pressure delivery leading to macroscopic air 
leaks and microscopic alveolar damage. As summarised by Parker et al. 
(Parker et al.,1993), animal models have shown disruption of the endothelial 
barrier when high inspiratory pressures are used. This causes increased 
permeability of the microvascular barrier between the alveoli and the pulmonary 
vessels leading to leakage of fluid and protein into the airways. This leads to 
pulmonary oedema and reduced lung compliance. Clinically, macroscopic air 
leaks manifest as pulmonary interstitial emphysema (PIE), pneumothorax, 
pneumomediastinum, pneumopericardium and pneumoperitoneum (Parker et 
al., 1993).  
The pulmonary oedema and structural damage seen in animal models 
(Dreyfuss et al., 1992) ventilated with high airway pressures were originally 
thought to be the main cause of VALI (Dreyfuss et al., 1992). However, 
subsequent work has shown that the majority of VALI is probably due to 
excessive tidal volumes (Hernandez et al. 1989; Parker et al., 1993).  
2.4.2 Volutrauma 
Volutrauma is the result of excessive inspiratory volume delivery to the alveoli. 
This has a shearing effect causing disruption of the alveolar type I cells (which 
line the alveoli and are responsible for gas exchange) and the epithelial and 
endothelial layers. Disruption of these cell layers leads to leakage of proteins 
and fluid from the capillaries into the alveoli (Wada et al., 1997; Jarreau, 2015). 
In animal models this can lead to low lung compliance, impaired gas exchange, 
reduced ventilator efficacy and reduced response to surfactant (Bjorkland et 
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al.,1997). Pulmonary oedema and the production of pro-inflammatory cytokines 
can arise, contributing to the arrest of alveolarisation (Jobe, 1999). Other 
aspects of alveolarisation, such as epithelial cell proliferation, elastin remodeling 
and angiogenesis, are also affected by excessive stretch of the alveoli due to 
overdistention during ventilation (Alvira et al., 2017). The compliant chest wall of 
preterm infants increases the risk of VALI as it enables the lungs to expand 
further for any given pressure than the lungs of older children or adults. 
Hernandez et al. (Hernandez et al., 1989) compared varying degrees of peak 
inspiratory pressure (PIP) - 15, 30 and 45 cmH2O - on three different groups of 
rabbit models. In the first group, the isolated lungs alone were ventilated. In the 
second group, rabbits were ventilated with intact chest walls that were allowed 
to expand normally during inflation. In the third, rabbits were placed in thoraco-
abdominal casts in order to prevent expansion of the chest wall during 
ventilation. The casts prevented an increase in tidal volumes during lung 
inflation despite the use of increasing PIPs. They found that the isolated lungs 
showed the greatest evidence of VILI even at the lowest PIP level (15 cmH2O). 
The lungs of rabbits with intact chests showed significant evidence of damage 
when ventilated at 30 and 45 cmH2O.  However, the lungs of rabbits with tidal 
volumes restricted by the thoraco-abdominal casts showed no evidence of lung 
injury, even at the highest PIP levels. Similar results were seen in other animal 
studies (Parker et al., 1993) in which greater alveolar epithelial damage was 
caused by large tidal volumes than by high airway pressures (Parker et al., 
1993). These results support the argument that it is the ‘stretch’ caused by 
excessive tidal volume delivery rather than delivery of excessive pressures that 
lead to VILI (Korones, 2011).  
Bjorklund et al. (Bjorklund et al., 1997) demonstrated that even tidal volumes 
that are not considered excessive can cause injury to the surfactant deficient 
lung. They investigated the effects of positive pressure ventilation in a small 
group of preterm lambs immediately after birth. Pairs of lambs were 
investigated. One from each pair was randomly assigned to receive positive 
pressure ventilation followed by surfactant and mechanical ventilation. The 
other was assigned to receive just surfactant and mechanical ventilation. 
Importantly, the volumes of gas administered to the lambs that received positive 
pressure ventilation were less than the potential lung volumes of those lambs. 
 10 
The authors found clinical evidence of lung injury and more persistent 
respiratory failure in the lambs that received positive pressure ventilation 
compared to those that did not. The extent of lung injury seen in histology 
specimens was also greater in the lambs that received positive pressure 
ventilation. These results remain important today in considering how to limit 
volutrauma in the delivery room immediately after birth in an infant who is likely 
to be surfactant deficient.   
Excessive alveolar stretch due to mechanical ventilation may also lead to 
altered expression of genes related to normal pulmonary development (Jarreau, 
2015). This excessive stretch disrupts the normal generation of elastin and 
extracellular matrix proteins leading to abnormal septation of alveoli and 
abnormal microvasculature (Jarreau, 2015).  
Therefore the evidence supporting volutrauma as a prime mediator of lung 
injury also indicates that, once injury has occurred, it may not be possible to 
reverse. In addition, it may be perpetuated by alterations in physiological and 
genetic pathways.  
2.4.3 Atelectotrauma 
Atelectotrauma describes lung injury caused when alveoli repeatedly collapse 
and re-open (Pinhu et al., 2003). Alveolar collapse is caused by loss of 
functional residual capacity and under-expansion of the alveoli with inadequate 
tidal volume delivery (Attar et al., 2002; Jobe, 1999). The alveoli are re-opened, 
either by the tractional forces exerted by adjacent open alveoli, or by further 
ventilation (Pinhu et al., 2003). Re-opening collapsed alveoli can cause a 
shearing effect that damages the alveolar lining (Pinhu et al., 2003). It can also 
lead to pulmonary oedema and inflammation (Jobe, 1999).  
The preterm neonatal lung has very small tidal volumes and is usually 
surfactant deficient. Although the clinician may target an appropriate tidal 
volume using a ventilator this volume will not be delivered to closed lung units 
and therefore may lead to the overexpansion of other lung units (causing 
volutrauma) (Attar et al., 2002). As a result, unequal ventilation of alveoli 
promotes atelectotrauma and volutrauma simultaneously (Jobe et al., 1999). 
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2.4.4 Biotrauma 
Biotrauma is the result of exposure of preterm lungs to inflammatory mediators. 
These are generated in the context of in-utero or postnatal infection (Donn et 
al., 2011), mechanical ventilation (Attar et al., 2002) or reactive oxygen species 
(Alvira et al., 2017). In-utero exposure to inflammatory mediators may also 
disrupt development of the fetal lung (Alvira et al., 2017). Therefore, a preterm 
infant’s lung may be susceptible to biotrauma even before birth. Postnatal 
infection is also an independent risk factor for BPD (Alvira et al., 2017).  
High inflation pressures and large tidal volumes lead to increases in 
inflammatory cytokines in animal models (Tremblay et al., 1997) and ventilated 
adult humans (Ranieri et al, 1999). In a study of adults with acute RDS, Ranieri 
et al. (Ranieri et al, 1999) found increased concentrations of inflammatory 
mediators in blood and bronchoalveolar lavage samples in patients randomised 
to ventilation with larger tidal volumes. Preterm infants have different pulmonary 
structure and different underlying pathologies to adults requiring ventilation. 
However, similar findings have been noted in neonatal populations (Speer 2003 
and 2009). 
Lung injury may also cause dissemination of inflammatory markers to other 
organs. Animal studies have shown that cytokines and bacteria from injured 
lungs translocate into the systemic circulation. This leads to the involvement of 
other organs in the inflammatory response. (Pinhu et al., 2003).  
Therefore, mechanical ventilation can either precipitate or potentiate biotrauma 
in preterm infants who are already predisposed to VALI. 
2.5 Management options to limit VALI 
2.5.1 Antenatal administration of maternal glucocorticoids 
Antenatal glucocorticoids administered to a pregnant woman have a number of 
effects on the fetal lung. They improve lung maturity by accelerating the 
development of the alveolar wall lining (Jobe, 2011), thereby improving gas 
diffusion potential. They increase lung gas volume and surfactant production 
(Jobe, 2006), and work synergistically with exogenous surfactant to improve 
lung volumes (Jobe, 2006). 
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Administration of antenatal glucocorticoids to women at risk of preterm delivery 
between 24+0 and 34+6 weeks’ gestation is now a standard of care in the 
United Kingdom (Roberts, 2010). The decision to use antenatal glucocorticoids 
in women who may deliver at 23+0 - 23+6 weeks’ gestation is one made jointly 
by these women and senior clinicians (Roberts, 2010). A recent Cochrane 
review described a meta-analysis of 30 studies including 8158 infants (Roberts 
et al., 2017) which showed that administration of antenatal maternal 
glucocorticoids was associated with several positive neonatal outcomes. These 
included a reduction in RDS (risk ratio 0.66, 95% confidence interval 0.56 – 
0.77, 7764 infants) and a reduction in the outcome of “moderate to severe RDS” 
(risk ratio 0.59, 95% confidence interval 0.38 – 0.91, 1686 infants). The 
reduction in RDS was seen if glucocorticoids were given up to seven days 
before delivery. No significant improvement was seen for chronic lung disease.  
2.5.2 Supplemental oxygen therapy 
Hyperoxia can have deleterious effects on the preterm lung and on mortality 
and morbidity in infants born prematurely. Hyperoxia leads to the development 
of free radicals and contributes to oxygen toxicity (Parker et al., 1993; Alvira et 
al., 2017). In animal models, hyperoxia has been shown to contribute to the 
process of arrested alveolarisation (Alvira et al., 2017) and inflammation 
(Jarreau, 2015). 
2.5.3 Non-invasive respiratory support 
The use of non-invasive ventilation (NIV) for infants born prematurely has 
increased dramatically in recent years (Schmalisch et al., 2015). As a result, 
fewer infants are now ventilated although reports vary as to whether this has 
had a positive impact on the rates of bronchopulmonary dysplasia (BPD) 
(Schmölzer et al., 2013). There are several different types of NIV, including 
nasal continuous positive airway pressure (CPAP), humidified high flow nasal 
cannulae (HHFNC), and nasal intermittent positive pressure ventilation (NIPPV) 
(Kugelman, 2015). NIV aims to provide a constant distending pressure 
throughout the respiratory cycle. This maintains functional residual capacity, 
prevents atelectasis at the end of expiration and prevents the shearing damage 
to the alveolar epithelium during inspiration (Parker et al., 1993). It has the 
potential to stent the upper airways open (Davis et al., 2009). Judicious use of 
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NIV, accompanied by close monitoring and supportive care, in a preterm infant 
can avoid the need for mechanical ventilation. European Consensus Guidelines 
on the management of RDS suggest using CPAP from birth if possible (Sweet 
et al., 2017). However the authors indicate that a fractional inspired 
concentration of oxygen (FiO2) >0.3 – 0.4 should warrant consideration of 
escalation of respiratory support through administration of surfactant. 
2.5.4 Surfactant 
Endogenous surfactant is produced by type II pneumocytes. It acts to reduce 
the surface tension of the alveoli, thus limiting or preventing atelectasis (Parker 
et al., 1993). Type II pneumocytes may not be present, or may only be present 
in very small numbers, in extremely preterm infants born at <28 weeks’ 
gestation (Parker et al., 1993). The number of functional type II pneumocytes 
present at birth should increase as gestational age at birth increases. However, 
even late preterm infants may not produce sufficient surfactant to prevent RDS 
(Donn et al., 2017b). In addition to being produced in adequate quantity, 
surfactant must also be adequately active. Factors such as infection, meconium 
aspiration, perinatal hypoxic events and structural lung abnormalities can all 
lead to deactivation of any surfactant that is produced (Kumar, 2015).  
Administration of exogenous surfactant to infants with suspected surfactant 
deficiency or inactivation has been a standard of care for many years (Sweet et 
al., 2017). The aim is to reduce VALI by limiting atelectasis. However, alveolar 
epithelial disruption and leakage of proteins into the airways can inactivate or 
reduce surfactant production. Pulmonary repair mechanisms, including the 
formation of fibrin, can reduce the function and distribution of surfactant (Parker 
et al, 1993).  
Therefore exogenous surfactant given in the early stages of RDS reduces VALI 
in the form of air leaks and BPD (Bahadue et al., 2012). However, surfactant 
deficiency or inactivation may persist in some infants due to ongoing lung injury.   
2.5.5 Caffeine therapy 
Caffeine citrate is now considered standard therapy for preterm infants requiring 
respiratory support (Sweet et al., 2017). Whilst its primary role is in prevention 
of apnoea of prematurity it is also associated with other outcomes. These 
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include a reduction in unsuccessful extubation (Henderson-Smart et al., 2010), 
reduced rates of BPD, and earlier cessation of mechanical ventilation, NIV and 
supplemental oxygen (Schmidt et al., 2006). It is also associated with reduced 
rates of death or adverse neurodevelopmental outcomes at 18 to 21 months 
(Schmidt et al., 2007). Therefore, it has a role as an adjunctive treatment in 
limiting the impact of VALI and the long-term effects of VALI. 
2.5.6 Postnatal corticosteroid administration 
Corticosteroids reduce pulmonary inflammation and therefore would appear to 
be useful adjuncts in reducing VALI. There has been much research and 
changes in practice regarding corticosteroid administration over the years. A 
recently published Cochrane review indicated that the benefits of early systemic 
corticosteroids, given within the first eight days of life, did not outweigh the 
adverse side effects (Doyle et al., 2017a). However, a review of systemic 
corticosteroids given after seven days of life did show a reduction in 
unsuccessful extubation and in BPD at 36 weeks’ corrected gestational age 
(Doyle et al., 2017b). Therefore, systemic corticosteroids appear to limit VALI to 
some extent but the long-term outcomes are not established. They are also 
associated with important side effects such as growth restriction and metabolic 
effects (Doyle et al., 2017b). Inhaled corticosteroids (Shah et al., 2017) and low-
dose systemic corticosteroids (Yates et al., 2016) are now a focus of research. 
2.5.7 Mechanical ventilation via an endotracheal tube 
Despite the increase in the use of NIV, mechanical ventilation via an 
endotracheal tube (ETT) remains the mainstay of treatment for infants for whom 
NIV is not adequate. Although some centres aim to use NIV for all 
spontaneously breathing infants, regardless of their gestational age at birth, 
many centres continue to use mechanical ventilation for infants born at the 
extremes of prematurity (Sinha et al., 2011). Therefore, mechanical ventilation 
remains a fundamental treatment strategy for the management of infants with 
respiratory failure. 
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2.6 Modern ventilator techniques 
2.6.1 Synchronisation 
Synchronisation is now a common aspect of neonatal ventilation. Ventilator 
algorithms aim to synchronise delivery of the ventilator’s positive pressure 
inflation with the infant’s spontaneous respiratory effort. This is referred to as 
patient-triggered ventilation (Sinha et al., 2011). Synchronisation can be 
achieved using a pneumotachograph or a hot wire anemometer to detect 
signals from the infant indicating the start of spontaneous inspiration (Donn et 
al., 2015). These signals are usually changes in airway pressure or flow rate. 
They then ‘trigger’ the ventilator to deliver an inflation (Donn, 2009). 
Synchronisation is associated with a reduction in the incidence of 
pneumothorax and a reduction in duration of ventilation. However the efficacy of 
synchronisation is rarely reported in published trials (Greenough et al., 2016). 
2.7 Types of mechanical ventilation 
There are many different strategies to deliver mechanical ventilation via an 
endotracheal tube. They are split into two groups, tidal ventilation and high 
frequency ventilation (Donn, 2009). Tidal ventilation encompasses many types 
of ventilation. These modes aim to mimic physiological negative pressure 
respiration by delivering positive inspired inflations and enabling passive 
expiration using the lung’s elastic recoil. High frequency ventilation delivers 
smaller gas volumes at very high rates using relatively high constant distending 
airway pressures. 
2.7.1 Tidal ventilation 
The different types of tidal ventilation can be classified according to the control 
variable that is targeted by the clinician (Sinha et al., 2008). These variables 
consist of pressure, volume and flow. In practice, volume is the integral of flow 
(Sinha et al., 2008) and these two variables are controlled together. Control of 
volume and flow forms the basis of volume-controlled ventilation (VCV) that will 
be discussed in more detail in Section 2.10.1. Therefore conventional 
ventilation is delivered using either volume or pressure as the target variable.  
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Tidal ventilation can subsequently be sub-divided into modalities according to 
the variables that trigger, limit or end the inflation. These variables are known as 
phase variables (Donn et al., 2015). Pressure, volume, flow and time can all be 
used as phase variables (Sinha et al., 2008). 
Control and phase variables are combined to deliver inflations comprise the 
mode of ventilation. Modes include: 
• intermittent mandatory ventilation (IMV), 
• synchronised intermittent mandatory ventilation (SIMV), 
• assist/control ventilation (A/C), 
• pressure support ventilation (PSV). 
Table 2-2 summarises the way control and phase variables that can be applied 
to different modes. 
Mode Control variables Phase variables 
Intermittent mandatory 
ventilation 
Pressure Time, pressure, flow 
Synchronised 
intermittent mandatory 
ventilation 
Pressure or volume/flow Time, pressure, flow 
Assist/control ventilation Pressure or volume/flow Time, pressure, flow 
Pressure support 
ventilation 
Pressure Flow 
Table 2-2 Control and phase variables for different ventilator modes 
2.7.2 High frequency oscillatory ventilation  
High frequency ventilation facilitates gas exchange in a very different way 
compared with tidal ventilation. There are several types of high frequency 
ventilation although, in the context of this thesis, only one will be discussed 
here. High frequency oscillatory ventilation (HFOV) uses a mean airway 
pressure higher than that which would be generated using equivalent tidal 
ventilation. It combines this with very small tidal volumes delivered at a very fast 
rate. The tidal volumes may be less than the anatomical dead space. Within a 
HFO ventilator a diaphragm is used to oscillate a bias flow of gas that creates 
both an active expiration phase as well as an active inspiration phase (Bollen et 
al., 2015). 
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2.8 Types of tidal ventilation 
2.8.1 Intermittent mandatory ventilation 
In this mode, the clinician sets the desired PIP (control variable), PEEP, 
inspiratory time (phase variable) and mandatory rate (the number of inflations 
delivered per minute). The infant can breathe spontaneously but breathing is 
not synchronised with delivered inflations during inspiration or expiration. If 
spontaneous breathing is faster than the mandatory rate, or asynchronous with 
the ventilator, those breaths will only be supported by PEEP (Donn et al., 2015). 
In this mode, the volume of gas reaching the infant is not controlled by the 
ventilator and will vary according to the PIP and the infant’s lung compliance. 
2.8.2 Synchronised intermittent mandatory ventilation  
This mode synchronises delivered inflations with the infant’s spontaneous 
respirations. It can be used with either pressure or volume as the control 
variable. If pressure is the control variable, the clinician sets the desired PIP 
(the control variable), the PEEP, the inspiratory time (phase variable) and the 
mandatory rate. The ventilator aims to synchronise all inflations per minute with 
the infant’s spontaneous breaths. If the infant’s spontaneous respiratory rate is 
higher than the mandatory rate, the extra breaths will only be supported with 
PEEP. As with IMV, the volume of inspired gas is not controlled by either the 
ventilator or the clinician (Donn et al., 2015).  
2.8.3 Assist/control ventilation 
In assist/control (A/C) ventilation, every spontaneous breath that reaches the 
trigger threshold is supported by a delivered inflation from the ventilator. 
Therefore, all of the infant’s spontaneous respirations will be supported unlike 
the SIMV mode that only supports the mandatory rate. The control variables for 
A/C ventilation can be either pressure or volume (combined with flow). In 
pressure assist/control ventilation (PCV), the clinician selects the desired PIP 
(control variable) as well as the PEEP, inspiratory time and mandatory rate. The 
volume of gas reaching the infant is not controlled by either the infant or the 
clinician (Sinha et al., 2011). In volume assist/control ventilation (VCV), the 
control variables are volume and flow. These are fixed at the desired level by 
the clinician and therefore the volume of gas reaching the infant can be directly 
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controlled. The clinician can also set the PEEP and the mandatory rate, but the 
PIP is not controlled by the clinician (Sinha et al., 2011). This will be described 
in more detail in Section 2.10.1. 
2.8.4 Pressure support ventilation 
Pressure support ventilation (PSV) can be used alone or in combination with 
SIMV but it requires the infant to be breathing spontaneously. In this mode 
spontaneous breaths that reach the trigger threshold are supported by a set 
inspiratory pressure. However, the duration of the inflation is limited by the flow 
rate. When the flow rate reaches a set proportion, the ventilator cycles into 
expiration. This aims to enable the ventilator to synchonise with the infant’s 
spontaneous expiration as well as inspiration. If the infant is apnoeic, no 
inflations will be delivered (Donn, 2009). 
2.9 Pressure-limited ventilation  
Pressure-limited ventilation (PLV) encompasses several different modes, 
including time-cycled pressure-limited ventilation (TCPL), pressure A/C 
ventilation, pressure SIMV and PSV. Historically, PLV has been in use in 
neonatology longer than volume-targeted modes due to previous technical 
limitations that made volume-targeted ventilation (VTV) impractical (Sinha et al., 
2011). The neonatal community has therefore had more experience of using 
PLV.  
In PLV, the clinician targets the pressure of gas being delivered to the infant. In 
practical terms, this usually involves adjustment of the PIP according to the 
infant’s condition and gas exchange. The ventilator aims to achieve the desired 
pressure as quickly as possible during inspiration and sustain that pressure until 
expiration. It does so by delivering gas using a variable flow rate, with the gas 
flow to the infant being fastest at the start of inspiration before slowing down 
towards the end of inspiration. Figure 2-2 demonstrates the pressure, flow and 
subsequent volume wave patterns seen on pulmonary graphics during one 
inflation (Sinha et al., 2011). 
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Figure 2-2 Pulmonary graphics during one inflation of PLV 
During PLV the ventilator will always aim to deliver the PIP set by the clinician, 
regardless of the lung compliance. The volume of gas reaching the infant is not 
controlled. As lung compliance improves, lung expansion will be greater for any 
given pressure. Therefore, using PLV, the volume of gas reaching the infant’s 
lungs will increase despite the PIP remaining unchanged. This can lead to 
volutrauma. Likewise, if lung compliance worsens, the volume of gas reaching 
the infant’s lungs will decrease if the PIP remains unchanged, leading to 
atelectotrauma.  
Since advances in technology have made the use of VTV possible over the last 
twenty years (Sinha et al., 1997) various modes of VTV have been introduced 
into neonatal units with the aim of limiting volutrauma and atelectotrauma.  
2.10 Volume-targeted ventilation 
Volume-targeted ventilation (VTV) modes allow the clinician to control the 
volume of gas delivered to the infant with the aim of limiting volutrauma and 
atelectotrauma. Different VTV modes control gas volumes in different ways. 
VCV and volume SIMV are ‘pure’ volume-targeted modes in that the desired 
volume (and flow) are set by the clinician. Other VTV modes are referred to as 
hybrid modes. These modes deliver pressure and gas flow in the same way as 
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PLV but do so in a way that targets the desired tidal volume (Sinha et al., 2011). 
This shall be discussed in more detail below.   
2.10.1 Volume-controlled ventilation  
When using volume-controlled ventilation (VCV) the primary aim is to keep the 
expired tidal volume within a desired range. The expired tidal volume is 
measured by a flow sensor situated as close to the ETT as possible. The flow 
sensor monitors many parameters including airway pressures, tidal volumes 
and gas flows to and from the ventilator and the infant. 
The clinician sets the desired volume of gas that the ventilator will deliver to the 
infant whenever the infant inspires (or according to the pre-set mandatory 
respiratory rate if the infant is apnoeic). The ventilator aims to deliver this 
volume irrespective of the lung compliance or the peak inspiratory pressure 
(PIP) required to deliver it. The gas is delivered at a constant flow rate also set 
by the clinician. However, not all of the volume of gas that leaves the ventilator 
reaches the infant’s lungs. Much of it remains within the circuit between the 
ventilator and the infant and is referred to as “compressible volume loss”. Some 
is also lost as leak around the uncuffed ETT. The compressible volume loss 
increases as lung compliance decreases. The clinician intermittently adjusts the 
set volume manually on the ventilator to aim to deliver a volume to the infant’s 
lungs that is within a desired range and achieves acceptable gas exchange 
(Donn et al., 2011; Sinha et al., 2011).  
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Figure 2-3 Pulmonary graphics during one inflation of VCV 
When using VCV the clinician aims to ensure that the tidal volumes are kept 
within a desired range by adjusting the delivered volume. However it may not be 
practically possible to achieve specific tidal volumes with each inspiration. The 
volume of gas that actually reaches the infant is dependent on lung compliance, 
which can vary rapidly and frequently. It is also dependent on the clinician who 
may not make adjustments frequently enough to respond to the rapidly 
changing lung compliance (Sinha et al, 2011). A reduction in tidal volumes will 
be seen with worsening lung compliance unless the delivered volume is 
increased by the clinician. Excessive tidal volumes will be generated as lung 
compliance improves unless the clinician weans the delivered volume. Careful 
titration according to lung compliance and the infant’s condition is required to 
limit the risk of volutrauma and atelectotrauma. 
Regarding inspiratory pressure the ventilator will generate whatever PIP is 
necessary to deliver the pre-set tidal volume (although this can be limited by the 
clinician for safety reasons). There is, therefore, an increase or reduction in the 
generated PIP as lung compliance deteriorates or improves respectively. 
However the PIP is not specifically controlled by the ventilator (Donn et al, 
2011; Sinha et al., 2011) and this may contribute to barotrauma.  
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2.10.2 Volume guarantee  
The term ‘volume guarantee’ is a misnomer because, when used in combination 
with a PLV mode, the ventilator aims to deliver the desired tidal volume with 
every inspiration but cannot guarantee it (Keszler et al., 2007). VG can be used 
with several PLV modes, including TCPL, SIMV, PCV and PSV. For the 
purpose of this review, the term VG shall be used to refer one specific mode, 
pressure assist/control ventilation combined with VG (pressure A/C + VG). 
When discussing other PLV modes combined with VG, the full name shall be 
stated (eg. PSV+VG). 
Volume guarantee is combined with pressure-limited modes to create a hybrid 
mode. This hybrid mode generates flow and pressure in the same way as its 
reference PLV mode (see Figure 2-2) whilst also aiming to control the tidal 
volume. It uses a servo-controlled mechanism and relies on microprocessor 
technology within the flow sensor to enable an automated feedback 
mechanism. This enables the ventilator to make specific changes to the PIP in 
order to target a specific tidal volume (Sinha et al., 2011).  
When using this mode, the clinician sets a desired tidal volume of gas. The 
ventilator aims to deliver this volume by adjusting the PIP on a breath-by-breath 
basis. It uses the infant’s expired tidal volume, measured by the flow sensor, as 
a reference. It then adjusts the PIP up or down to aim to deliver the desired tidal 
volume. Adjustments to the PIP are made in small increments to avoid large 
fluctuations in volume delivery (Keszler et al., 2007). The gas flow rate is 
variable and occurs more rapidly at the beginning of an inspired breath. This 
mechanism aims to overcome the problem of compressible volume loss and the 
breath-by-breath adjustments aim provide tighter control over the targeting of 
volume with each inspiration (Sinha et al., 2011) (see Figure 2-4).    
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Figure 2-4 Changes in peak inspiratory pressure and tidal volume during 
volume guarantee ventilation. (Adapted from Keszler et al., 2007) 
Figure 2-4 demonstrates the effect of automated adjustments to the PIP in order 
to achieve the target tidal volume during VG. During the first inspiration in 
Figure 2-4 the desired tidal volume is not achieved using the PIP generated 
during that breath. The PIP is increased during the second inspiration and the 
target tidal volume is achieved. The ventilator then uses the same PIP to deliver 
the third tidal volume but, during this inspiration, the desired tidal volume is not 
achieved. The ventilator therefore increases the PIP again during the next 
inspiration to aim to deliver the desired tidal volume. During the fifth inspiration 
the tidal volume delivered is greater than the desired volume. The PIP is 
therefore reduced during the sixth inspiration and the target tidal volume is 
achieved.  
Another important difference between VCV and VG is the way in which gas flow 
differs during inspiration. In VCV, the clinician sets the flow so that gas flow is 
constant throughout inspiration and therefore the maximal tidal volume and PIP 
are reached at the end of inspiration. In VG the flow is maximal at the beginning 
of inspiration meaning that PIP and tidal volume are achieved earlier in 
inspiration. When the designated PIP has been achieved the gas flow rate 
decreases during the remainder of inspiration (see Figure 2-5) (Sinha et al., 
2011). It is suggested that a high flow rate earlier in inspiration may be 
beneficial for infants with poorly compliant lungs who require high opening 
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pressures and therefore may offer a theoretical advantage over other forms of 
VTV in the acute stage of RDS (Sinha et al., 2011). 
 
Figure 2-5 Differences in gas flow and pressure waveforms in VCV and VG 
Figure 2-5 demonstrates the pressure, flow and volume waveforms seen during 
inspiration using both VCV and VG. In VCV, the flow is constant throughout 
inspiration so that pressure increases during, and is maximal at the end of, 
inspiration. In VG, gas flow is maximal at the start of inspiration so that the peak 
pressure is achieved early and is sustained throughout inspiration. As it is a 
hybrid mode, the waveforms seen when VG is used are the same as those 
seen when PLV is used.  
2.10.3 Pressure-regulated volume control ventilation 
Pressure-regulated volume control (PRVC) is another hybrid mode of 
ventilation. It is similar to VG in that the ventilator uses an automated feedback 
mechanism to increase PIP to achieve a preset tidal volume. It differs from VG 
in that PIP is adjusted based on the average PIP of the four previous breaths. 
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The initial breath is delivered using a PIP generated at 10cmH2O above the 
positive end expiratory pressure. The ventilator then uses the infant’s lung 
compliance to calculate the PIP required to deliver the set tidal volume. It 
delivers the next three breaths using PIPs at 75% of that calculated. If the target 
tidal volume is not achieved the ventilator increases the PIP by 3cmH2O (Sinha 
et al., 2011).  
2.10.4 Volume-assured Pressure Support ventilation  
Volume-assured pressure support ventilation (VAPS) is a hybrid mode that 
combines the principles of PSV and VCV. Like PSV, it can only be used if the 
infant is spontaneously breathing (Sinha et al., 2011). When an inflation is 
triggered the ventilator delivers gas at a variable flow rate. The volume of 
delivered gas is measured when the flow has decelerated to a specific level. If 
the desired volume has been achieved the ventilator cycles into expiration, 
similar to PSV. If the desired volume has not been achieved the ventilator 
continues the inflation but uses the principles of VCV. In this way, inspiratory 
flow is continued at a constant rate and the inspiratory time is increased until 
the desired volume has been achieved. The PIP may also be increased to 
ensure that the desired volume is reached. The pulmonary graphic waveforms 
look similar to those seen in VCV at this point, with a partially or completely 
square flow waveform and a ‘shark fin’ pressure waveform (Sinha et al., 2011). 
2.11 Other modes of VTV 
Other hybrid modes of VTV include volume support ventilation and pressure 
augmentation. Volume support ventilation combines elements of PSV and 
PRVC. It relies on spontaneous breathing and, like PSV, is flow-cycled. As with 
PRVC, the PIP is adjusted with every breath to aim to achieve the target tidal 
volume (Sinha et al., 2011). Pressure augmentation also requires spontaneous 
breathing. It aims to achieve a minimal tidal volume by adjusting inspiratory flow 
during inspiration (Sinha et al., 2011). 
2.12 Review of the literature on the use of VTV in newborn infants 
Much of the evidence for the use of volume-targeted ventilation (VTV) comes 
from clinical trials with short-term primary outcome measures. Such outcome 
measures include  
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• ventilatory or physiological parameters (Abubakar et al, 2001; Cheema 
et al., 2001; Herrera et al., 2002; Olsen et al., 2002; Keszler et al., 
2004; Lista et al., 2004; Abubakar et al., 2005; Lista et al., 2006; 
Nafday et al., 2005; Hummler et al., 2006; Polimeni et al., 2006; 
Cheema et al., 2007; Scopesi et al., 2007; Swamy et al., 2008), 
• clinical outcomes before discharge from hospital (Piotrowski et al., 
1997; Sinha et al., 1997; D’Angio et al., 2005; Singh et al., 2006; 
Duman et al., 2012; Guven et al., 2013).  
Only two clinical trials have reported medium-term respiratory and neurological 
outcomes (Singh et al, 2009; Stefanescu et al., 2015). Many of the early studies 
were small feasibility studies and subsequent trials used small sample sizes. 
However, despite their modest sizes, these studies provide useful data on the 
safety and efficacy of VTV in the clinical setting.  
2.12.1 Using VCV to target tidal volumes 
Sinha et al. (Sinha et al., 1997) published a randomised controlled trial 
comparing TCPL ventilation with VCV. This was the first study to investigate the 
safety and efficacy of VCV using fixed inspiratory flow in preterm infants. Fifty 
preterm infants with a birth weight >1500g and a diagnosis of RDS requiring 
mechanical ventilation were enrolled. All infants received surfactant but less 
than half were exposed to antenatal glucocorticoids. The target tidal volume in 
both groups was 5-8 mls/kg. Therefore the only difference between groups was 
the mode of ventilation. The authors defined ‘success’ criteria (alveolar-arterial 
oxygen gradient of <13 kPa or a mean airway pressure of <8 cmH2O for at least 
12 hours, or until extubation if this occurred sooner) to standardise the primary 
outcome measure.  
By targeting tidal volumes using VCV, infants achieved the ‘success’ criteria 
significantly faster compared with those in the TCPL group (65.5 hours versus 
125.8 hours respectively, p<0.001). The strengths of the study included the use 
of a strict protocol, objective criteria to measure the primary outcome and the 
use of the same ventilator in both groups, thereby eliminating device-related 
differences. One limitation is the small sample size that is acknowledged by the 
authors in relation to interpretation of the findings that BPD and major 
abnormalities on cranial ultrasound scan were less frequent in the VCV group. 
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This was a small single centre study, limiting the generalisability of the results. 
However, this study was designed to assess the safety and efficacy of VCV in 
preterm infants and it was the first study to do so. Therefore, although it does 
not provide definitive results, the study achieved its purpose of demonstrating 
safety and efficacy. 
The study was subsequently repeated by Singh et al. (Singh et al., 2006) in a 
two-centre study to test the safety and efficacy of VCV in smaller and more 
preterm infants. The same study protocol was used. There was no significant 
difference between the two groups in the time taken to achieve the success 
criteria. A post hoc analysis of infants weighing <1000g showed that infants in 
the VCV group met the ‘success’ criteria significantly faster than infants in the 
TCPL group (21 hours versus 58 hours respectively, p=0.03). Again, this study 
achieved its aims of assessing whether VCV was safe and efficacious in 
extremely small and preterm infants but its very small sample size means that it 
does not provide definitive results. 
Swamy et al. (Swamy et al., 2008) reviewed the respiratory parameters 
documented hourly during the first 72 hours of ventilation (or until extubation if 
that occurred sooner) in 86 of the infants enrolled into the study by Singh et al. 
(Singh et al., 2006). They reported that expired tidal volumes were significantly 
less variable in the VCV group compared with the TCPL group (mean (SD) 
0.871 (0.25) mls/kg versus 1.121 (0.56) mls/kg respectively, p=0.009). This was 
achieved using significantly higher PIPs (VCV mean (SD) 16.953 (3.79) cmH2O 
versus TCPL 15.319 (3.12) cmH2O, p=0.03) that were also more variable (VCV 
mean (SD) variability of 3.28 (1.38) cmH2O versus TCPL 2.66cm (1.22) H2O, 
p=0.032).  
These data were taken from a prospective randomised controlled trial by Singh 
et al. (Singh et al., 2006). Therefore comparison groups were subject to a 
prospectively planned trial protocol and the data used by Swamy et al. (Swamy 
et al. 2008) were recorded prospectively. However this study was limited in 
several ways. It was retrospective in nature which introduces measurement 
bias. The validity of data recorded manually once every hour was not explored 
meaning that the results and conclusions are not validated. Not all infants had 
complete datasets for analysis, meaning that data from some infants from the 
 28 
trial by Singh et al. (Singh et al. 2006) were not included in this study. This limits 
the reliability of the data published by Swamy et al. (Swamy et al. 2008) 
In summary, VCV using fixed inspiratory flow may target tidal volumes more 
effectively using higher but more variable PIPs to achieve faster weaning of 
ventilation. However, these results are not definitive. Larger trials that include 
greater numbers of infants and use validated means of collected data on tidal 
volumes and airway pressures would provide more reliable data. 
2.12.2 Using VG to target tidal volumes  
VG is the most commonly studied mode of VTV in clinical trials of neonatal 
ventilation. The feasibility and effects of combining VG with pressure-limited 
modes in preterm infants were demonstrated in small crossover studies or 
randomised controlled trials looking at short-term end points such as ventilator 
parameters and their variability (Cheema et al., 2001; Abubakar et al., 2001; 
Herrera et al., 2002; Olsen et al., 2002; Keszler et al., 2004; Abubakar et al., 
2005; Nafday et al., 2005; Scopesi et al., 2007) and short-term clinical 
outcomes (Cheema et al., 2007; Duman et al., 2012; Guven et al., 2013).  
2.12.3 The effect of VG on tidal volumes 
Most of these studies showed that mean tidal volumes were similar when VG 
was used to target tidal volumes compared with a pressure-limited mode 
(Cheema et al., 2001; Abubakar et al., 2001; Keszler et al., 2004; Abubakar et 
al., 2005; Scopesi et al., 2007) although in one study (Herrera et al., 2002) 
mean tidal volumes were lower in the VG groups compared with SIMV. 
However, tidal volumes were less variable in VG modes compared with 
pressure-limited modes, often reaching significance (Abubakar et al., 2001; 
Keszler et al., 2004; Scopesi et al., 2007). Herrera et al. (Herrera et al., 2002) 
demonstrated that the proportion of tidal volumes exceeding 7mls/kg was 
significantly lower when SIMV+VG was used at tidal volumes of 4.5mls/kg and 
3.0mls/kg compared with SIMV alone. 
The data from the studies above refer to the first few hours or days after birth. 
Traditionally, a target tidal range of 4-6mls/kg has been used for ventilated 
preterm infants (Van Kaam et al., 2015). However there is some evidence to 
suggest that targeting tidal volumes >6mls/kg may be more appropriate for 
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infants who are ventilated for more than a few days. Keszler et al. (Keszler et 
al., 2009) undertook a retrospective review of the tidal volumes generated over 
the course of three weeks in extremely low birth weight (ELBW) infants (birth 
weight <800g) who were receiving pressure A/C+VG or PSV+VG. Reported 
practice in the unit was to allow mild permissive hypercapnia after the first few 
days of ventilation. They observed that both set and measured tidal volumes 
increased over time, indicating that ventilator-dependent ELBW infants may 
require higher tidal volumes over time to achieve a target ventilation strategy. 
The study is limited, however, by its retrospective nature and exclusion of both 
larger preterm infants and other infants who were switched to other ventilatory 
modalities.  
Hunt et al. (Hunt et al., 2018) reported similar findings in a small crossover 
study of 18 infants born at <32 weeks’ gestation and ventilated for at least a 
week. They found that the infants’ mean expired tidal volumes were greater 
prior to the introduction of VTV than when a target tidal volume of 4mls/kg was 
used in conjunction with VTV. They also found that the infants’ work of 
breathing was reduced when a tidal volume of 7mls/kg was used instead of 4-
6mls/kg. The strengths of this study include its prospective, randomised design 
and use of an objective measure of work of breathing (transdiaphragmatic 
pressure-time product, PTPdi). However, the study is small and undertaken in 
one centre which limits its generalisability. Two infants received SIMV whereas 
16 received A/C ventilation. The use of SIMV may have impacted on those two 
infants’ work of breathing as not all breaths are supported with SIMV. The 
authors do not state which mode of VTV was used.  
Whilst the studies by Keszler et al. (Keszler, 2009) and Hunt et al., (Hunt et al., 
2018) have several methodological limitations they do highlight an area for 
further research. Whilst many infants are extubated within a few days, some 
require longer periods of ventilation and a higher target tidal volume range may 
be more suitable for these infants.  
2.12.4 The effect of VG on airway pressures 
Two crossover studies reported that PIP was lower when VG was compared to 
pressure-limited modes without VG (Cheema et al., 2001; Scopesi et al., 2007). 
When comparing two VG modes, Abubakar et al. (Abubakar et al., 2005) found 
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that PIP was significantly lower when VG was combined with pressure assist-
control (A/C) compared with SIMV+VG. However, this difference was only found 
when ventilator-supported breaths were analysed. Not surprisingly, when lower 
tidal volumes are targeted, mean PIP is lower (Herrera et al., 2002). 
The crossover studies demonstrated that VG is safe and effective in newborn 
infants but many are limited by methodological factors such as inclusion bias, 
short duration of study periods and lack of randomisation. In one study 
(Cheema et al., 2001), the results should be interpreted with particular caution 
because the maximum PIP limit, a safety limit set by the clinician to prevent the 
ventilator generating pressures higher than that limit, was not adjusted during 
the study. This will have prevented the ventilator from increasing the PIP 
beyond this limit if required to achieve the set tidal volumes. In turn, this may 
have affected the reported PIP and tidal volumes values.  
2.12.5 Evidence for other modes of VTV 
Markstrom et al. (Markstrom et al., 1996) studied 13 surfactant-depleted piglets 
and found that the decelerating inspiratory flow pattern in PRVC led to 
increased carbon dioxide removal (and therefore presumed better alveolar 
ventilation) than the constant flow pattern of VCV. There are no studies in 
human infants to corroborate this. In two studies (Piotrowski et al., 1997; 
D’Angio et al., 2005) PRVC ventilation was used as the volume-targeted mode 
but was compared with a PLV mode. Piotrowski’s study (Piotrowski et al., 1997) 
of PRVC is reviewed below in section 2.12.7. D’Angio et al. (D’Angio et al., 
2005) claim that the same minute ventilation is achieved using lower VT and 
lower PIP in the PRVC group compared to the SIMV group. However, the 
quoted VT values are inspiratory and measured at the ventilator, therefore not 
taking account of ETT leak and compressible volume loss.  
2.12.6 Maintaining partial pressure of carbon dioxide  
There is a recognised link between hypocarbia and severe intracranial 
pathologies (Fujimoto et al., 1994; Okumura et al., 2001). Therefore it is 
imperative to prevent hypocarbia when ventilating preterm infants using VTV. 
Many studies report blood gas results as a measure of gas exchange, either 
from arterial or capillary samples or from transcutaneous recordings. Some 
 31 
found no difference when VG is compared to pressure-limited modes (Herrera 
et al., 2002; Cheema et al., 2007; Scopesi et al., 2007). Keszler et al. (Keszler 
et al., 2004) found that the partial pressure of carbon dioxide (PaCO2) was 
below the target range on fewer occasions when VG was used to target tidal 
volumes (20.1% pressure A/C+VG versus 36.3% pressure A/C, p<0.001) 
although there was no difference in the proportion of episodes above the target 
range.  
A retrospective cohort study reported that, in the 38 preterm infants who 
received SIMV+VG for 48 hours after admission, 92% of PaCO2 values were 
between the pre-specified range of 25 and 65 mmHg (3.3 - 8.7kPa) (Dawson et 
al., 2005). The mean target tidal volume was 3.98mls/kg and ranged from 3.5-
5.1mls/kg. However, this study is limited by its retrospective design and lack of 
comparison group. 
In a prospective randomised controlled trial in which SIPPV was compared with 
SIPPV+VG in 40 preterm infants with RDS, fewer episodes of hypocarbia were 
reported in the SIPPV+VG group (32%) than in the SIPPV group (57%) 
(Cheema et al., 2007). The difference did not reach statistical significance, 
possibly due to the small sample size. Infants born at >25 weeks’ gestation had 
significantly fewer episodes of hypocarbia, defined as PaCO2 <5kPa, when 
SIPPV+VG was used compared with SIPPV (27% versus 61% respectively, 
p=0.048). All PaCO2 values were outside the normal range in the SIPPV+VG 
group in infants born at 23-25 weeks’ gestation. However, this was a post-hoc 
stratification of data analysis and only seven infants in total were born at <25 
weeks’ gestation, limiting the reliability and applicability of this result.   
2.12.7 Duration of ventilation 
The term ‘duration of ventilation’ may apply to the total duration of mechanical 
ventilation via an ETT or it may apply to the first period of ventilation only. 
Clinicians may have differing opinions as to when an infant is ready for 
extubation. This can impose substantial bias unless this outcome is clearly 
defined in a study protocol. 
Piotrowski et al. (Piotrowski et al., 1997) described clear clinical criteria (FiO2 
<0.25, PIP <12 cmH2O and a set rate of <12 breaths per minute followed by a 
30-60 minute trial of endotracheal CPAP) in order to standardise the timing of 
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extubation. They did not find a significant difference in the time to extubation in 
infants ventilated with TCPL compared with infants ventilated with PRVC 
(median time to extubation was eight days in both groups). They did 
demonstrate a significantly shorter time to extubation in the PRVC group in 
infants weighing <1000g (11 days, 95% CI 3-19 days, in the PRVC group 
versus 32 days, 95% confidence interval 3-61 days, in the TCPL group, 
p=0.025). However this was a post-hoc analysis and the large confidence 
intervals (CIs) reflect the small sample size and limited validity of these data.  
Sinha et al. (Sinha et al., 1997) and Singh et al. (Singh et al, 2006) used 
predefined ‘success’ criteria as a primary outcome measure, rather than the 
moment of extubation itself, in order to determine the speed of weaning. These 
consisted of maintenance of an alveolar-arterial oxygen gradient (AaDO2) <13 
kPa or MAP <8 cmH2O for 12 consecutive hours. Duration of ventilation was a 
secondary outcome in these studies and referred to total duration of mechanical 
ventilation via an endotracheal tube. In the first study (Sinha et al, 1997) infants 
in the VCV group achieved the ‘success’ criteria significantly faster (mean 65.5 
hours VCV versus 125.8 hours TCPL, p<0.001) and had a significantly shorter 
total duration of ventilation (VCV mean 122.4 hours versus TCPL mean 161.9 
hours, p<0.001). In the second study (Singh et al., 2006) into which smaller and 
more immature infants were enrolled, there was no significant difference 
between the two groups in the time to reach the success criteria. A planned 
subgroup analysis of infants weighing <1000g at birth (n=59) showed that 
infants in the VCV group reached the ‘success’ criteria significantly faster than 
those in the TCPL group (VCV mean 21 hours, 95% CI 17-24, versus TCPL 
mean 58 hours, 95% CI 42-74; hazard ratio 1.83, 95% CI 1.04-3.2, p=0.03). 
The use of clearly defined ‘success’ criteria in these two studies ensured that 
objective measures of oxygenation and ventilator support were used to reflect 
routine clinical practice. This is a major strength of both studies. However 
objective measurements of spontaneous respiratory effort, which is an essential 
component of ‘readiness for extubation’, were not included.  
Two more recently published trials report duration of ventilation as a primary 
outcome (Duman et al., 2012; Guven et al., 2013). Duman et al. (Duman et al., 
2012) used extubation success at 48 hours as the primary outcome when 
comparing pressure A/C with pressure A/C+VG in a study of 45 infants. At 48 
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hours, 60% of infants in the pressure A/C+VG group had been successfully 
extubated compared to 40% in the pressure A/C group although this was not 
significant (p=0.315). They used pre-determined criteria (FiO2 <0.3 and an 
expiratory time of 5 seconds having been loaded with aminophylline) but do not 
state how long infants were expected to sustain these end-points prior to 
extubation. Therefore the primary outcome may still have been open to 
subjective bias by the preferences of clinicians’ regarding the timing of 
extubation.  
Guven et al. (Guven et al., 2013) used duration of ventilation as a primary 
outcome in their randomised controlled trial comparing SIMV with SIMV+VG. 
They specified pre-determined criteria for extubation (ventilator rate 20/minute, 
loaded with aminophylline, PaCO2 <60 mmHg, FiO2 <0.3 and PIP <15 cmH2O 
for eight hours) and found that SIMV+VG resulted in a significantly shorter 
duration of ventilation than SIMV (SIMV+VG mean (SD) 3.02 (6.76) days vs 
6.93 (7.81) days, p<0.001). However the study was underpowered with only 72 
infants completing the study instead of the required 90. 
Therefore, duration of ventilation is an important short-term clinical outcome 
when evaluating the effect of VTV. It has important clinical and financial 
implications. However, varying definitions of duration of ventilation make 
evaluation of the evidence difficult. The evidence from studies that use objective 
criteria (Piotrowski et al., 1997; Sinha et al., 1997, Singh et al., 2006) suggest 
that VTV results in the need for shorter periods of ventilation, particularly in 
extremely low birth weight infants. Trial protocols should include objective 
criteria for extubation, or readiness for extubation, that are used to standardise 
practice when extubating trial participants.  
2.12.8 Use of VTV in hypoxaemic episodes 
Three studies have reported the effect of VTV on hypoxaemic episodes.  
In a very small pilot study, Hummler et al. (Hummler et al., 2006) concluded that 
volume-controlled SIMV did not reduce the duration of hypoxemic episodes 
(oxygen saturations <80%) in extremely preterm infants compared with 
pressure-controlled SIMV. In a small, crossover study Jain et al. (Jain et al., 
2016) found a small reduction in the duration of hypoxemic episodes (oxygen 
saturations <85% for at least 20 seconds) when VG was used compared to 
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either SIMV+PS or pressure A/C ventilation. Although the reduction was 
statistically significant the clinical difference was only three seconds which limits 
the relevance of the results, something acknowledged by the authors. 
Polimeni et al. (Polimeni et al., 2006) reported that the use of SIMV+VG did not 
alter the frequency of hypoxaemic episodes (oxygen saturations <88%) when 
compared to SIMV but did lead to a shorter mean duration of episodes in 
extremely preterm infants with a mean chronological age of 37.5 days if a target 
tidal volume of 6 mls/kg is used. The criteria for increasing supplemental 
oxygen were defined prior to the trial. However the adjustments to the 
supplemental oxygen made by the researchers were not recorded so that the 
effect of these adjustments cannot be accounted for.  
2.12.9 Work of breathing 
Patel and colleagues studied the work of breathing in ventilated preterm infants 
during the acute phase of RDS (Patel et al., 2010) and the recovery phase 
(Patel et al., 2009). They used the PTPdi, based on oesophageal and gastric 
pressures, as a measure of work of breathing. In both studies they found that 
targeting a volume of 4 mls/kg resulted in a higher mean PTPdi than those 
measured when volumes of 6 mls/kg were targeted (but not 5 mls/kg) and at 
baseline when volume-targeting was not employed. 
2.12.10 Biological markers of lung injury 
Lista et al. (Lista et al., 2004; Lista et al., 2006) analysed concentrations of 
inflammatory mediators (cytokines) in tracheal aspirates in two randomised 
controlled trials involving preterm infants with RDS. Cytokine concentrations 
were higher when PSV was compared with PSV+VG (Lista et al., 2004), 
indicating that breath-to-breath volume targeting may result in lower levels of 
lung inflammation. When target tidal volumes of 5 mls/kg were compared with 3 
mls/kg using SIPPV+VG in both groups, higher concentrations of cytokines 
were isolated when tidal volumes of 3 mls/kg were targeted (Lista et al., 2006).  
These results indicate that ventilating at low tidal volumes may cause 
atelectotrauma and greater lung inflammation. Lung inflammation may be a 
reflection of VILI and therefore achieving an optimal tidal volume using VTV 
may limit VILI. However these studies were both very small, with the first (Lista 
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et al., 2004) enrolling 53 patients and the second (Lista et al., 2006) enrolling 
only 30 patients. This greatly limits the generalisability and validity of these 
results. Investigating the levels of inflammation associated with different modes 
of VTV is important and these studies do provide exploratory data that are 
worthy of investigation in larger studies. However, the small numbers of infants 
randomised means that these results are not definitive. 
2.12.11 Long-term clinical outcomes 
Singh et al. (Singh et al., 2009) evaluated respiratory and gross 
neurodevelopmental outcomes at a median age of 22 months in infants 
ventilated with TCPL or VCV (Singh et al., 2006). Masked follow-up of 93% of 
surviving infants revealed that fewer children in the VCV group were using 
inhalers (odds ratio 0.32, 95%CI 0.1-0.9, p=0.04). However, the original study 
was not powered to assess long-term outcomes and there were so few cases of 
severe neurodevelopmental impairment that meaningful analysis was not 
possible. D’Angio et al. (D’Angio et al., 2005) reported neurodevelopmental 
outcome data for a proportion of infants in their trial. Although they did not find 
any differences in these outcomes, this study was not powered to detect 
differences in these outcomes. 
Stefanescu et al. (Stefanescu et al., 2015) reported the results of a 
retrospective observational cohort study of infants with a birth weight of ≤1250g. 
During the first epoch, infants received pressure-controlled ventilation. In the 
second infants received PSV+VG. The authors examined the effect of these 
ventilator modes on the combined outcome of severe neurodisability or death at 
18 months’ corrected gestational age. There were no significant differences 
between groups in the combined outcome. However, the design of this study 
limits its applicability in several aspects. PSV+VG requires the infants to be 
spontaneously breathing whereas pressure-control ventilation does not. This 
characteristic makes the groups substantially different. Outcome data on a large 
proportion of the infants (30%) could not be obtained. The retrospective nature 
of the study means that practices were not controlled by a protocol. Therefore 
the likelihood of bias, including selection and performance bias is high. The lack 
of randomisation indicates that prognostic factors in the two groups may not be 
balanced.    
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None of these studies were designed to assess long-term respiratory or 
neurodevelopmental outcomes as a primary outcome. Therefore, although 
these results may be interesting they are by no means definitive. Therefore 
there is a lack of long-term respiratory or neurodevelopmental outcome data 
regarding the use of VTV in infants. These are crucial outcomes in neonatology, 
particularly in trials of respiratory practice, and large prospective trials powered 
to assess these outcomes are needed to provide definitive data. 
2.12.12 Meta-analyses of VTV 
Currently, the only method of evaluating major morbidities such as death or 
CLD is by systematically combining results of different trials. A Cochrane review 
published in 2010 (Wheeler et al., 2010) and meta-analysis published in 2011 
(Wheeler et al., 2011) comparing VTV with PLV combined the results from 12 
and nine trials respectively. Overall, VTV was associated with reductions in the 
combined outcomes of death and BPD (number needed to treat = 8), the rate of 
pneumothoraces, duration of ventilation, hypocarbia, and the combined 
outcomes of periventricular leukomalacia (PVL) or grade III-IV intraventricular 
haemorrhage (IVH). Another meta-analysis by a different group of authors 
(Peng et al., 2014) published in 2014 consisted of 18 studies, some of which 
were excluded by the authors of the previous reviews or were published since 
the previous reviews. They reported similar findings but found no difference in 
the incidence of death. 
The Cochrane review of 2010 (Wheeler et al., 2010) was recently updated and 
published in 2017 (Klingenberg et al., 2017). Several additional studies were 
included since the previous publication, most of which are discussed in this 
thesis. Only the study by Liu et al. (Liu et al., 2011) could not be reviewed in 
detail as it was published in Chinese and only the abstract was available in 
English. The authors of the 2017 Cochrane review reported similar findings to 
that of the previous Cochrane review. The evidence favouring the use of VTV 
compared to PLV was stronger in the more recent review and in both reviews 
the authors recommended that future studies compare different VTV modes and 
strategies.   
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2.12.13 Limitations of the data on use of VTV in newborn infants 
The limitations of the individual studies have been discussed in the previous 
sections. All of them are small and many are single-centre which limits 
generalisability. Many only focus on short-term outcomes and none are 
powered to demonstrate significant differences in important long-term 
outcomes. The methodology used by some of the trials is likely to have 
introduced substantial bias. As a collection of studies, they are very 
heterogeneous, using different patients, different ventilators, different modes of 
VTV and control groups, and different outcomes. This heterogeneity impacts on 
the ability of the meta-analyses to provide strong data on the use of VTV in 
newborn infants. Therefore, this remains an area of neonatology in which robust 
data are lacking. 
2.12.14 Conclusions 
Most studies favour VTV with respect to short- and medium-term outcomes 
when compared with pressure-limited modes (Klingenberg et al., 2017). VTV 
maintains tidal volumes within a given range, often using lower airway 
pressures and achieving equivalent or improved carbon dioxide elimination. 
VTV modes appear to achieve this more effectively than pressure-limited 
ventilation even when tidal volumes are targeted in both modes. The 
relationship between these outcomes and clinical manifestations of VALI can be 
difficult to establish as studies are often limited by small sample sizes, lack of or 
suboptimal randomisation, and methodological bias. Therefore long-term 
outcome measures are preferable but difficult to achieve without large multi-
centric studies. Recent reviews combining the results of several studies favour 
VTV over pressure-limited ventilation (Wheeler et al., 2010; Wheeler et al., 
2011; Peng et al., 2014; Klingenberg et al., 2017) with regards to important 
short- and medium-term outcomes.  
Now that VTV is considered a standard of care (Sweet et al., 2017), it is 
necessary to compare different VTV modes using prospective randomised 
clinical trials. Short-term outcomes such as readiness for extubation or duration 
of ventilation are still relevant to assess the safety and efficacy of protocols 
because these outcomes have important health and financial implications. 
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However, it is vital to define these outcomes a priori using objective criteria in 
order to avoid bias. 
Published studies to date have compared VG or VCV with pressure-limited 
modes. However there is no published study comparing VG with VCV as a 
means of providing VTV in preterm infants. The aim of this trial was to compare 
VG with VCV using short-term clinical outcomes with preterm infants with RDS. 
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Chapter 3 Methods 
3.1 Introduction 
There are many modes of VTV available and used widely around the world 
(Klingenberg et al., 2011a). Two of these modes, volume controlled ventilation 
(VCV) and volume guarantee (VG), work in different ways as discussed in 
Chapter 2. VCV delivers a set volume of gas at a constant flow throughout 
inspiration, generating whatever PIP is needed to deliver the set volume of gas. 
Inspiratory pressure is maximal at the end of inspiration. The maximal pressure 
generated depends on lung compliance, airway and circuit resistance, and 
compressible volume loss. The duration of inspiration is dependent on the time 
taken to deliver the set volume at the set flow rate, and can vary from breath to 
breath.  
When VG is used the volume and inspiratory times are set by the clinician. The 
flow rate peaks early in inspiration and then falls throughout the remainder of 
inspiration. Therefore the PIP is generated early in inspiration and maintained 
throughout inspiration. Using an automated, closed-loop feedback mechanism 
the ventilator varies the PIP with each breath in order to aim to deliver to deliver 
the volume set by the clinician. 
These modes are both used widely to provide mechanical ventilation to 
newborn infants. However there are no published clinical trials comparing the 
two modes. 
3.2 Ethical approvals 
This randomised controlled trial (RCT) was conducted according to a protocol 
approved by The North-East York Ethics Committee on 3rd July 2013 (see 
Appendix 9.1). This protocol was also approved by South Tees Hospitals NHS 
Foundation Trust Research and Development Department on 8th July 2013 (see 
Appendix 9.2), which acted as the trial’s sponsor. The sponsor funded the 
Principal Investigator’s (Dr Helen Chitty’s) salary but no other funding was 
required. The trial was registered on the ISRCTN trial registry and given a 
registration number of ISRCTN04448562. The name given to the trial was The 
VoluVent Trial. 
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3.3 Regulatory monitoring  
The South Tees Hospitals NHS Foundation Trust sponsored the trial. The 
Research and Development (R+D) department undertook two annual 
monitoring visits during the trial period. The conduct of the trial and its 
procedures, such as documentation, training, consent and data collection, were 
reviewed. Any recommendations made by the R+D department were 
undertaken. Favourable reports were given by the R+D department on both 
occasions. An interim report was also submitted to the North-East York Ethics 
Committee in 2014. 
The trial sponsor undertook two monitoring visits on 28th January 2014 and 30th 
March 2015. The sponsor gave favourable reports with no major concerns 
raised. Suggestions and requests made by the sponsor were implemented.    
3.4 Protocol amendments 
Four applications for the following protocol amendments were submitted to the 
North-East York Ethics Committee and the South Tees Hospitals NHS 
Foundation Trust Research and Development department during the course of 
the trial. All applications were written and submitted by the Principal Investigator 
(Dr. Helen Chitty) and all amendments were given a favourable opinion and 
approved. 
• 23rd July 2013: minor protocol amendment to enable Advanced Neonatal 
Nurse Practitioners to take consent 
• 18th November 2013: substantial protocol amendment to allow the use of 
deferred consent, recruitment period extended to June 2016. 
• 8th September 2014: minor protocol amendment to include the collection 
of mechanistic ventilator data for the purpose of process evaluation of 
the trial (see Chapter 5) 
• 2nd October 2015: substantial amendment to the Integrated Research 
Application System (IRAS) form regarding the co-enrolment of infants 
into other trials. The original IRAS form had been completed correctly but 
the sponsor requested clarification in the IRAS form that infants enrolled 
into this trial may subsequently also participate in other studies. This did 
not require a change to the trial protocol.  
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3.5 Objectives 
The purpose of this single centre RCT was to compare VCV with VG in preterm 
infants born at less than 34 weeks’ gestation with RDS. The aim was to 
determine whether these infants were ready for extubation faster in the VG 
group compared to the VCV group. 
3.6 Hypothesis  
The hypothesis for this trial was that infants in the VG group would be ready for 
extubation faster than infants in the VCV group. Two previous randomised 
controlled trials conducted in the same neonatal unit compared VCV with time-
cycled pressure limited (TCPL) ventilation in preterm infants with RDS (Sinha et 
al., 1997; Singh et al., 2006). Those trials used objective ‘success’ criteria 
defined a priori to standardise the primary outcome. Those criteria represented 
the level of ventilatory support at which most infants are ready for extubation. In 
this study, objective ‘success’ criteria were also defined a priori to represent 
readiness for extubation. Based on those previous data, the research team 
hypothesised that the use of VG would lead to a 33% reduction in the time 
taken to reach the ‘success’ criteria from 23 hours to 15 hours when compared 
with VCV.  
3.7 Primary outcome measure 
The primary outcome measure for this study was the duration of time of 
mechanical ventilation via an endotracheal tube (measured in hours) from study 
entry until the predetermined ‘success’ criteria were reached. The ‘success’ 
criteria consisted of  
• a mean airway pressure of <8 cmH2O and a fractional inspired oxygen 
concentration (FiO2) ≤0.35 maintained for six consecutive hours  
followed by 
• successful completion of a spontaneous breathing test (SBT).  
If there was a planned or unplanned extubation prior to reaching the ‘success’ 
criteria, after which the infant did not require reintubation for 24 hours, this was 
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also classed as ‘success’ and results were analysed on an intention-to-treat 
basis.  
The first two ‘success’ criteria (mean airway pressure and FiO2) were chosen 
because they reflect clinical and physiological parameters at which extubation 
would be considered as part of standard practice in the study unit. The SBT was 
used to assess the infants’ spontaneous respiratory drive. These objective 
criteria were used to standardise the primary outcome measure across both 
arms of the trial. When compared with other measures of minute ventilation in a 
study of 50 preterm infants, the SBT had a higher sensitivity (97%) and 
specificity (73%) (Kamlin et al., 2006). Similar tests have been reported and 
used in previously published studies (Wilson et al., 1998; Gillespie et al., 2003; 
Gupta et al., 2009).  
Data from any infants who died or were transferred to another hospital before 
reaching the ‘success’ criteria were censored. This was planned a priori and is 
detailed in the statistical analysis plan (SAP) (see Appendix 9.3) 
3.7.1 Measuring the primary outcome 
When prospective consent was used, study entry was defined as 
• the time of admission (as documented in the medical record) for infants 
who were intubated before admission to the unit and subsequently 
randomised to VCV after consent was obtained, 
• the time of randomisation (as documented in the medical record) for 
infants intubated before admission and subsequently randomised to VG 
after consent was obtained, 
• the time of randomisation (as documented in the medical record) for 
infants intubated after admission to the unit.  
When deferred consent was used, study entry was defined as 
• the time of admission (as documented in the medical record) for infants 
intubated before admission and randomised on admission to the unit, 
• the time of surfactant administration (as documented on the prescription 
chart in the medical record) for infants intubated and randomised after 
admission to the unit. 
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The time at which all ‘success’ criteria were reached was the time documented 
at the end of the successful SBT. Documentation of physiological parameters 
and timings during this test were done using a specifically designed worksheet 
demonstrated in Appendix 9.4. 
3.8 Secondary outcome measures 
The secondary outcome measures chosen were those that reflected short- and 
medium-term morbidities prior to discharge from hospital in preterm infants who 
receive mechanical ventilation. 
3.8.1 Respiratory outcome measures 
• Total duration (in hours) of mechanical ventilation via an ETT until first 
extubation. 
• Requirement for reintubation within 72 hours of extubation (in accordance 
with the trial protocol). 
• Total duration (in hours) of mechanical ventilation via an ETT until 
successful extubation. 
• Pulmonary air leak while receiving mechanical ventilation (including 
pneumothorax, pneumomediastinum, pneumopericardium, pneumatocele, 
and pulmonary interstitial emphysema) as reported on a chest x-ray by a 
Consultant Neonatologist or Paediatric Radiologist. 
• Number of episodes of hypocarbia during mechanical ventilation (defined as 
carbon dioxide tension of less than 4.0 kPa) requiring adjustment of 
ventilation. 
• Total duration (in hours) of non-invasive artificial respiratory support 
including nasal CPAP, bi-level nasal CPAP and HHFNC. 
• Number of infants requiring rescue treatment with high frequency oscillatory 
ventilation (as decided by a Consultant Neonatologist in accordance with the 
trial protocol). 
• Need for continuous or intermittent supplemental oxygen at a postmenstrual 
age of 28 days and at 36 weeks’ corrected gestational age. 
 44 
• Bronchopulmonary dysplasia (BPD) requiring home oxygen therapy or 
continuation of any form of respiratory support at home. 
3.8.2 Mortality 
• Death before discharge from hospital. 
3.8.3 Neurological outcomes 
• Severe intraventricular haemorrhage (grades 3 or 4 according to the Papile 
classification and reported using cranial ultrasonography by a Paediatric 
Radiologist or Specialist Paediatric Radiographers). 
• Periventricular leukomalacia (reported using cranial ultrasonography by a 
Paediatric Radiologist or Specialist Paediatric Radiographers). 
3.8.4 Other outcomes related to prematurity 
• Retinopathy of prematurity requiring laser treatment (as diagnosed by a 
Paediatric Ophthalmologist). 
• Patent ductus arteriosus (diagnosed on echocardiogram) requiring medical 
or surgical treatment (as decided by a Consultant Neonatologist). 
• Necrotising enterocolitis (Bell stage 2 or greater). 
• Intestinal perforation not due to necrotising enterocolitis. 
• Number of confirmed episodes of infection (positive cultures from blood and 
cerebrospinal fluid at a time when the infant showed clinical signs of 
infection). 
3.9 Serious adverse events 
The expected serious adverse events (SAEs) that could be reasonably 
expected to occur in infants in this trial included: 
• death, 
• BPD (defined as requirement for supplemental oxygen or positive 
pressure respiratory support at 36 weeks’ corrected gestational age), 
• requirement for re-intubation,  
 45 
• pulmonary air leak during mechanical ventilation, including 
pneumothorax, pneumomediastinum, pneumopericardium, 
pneumatocele, pulmonary interstitial emphysema (as reported by a 
Consultant Neonatologist or Paediatric Radiologist), 
• hypocarbia (pCO2 <4.0), 
• pulmonary haemorrhage (as diagnosed by a Consultant Neonatologist) 
• necrotising enterocolitis (any stage and diagnosed by a Consultant 
Neonatologist using clinical and radiological parameters and/or tissue 
histology), 
• intestinal perforation (diagnosed using clinical and radiological 
parameters and confirmed during surgery), 
• intracranial haemorrhage or focal white matter damage (diagnosed using 
cranial ultrasonography by a Paediatric Radiologist or Specialist 
Paediatric Radiographer), 
• persistent patent ductus arteriosus (diagnosed using echocardiography 
and requiring either medical or surgical treatment) 
• retinopathy of prematurity (any stage and diagnosed by a Paediatric 
Ophthalmologist) 
These SAEs did not require immediate reporting but were recorded 
prospectively in the medical records and managed by the treating clinician in 
accordance with standard unit practice. Expected SAEs were recorded on case 
report forms. 
3.10 Trial site 
This was a single centre study based at the neonatal unit at The James Cook 
University Hospital, Middlesbrough, UK. This is a level three neonatal unit that 
cares for infants of any gestation requiring intensive, high dependency or low 
dependency care. It does not provide surgical or cardiothoracic services. Infants 
requiring those services are transferred to other regional surgical centres. In the 
period during which the trial took place, the unit contained ten intensive 
care/high dependency cots and 12 special care cots. There were approximately 
4,300 infants delivered in the hospital each year during that time period and 
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approximately 500 admissions per year to the neonatal unit. Infants in other 
hospitals who require intensive care that could not be provided in their local unit 
were transferred to the trial site by the regional neonatal transport teams.  
For this trial, infants born at The James Cook University Hospital who were 
admitted to the neonatal unit were referred to as inborn infants. Infants who 
were transferred from other hospitals to The James Cook University Hospital 
neonatal unit were referred to as outborn infants. 
3.11 Inclusion criteria 
All infants admitted to the trial site were screened for eligibility. Infants were 
enrolled into this trial if they fulfilled the criteria below: 
• born at < 34 weeks’ gestation and, 
• < 24 hours old at the time of initial intubation and,  
• required intubation and mechanical ventilation for RDS and, 
• deferred written informed consent was obtained from parents within 36 
hours of intubation (after randomisation). 
The diagnosis of RDS was based on a combination of clinical signs (respiratory 
distress or apnoea), radiographic features (reticulogranular appearance with air 
bronchograms and diminished lung volume), and biochemical evidence of 
respiratory failure (respiratory acidosis on blood gas analysis).  
3.12 Exclusion criteria 
Infants were ineligible for inclusion in the trial if they fulfilled any of the criteria 
below: 
• required mechanical ventilation for reasons other than RDS or, 
• had a known congenital anomaly likely to adversely affect the respiratory 
system or life expectancy or, 
• written informed deferred consent was not obtained within 36 hours of 
intubation.  
3.13 Consent 
Infants were enrolled into the trial only if written informed consent was obtained 
from the parents after birth. Consent was not sought before birth. Written and 
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verbal information was offered to parents before birth if they presented to the 
hospital several hours before delivery but only if it was appropriate to do so. 
Otherwise it was offered to parents as soon as was appropriate after the 
delivery. 
3.13.1 The initial procedure for obtaining informed consent 
Initially eligible infants were enrolled into the trial only if parents had given 
prospective written informed consent after birth and within 12 hours of their 
infant’s intubation. Before consent was obtained eligible infants were ventilated 
using VCV as this was the standard ventilatory mode for preterm infants with 
RDS in the neonatal unit at that time.  
However, during the first three months of the trial it became apparent that 
prospective consent did not allow sufficient time for most parents to make an 
informed decision about participation. Some parents reported that they needed 
more than 12 hours to consider the information. Many also stated that they did 
not want to participate because the possibility of randomisation to VG would 
lead to a change to their infant’s mode of ventilation solely for the purpose of 
the trial. In the cases of outborn infants, most parents had not arrived at the 
hospital within 12 hours of initial intubation meaning that they could not be given 
the opportunity to consider participation in the trial.  
Therefore, in order to ensure that the consent process was more appropriate for 
parents to better enable them to make an informed decision, a protocol 
amendment was made to enable the use of deferred consent. 
3.13.2 A protocol modification to enable the use of deferred consent 
In November 2013, the protocol was amended so that deferred consent could 
be used. This meant that infants born at <34 weeks’ gestation and intubated 
within 24 hours of birth for RDS can now be randomised at the time of 
admission or at the time of intubation if they have been managed on CPAP 
initially. Parental consent was then sought after randomisation. The deadline for 
obtaining written parental consent was 36 hours from the time of intubation. 
This amendment was implemented after receiving a favourable opinion from the 
North East-York Ethics Committee and approval from the trial’s sponsor, South 
Tees Hospitals NHS Foundation Trust.  
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Infants for whom consent was obtained were managed according to the trial 
protocol. Infants for whom consent was not obtained remained on the mode of 
ventilation to which they were randomised. Subsequent management depended 
on the decision of the treating clinicians. 
The use of deferred consent in the context of emergency care, both in this trial 
and in other settings, is discussed further in Chapter 6 Consent. The rationale 
for the protocol amendment request was that this trial involved the comparison 
of two types of emergency intervention, both of which were already widely used 
and considered to be safe, standard treatments. The requirement for timely 
randomisation of infants was due to the emergency nature of the interventions. 
In accordance with current legislation (The Medicines for Human Use (Clinical 
Trials) and Blood Safety and Quality (Amendment) Regulations’, 2008) deferred 
consent was applicable for use in this trial because  
• the trial population required urgent treatment with the interventions, 
• for the purpose of the trial the interventions were required urgently, 
• meeting the requirements for prospective informed consent was not 
practicable at the time that the infants required the trial interventions, 
• an ethics committee had given its approval for the use of deferred 
consent.  
3.14 Management of infants before stratification 
Infants admitted to the unit who initially required NIV but not mechanical 
ventilation all received CPAP support and were treated in accordance with 
standard unit practice. To minimise bias in the management of these infants 
who may have subsequently become eligible for the trial, use of HHFNC was 
not allowed. This was in accordance with standard practice in the unit at the 
time. 
3.15 Stratification 
Infants born at <34 weeks’ gestation who had been intubated for RDS within the 
first 24 hours of life were stratified a priori into two groups according to their 
gestational age at birth. One group consisted of infants born at <28 completed 
weeks of gestation and the other consisted of infants born between 28 and 
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33+6 weeks’ gestation. Infants were randomised separately according to these 
two stratified groups.  
This stratification was chosen because infants born at <28 weeks’ gestation are 
likely to require longer periods of ventilation than those born at 28-33+6 weeks’ 
gestation. Extremely preterm infants (those born at <28 weeks’ gestation) have 
respiratory systems that are usually structurally and functionally more immature 
than infants born at ≥28 weeks’ gestation (Joza et al., 2015). They are also 
more likely to have a greater degree of surfactant deficiency than more mature 
preterm infants (Donn et al., 2017b). Their musculoskeletal and neurological 
systems are more immature, meaning that they are more likely to require 
mechanical ventilation and are more likely to require it for longer periods of 
time. 
Therefore gestational age was identified as a factor likely to have a large effect 
on the primary outcome. This stratification was chosen to ensure that 
randomisation was balanced for this prognostic factor (Lamb et al., 2015). 
3.16 Randomisation 
In accordance with standards for good conduct in trial design randomisation 
was achieved using computer generated block randomisation (with fixed block 
sizes of four) and serially numbered sealed opaque envelopes (Medicines and 
Healthcare Products Regulatory Agency, 2012; Lamb et al., 2015). Both 
stratification groups had separate block randomisation sequences. All 
procedures, including preparation of the envelopes containing the allocated 
modes of ventilation, were performed by the Deputy Director of the Clinical 
Effectiveness Unit at South Tees Hospitals NHS Foundation Trust (Medicines 
and Healthcare Products Regulatory Agency, 2012). He remained independent 
of the trial throughout. 
Some infants did not have radiographic or biochemical evidence of RDS prior to 
randomisation. These infants included those who had been intubated in the 
delivery suite and those intubated very shortly after admission to the neonatal 
unit. If the treating clinician had made the decision to intubate these infants on 
the basis of clinical signs of RDS, or because extreme prematurity made 
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surfactant deficiency highly likely, those infants were stratified and randomised 
to either VG or VCV. If subsequent clinical, radiographic and biochemical 
analyses were consistent with surfactant deficiency and RDS, those infants 
remain eligible for inclusion in the trial. 
3.17 Devices used 
Both VG and VCV were delivered using AVEA® ventilators (Carefusion, Yorba 
Linda, CA). They were used in accordance with the manufacturer’s 
recommendations (Carefusion AVEA® ventilator systems operator’s manual, 
L2786, revision M, 2011). Ventilator maintenance was performed by Carefusion 
engineers. The pneumotachographs used were hot wire anenometers (flow 
sensors). Variable orifice flow sensors could be used if hot wire anenometers 
were not available (Avea Crit Care manual). All other devices and equipment 
used for infants in the trial were the same as those used in clinical practice in 
the unit. HFOV was delivered using the SensorMedics 3100A (Carefusion, 
Yorba Linda, CA) device. 
3.18 Management of enrolled infants whilst ventilated    
Infants were managed according to a protocol that was as rigorous as possible 
whilst still being pragmatic enough to be feasibly implemented in an intensive 
care unit. The protocol mandated strict criteria regarding readiness for 
extubation (the ‘success’ criteria). It contained detailed guidance on the use of 
the trial modes of ventilation. Summaries of this guidance were included in the 
protocol appendices and in each infant’s trial pack. These summaries can be 
found in Appendices 9.5 and 9.6 of this thesis. The protocol also contained 
details of the standard care of infants and the standard operating procedures to 
which the trial was subject.  
Figure 3-1 and Figure 3-2 show the flow charts used at the cotside for the 
management of infants on VG and VCV. The relevant version according to the 
allocated mode at randomisation was included in each infant’s trial pack. The 
clinical teams could therefore refer to them at the cotside. 
The use of ‘rescue’ HFOV was permitted if an infant was deteriorating on the 
allocated trial mode of ventilation. The recommended criteria for the use of 
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HFOV were included in the protocol and the summaries and flow charts. These 
criteria, in the context of severe respiratory failure, included: 
• mean airway pressure ≥15 cmH2O and FiO2 ≥0.5 (50%) or 
• oxygenation index (OI) >25 or 
• intractable thoracic air leak or 
• evidence of pulmonary hypertension with right to left shunt on 
echocardiogram 
However, HFOV could also be used without meeting these criteria at the 
discretion of the treating Consultant Neonatologist depending on the clinical 
circumstances of each infant. 
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Figure 3-1 Cotside flow chart for management of infants randomised to VCV  
 53 
 
 
Figure 3-2 Cotside flow chart for management of infants randomised to VG  
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3.19 Adjunctive therapies 
Two adjunctive therapies were specified in the trial protocol. Others were not 
specified in the trial protocol and were used when the treating Consultant 
Neonatologist deemed them to be necessary. The decision to institute these 
therapies was often made as a joint decision between two or more of the unit’s 
Consultants Neonatologists. 
3.19.1 Adjunctive therapies specified in the protocol 
• All infants enrolled into the study received at least one dose of exogenous 
surfactant via the endotracheal tube after intubation. Further doses of 
surfactant were given if deemed necessary by the treating clinicians. The 
surfactant used was CUROSURF® (poractant alfa, Chiesi Farmaceutici 
SpA). 
• All infants enrolled into the study received a loading dose of caffeine citrate 
(20mg/kg) prior to extubation. This was usually given early in the infant’s 
course in accordance with unit practice (Davis et al., 2010). It was given 
before the mean airway pressure fell below 8cmH2O whenever possible. 
The infants then received daily doses of maintenance caffeine citrate (5-
10mg/kg). This was given either enterally via a nasogastric tube or 
intravenously. Maintenance caffeine citrate was continued until at least 34 
weeks’ corrected gestational age.  
3.19.2 Adjunctive therapies given according to standard unit practice 
These therapies can affect an infant’s respiratory course but, due to the 
pragmatic nature of the trial, were not mandated in the trial protocol. The 
reasons for this are discussed further in Chapter 7. 
• Infants with patent ductus arterioses that required medical treatment were 
treated with three to five doses of intravenous ibuprofen. Those that required 
surgical ligation were transferred to the regional cardiothoracic centre for 
surgery as a day case and were transferred back to the unit the same day. 
During transfer and during surgery they received modes of ventilation that 
were outwith the trial protocol. These include asynchronous PLV from the 
transport cot ventilator during transfer and pressure-controlled ventilation 
using a Daegar Primus® ventilator during the operation. The duration of 
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time during which they received other modes of ventilation was included in 
time-to-event analyses for primary and secondary outcomes. 
• Dexamethasone was used to facilitate weaning of ventilation for infants who 
became ventilator-dependent and for whom weaning proved difficult. These 
infants received dexamethasone according to the trial protocol used by the 
investigators of the ‘Dexamethasone: A Randomised Trial’ (DART) study 
(Doyle et al., 2006). They received more than one course, or prolonged 
courses, if these were felt to be necessary by the treating Consultant 
Neonatologist. The use of dexamethasone had potential to affect the 
primary outcome in the few infants who received it. Therefore it was 
prospectively defined as a covariate and was analysed using multivariable 
analysis and a Cox proportional hazards model.  
• Ventilated infants did not routinely receive sedation or muscle relaxant 
medication at the trial site. As this protocol was a pragmatic one the use of 
sedation or muscle relaxants were not specifically mandated. Infants who 
received sedation during the first period of ventilation (prior to reaching the 
‘success’ criteria) received intravenous morphine sulphate either as a bolus 
or as an infusion. The ‘success’ criteria included the use of a SBT. This was 
only performed if an infant had been not received any sedation for at least 
six hours. If sedation had been administered during that time, the SBT was 
deferred until six hours after the sedation had been administered. 
• Diuretics were not used routinely in the unit for infants requiring prolonged 
respiratory support. Therefore their use was not specified in the trial protocol 
3.20 Contamination 
No crossover between trial modes was allowed. Infants enrolled into the trial 
could receive only the mode of ventilation to which they were randomised 
(either VG or VCV) or ‘rescue’ HFOV. Other modes of ventilation were not 
permitted. 
3.21 Minimisation of bias 
The interventions in this trial were not masked as it was not considered practical 
or safe to blind the researchers or clinicians to the modes of ventilation being 
investigated. Therefore researchers and clinicians were all aware of the modes 
to which each infant had been randomised. This had the potential to introduce 
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performance bias. Therefore, other measures were put in place to aim to 
minimise bias. These included: 
• the design of a prospective RCT with a standardised comparison group 
(VCV) to measure the efficacy of the intervention in the intervention 
group (VG), 
• the use of ongoing training for all clinical team members to minimise 
performance bias,  
• the use of standardised cotside trial packs for each infant containing 
information on management of each infant according to the allocated 
mode of ventilation, 
• the use of block randomisation to minimise selection bias and aim for a 
balance of prognostic factors, 
• the aim of the clinical and research teams to approach all parents 
wherever possible to minimise selection bias, 
• the design of a detailed trial protocol to minimise performance bias, 
• the use of an objective primary outcome measure to minimise 
detection bias, 
• the use of a pre-defined SAP to minimise detection and reporting bias, 
• the use of standardised follow up and the aim to achieve complete 
follow up and data collection in order to minimise attrition bias. The 
primary outcome was designed such that complete data collection for 
that outcome could be achieved. 
3.22 Management of infants after extubation 
Almost all infants received CPAP for non-invasive respiratory support after 
extubation. This was administered using the Infant Flow Driver device (Infant 
Flow® LP nCPAP system, Carefusion, Yorba Linda, CA). The starting pressure 
was set at 6 cmH2O after extubation. Infants for whom CPAP was considered 
inappropriate (for example, infants who had had a pneumothorax) could receive 
HHFNC. Non-invasive respiratory support was administered at the treating 
clinicians’ discretion. 
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3.23 Data collection 
All infants were screened for eligibility on admission. A baseline assessment of 
eligbility form was completed for all infants born at <34 weeks’ gestation and 
admitted to the neonatal unit in order to determine the number of infants who 
were eligible but not enrolled as well as the number of infants of the same 
gestational age who were ineligible. The reasons for non-enrolment were 
recorded anonymously and included in documentation, presentation and 
publication of results in keeping with the CONSORT 2010 Statement on 
transparent and complete reporting of randomised trials (Schulze et al., 2010).  
All data were collected prospectively on trial-specific data collection forms. An 
example of a data collection form is shown in Appendix 9.7.  
3.24 Statistical considerations 
3.24.1 Trial oversight review  
As this was a pilot trial the sponsor (South Tees Hospitals NHS Foundation 
Trust) confirmed that a formal interim analysis by a Data Safety and Monitoring 
Committee was not required. However, an external trial oversight review was 
undertaken by an independent statistician and an independent clinical reviewer. 
The independent statistician was from the Institute for Health and Society’s 
Biostatistics Research Group at Newcastle University. The clinical reviewer was 
a Consultant Neonatologist from Birmingham Heartlands Hospital.  
The statistician undertook interim analyses of data from the first 50 enrolled 
infants. The statistician received coded data on: 
• maternal and neonatal characteristics,  
• delivery details, 
• respiratory and ventilation parameters at trial entry,  
• primary outcome data. 
These data were coded so that the statistician was blinded to the allocated 
modes of ventilation. Version 6 of the SAP, dated 17th July 2015, was used to 
undertake the independent interim analyses which were reported on 21st 
September 2015. The report of these analyses was then sent to the clinical 
reviewer who reviewed the data. The reviewer produced a favourable report, 
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dated 15th January 2016, It contained recommendations regarding the sample 
size calculation. This report is included in Appendix 9.8. 
The trial oversight report was reviewed by the Principal Investigator and 
supervisors. At this stage it remained coded so that the research team were 
blinded to treatment allocation in the interim analyses. On the basis of the 
report, the SAP was amended and updated. A final version was finalised on 8th 
July 2016 and is included in Appendix 9.3 of this thesis. Final analyses of trial 
data from all infants were only undertaken once all infants had completed the 
trial and data collection was complete.  
3.24.2 Sample size calculation 
This section describes how the sample size was determined when the trial was 
originally designed. In summary, the sample size was originally based on data 
reported in a study by Singh et al. (Singh et al., 2006). In that paper the primary 
outcome data were reported as mean values. Therefore, when The VoluVent 
Trial was designed in 2013, parametric tests were used to calculate the sample 
size (see Section 3.24.3).  
However, the trial oversight reviewer identified that the primary outcome data 
were likely to be non-normally distributed. Therefore, a statistical approach 
based on Jung’s methodology (Jung, 2008) for randomised phase II trials with a 
prospective control arm was used. This is discussed in further detail in Section 
3.24.4. 
3.24.3 Original sample size calculation 
Data from two previous studies undertaken at the trial site (Sinha et al., 1997; 
Singh et al., 2006) were used as references with which to determine the original 
sample size.  
In the first of the two previous studies, VCV was compared with PLV in preterm 
infants with RDS (Sinha et al., 1997). Fifty infants (25 in each arm) weighing 
≥1200g were randomised to either VCV or PLV. Predetermined ‘success’ 
criteria were used as primary outcome measures (time to achieve an alveolar-
arterial oxygen gradient of <13 kPa or mean airway pressure of <8 cmH2O, 
maintained for >12 hours). In the VCV group, the mean (SD) time taken to 
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reach the ‘success’ criteria was 65.5 (55.7) hours. For infants in the PLV group 
the mean (SD) time was 125.8 (131.8) hours, p<0.001).  
In the second trial, Singh et al. (Singh et al., 2006) compared VCV and PLV in 
smaller and more premature infants using the same ‘success’ criteria. One 
hundred and nine infants (57 in one arm and 52 in the other arm) born between 
24 and 31 completed weeks’ gestation and weighing between 600 and 1500g 
were recruited. Although there was no significant difference between the two 
groups in the time taken to meet the ‘success’ criteria, infants assigned to VCV 
achieved the criteria faster than infants in the PLV group (mean time of 23 
hours versus 33 hours respectively, p=0.15). A sub-group analysis showed that 
in infants weighing <1000g, VCV significantly reduced the time taken to achieve 
the ‘success’ criteria compared with PLV (mean time of 21 hours and 58 hours 
respectively, p=0.03). 
Using known values from those two published trials, a one sample Student’s t-
test was used to calculate the sample size for The VoluVent Trial. This is 
demonstrated in Table 3-1. 
 Sinha et al 
(1997) 
Singh et al 
(2006) 
Known mean value of time to reach 
‘success’ criteria in VCV group 
65.6 hours 23 hours 
Standard deviation of the known value 55.7 19.26 
Reduction in time to reach ‘success’ 
criteria (effect size) 
33% 33% 
Mean value if a 33% reduction in time 
to ‘success’ criteria occurred in VG 
group 
43.952 hours 15.41 hours 
2-sided alpha 0.05 0.05 
Power 0.8 0.8 
Sample size 52 in each arm 51 in each arm 
Table 3-1 Determination of the sample size using data from previous studies 
A decision was made to use the data from Singh et al’s study (Singh et al., 
2006) on which to base the sample size calculation for The VoluVent Trial. The 
rationale for this was that the trial population and the clinical practices (including 
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use of maternal antenatal steroids and postnatal surfactant) reported in the trial 
by Singh et al. (Singh et al., 2006) more closely reflect current practice than 
those of Sinha et al. (Sinha et al., 1997).  
The hypothesis for The VoluVent Trial was that, because VG aims to target tidal 
volumes on a breath-by-breath basis, the time taken to reach the ‘success’ 
criteria would be shorter in the VG group. Therefore, a sample size of 102 
infants (51 in each arm) was needed to show a 33% reduction in the time taken 
to reach the ‘success’ criteria from 23 hours in the VCV group to 15 hours in the 
VG group with a 2-sided alpha of 0.05 and a power of 80%. To account for a 
10% withdrawal rate, the overall recruitment target was a sample size of 112 
infants.  
3.24.4 Retrospective sample size calculation using non-parametric tests 
As explained above the primary outcome data reported by Singh et al. (Singh et 
al., 2006) were reported as mean values. Therefore, a parametric test was used 
for the original sample size calculation for this trial. However, the trial oversight 
review identified that the data from The VoluVent Trial was likely to be non-
normally distributed. The independent reviewer recommended a retrospective 
calculation using a log-rank analysis of the data by Singh et al. (Singh et al., 
2006) to determine how to present the final analysis of data. 
Therefore a retrospective sample size calculation with a log-rank test was 
performed using the data reported by Singh et al. (Singh et al., 2006). The 
software used was Sample Size Tables for Clinical Studies Software Program, 
version 1.0, July 2008. The proportions were based on taking an end point of 48 
hours on the Kaplan-Meier curve from the paper by Singh et al. (Singh et al., 
2006) and comparing the associated cumulative survival points. At 48 hours, 
the cumulative survival in the VCV arm was approximately 0.05 and in the 
TCPL arm it was 0.15. If the expected number of events (number of infants 
reaching ‘success’ criteria) in each arm was 52 (based on the original sample 
size calculation for The VoluVent Trial), based on a power of 80%, an allocation 
ratio of 1:1, a first proportion of 0.05, a second proportion of 0.15 and 
significance level 0.05, the sample size would need to be 178.  
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Therefore the planned sample size of 112 infants for The VoluVent Trial was 
not large enough to have sufficient power to demonstrate statistical 
significance. A different approach was then considered. 
3.24.5 Analysis of results using differences in response rates. 
A different approach to statistical analysis of data from this trial is that described 
by Jung (Jung, 2008) for design of randomised phase II trials with a prospective 
control arm. This involves an initial stage of research that Jung refers to as the 
“single-stage” element. This equates to a pilot trial in which response rates to an 
intervention in the control arm and in the comparison arm are compared. If the 
difference between the response rates is sufficiently large that it reaches a pre-
determined level at the end of that initial stage, the trial team then proceeds to a 
larger trial to aim for a definitive result. If the difference between the two arms is 
not sufficiently large and does not reach the pre-determined level it is unlikely 
that there is a difference between the two arms and further research is not 
undertaken. 
Using this approach to interpret the data by Singh et al. (Singh et al., 2006), the 
response rates can be defined as the proportion of infants who had reached the 
‘success’ criteria at a particular time point. According to the Kaplan-Meier curve 
reported by Singh et al. (Singh et al., 2006), the cumulative survival (the 
proportion of infants that had not reached the ‘success’ criteria) at 48 hours was 
approximately 0.05 in the VCV arm and 0.15 in the TCPL arm. This also meant 
that the proportion reaching the ‘success’ criteria by 48 hours was 0.95 in the 
VCV group and 0.85 in the TCPL group. The sample size for that trial was 109, 
meaning that the response rate was approximately 85% of infants in the TCPL 
group and approximately 95% of infants in the VCV group at 48 hours. In terms 
of clinical relevance this meant that approximately 10 more infants had met the 
‘success’ criteria by 48 hours in the VCV group compared to the TCPL group. 
This is an important clinical difference between the two groups. 
The methodology described by Jung (Jung, 2008) was considered appropriate 
for The VoluVent Trial because, as a pilot trial, its aim was to inform the 
direction of a larger trial or body of research rather than provide a definitive 
result.  
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3.25 Descriptive analyses of the primary outcome measure 
The detailed SAP is included in Appendix 9.3. This was written and in place 
prior to analysis of any data. In summary, initial planned analyses of the primary 
outcome measure included summary statistics including:  
• the display of Kaplan-Meier time-to-event curves,  
• the presentation of median time-to-event values with interquartile ranges, 
• the use of Cox proportional hazards models to calculate hazards ratios 
and 95% CIs,  
• response rates (numbers of infants reaching the ‘success’ criteria) by 48 
hours. 
3.26 Analysis of covariates 
A Cox proportional hazards model was used to investigate the effects of 
covariates on the primary outcome. Univariable and multivariable analyses were 
undertaken. The results were presented as hazards ratios with CIs. The 
covariates likely to affect the primary outcome were specified a priori in the SAP 
and included:   
• the administration of maternal antenatal steroids prior to delivery,  
• the administration of postnatal steroids to facilitate extubation,  
• surgical management of a patent ductus arteriosus. 
3.27 Subgroup analyses 
Data from all infants in the trial were analysed and presented. Subgroup 
analyses were also undertaken as planned a priori in the SAP. Infants were 
stratified into two groups according to gestational age at birth; those born at <28 
weeks of gestation and those born between 28 – 33+6 weeks of gestation. Data 
from both stratified groups were presented and described separately but were 
not tested for significance. Descriptive analysis of primary outcome data on 
inborn infants was also planned. This was undertaken because inborn infants 
were managed according to the trial protocol throughout, whereas outborn 
infants were likely to receive other modes of ventilation before admission to the 
trial site.  
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3.28 Descriptive analyses of the secondary outcome measures 
Analyses of secondary outcome data were planned as descriptive analyses. 
The trial was not powered to detect significant differences in these outcomes 
measures. Normally distributed data were analysed using an unpaired t-test. 
Non-parametric tests (such as Mann Whitney U test or Wilcoxon rank-sum test) 
were used if data were not normally distributed. Presentation of continuous data 
was planned as mean values with standard deviations. For non-normally 
distributed data, presentation of data as median values with inter-quartile 
ranges was planned. Categorical data were compared using chi-squared 
contingency table tests or a Fisher exact test. Dichotomous outcomes were 
presented as odds ratios with CIs. 
3.29 Intention-to-treat definition 
Analyses were planned on an intention-to-treat basis. Initially, when prospective 
consent was planned, the intention-to-treat definition included comparing 
outcomes for all infants regardless of whether they received the allocated 
treatment mode. However, after the introduction of deferred consent, a strict 
intention-to-treat definition could no longer be applied as data from some 
randomised infants could not be analysed as consent was not obtained. 
Therefore, the intention-to-treat definition had to be modified to include only 
infants who were eligible, had been randomised, and for whom consent had 
been obtained.   
3.30 Statistical software 
All statistical analyses were carried out using an SPSS statistical software 
package (IBM SPSS Statistics for Macintosh, version 20.0.0, 2011. Armonk, 
NY: IBM Corp). 
3.31 Duration of the trial 
Infants remained in the trial until discharge from hospital, or until death if they 
died before discharge. Secondary outcome data were collected until either 
death or discharge form hospital. The active phase of the trial was planned to 
end when the last remaining infant had died or been discharged from hospital. 
Data collection and analysis, compilation of reports, presentation and 
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publication in peer-reviewed journals were planned to continue after the active 
phase.  
The planned recruitment period was based on previous data from the trial site. 
These are shown in Table 3-2. 
 
Year Number of infants born at 34 
weeks’ gestation requiring 
ventilation at the trial site 
January - December 2010 97 
January - December 2011 88 
January - December 2012 92 
Table 3-2 Data on ventilated infants born at <34 weeks’ gestation at the trial site 
from 2010 - 2012 
From January 2010 to December 2012 there were 277 infants born at <34 
weeks’ gestation who required ventilation at the trial site. This produced a mean 
of 7.7 potentially eligible infants per month. The anticipated recruitment rate was 
five infants per month into the trial. Recruitment was therefore expected to take 
18 - 24 months. 
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Chapter 4 Results  
4.1 Introduction 
The results of The VoluVent Trial are discussed in this chapter. The trial’s SAP 
was used as the framework for presentation of the results. In the SAP, some of 
the template tables indicated that mean values with standard deviations (SD) 
would be presented. In this chapter, the tables do present normally distributed 
data as mean values with SDs. However, if the data were not normally 
distributed, they were presented as median values with interquartile ranges 
(IQR).   
4.2 Recruitment 
Recruitment started on 22nd July 2013, and was completed on 6th December 
2015. This was longer than the initial expected recruitment period of 18 - 24 
months due to the challenges in seeking informed parental consent during the 
first four months of the trial, and due to an increase in the use of non-invasive 
ventilation in the trial unit (Garg, 2014). The final patient remaining in the trial 
was discharged from hospital in April 2016 and data collection was completed 
shortly after.  
During the trial period, 377 infants born at less than 34 weeks of gestation were 
screened for eligibility. Infants were included in the trial if they met all of the 
inclusion criteria, including the need for written parental consent.  
Therefore, only infants for whom consent was obtained were included in the 
trial. Figure 4-1 illustrates the reasons for screening and recruitment in 
accordance with CONSORT guidelines (Schulz et al., 2010).
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Figure 4-1 CONSORT diagram demonstrating the number of infants screened 
for eligibility, randomised, and enrolled into The VoluVent Trial.
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4.2.1 Recruitment before and after the introduction of deferred consent 
4.2.1.1 Before the introduction of deferred consent 
Recruitment was expected to take 18 - 24 months. It was anticipated that five 
infants per month would be recruited. However, as shown in Figure 4-2 the 
actual number of ventilated infants born at <34 weeks’ gestation and admitted 
to the trial site was lower than expected. Only six out of 24 potentially eligible 
infants were recruited in four months. This equates to a recruitment rate of 1.5 
infants per month. These infants were all inborn infants. Three of these infants 
were triplets whose parents had received written and verbal information about 
the trial at an earlier antenatal appointment. Therefore, only four sets of parents 
gave consent for the trial before the change in the consent method. 
4.2.1.2 Reasons for the initially low recruitment rate before the 
introduction of deferred consent 
Between July and November 2013, prospective consent was used. This meant 
that an infant could only be randomised if parents had given written informed 
consent within 12 hours of intubation. Prior to consent and randomisation, 
potentially eligible infants received VCV after birth in accordance with the 
protocol as this was standard unit practice.  
The clinical and research teams aimed to approach as many parents as 
possible before delivery if appropriate. Despite this the recruitment rate 
remained lower than expected. This was for three main reasons.   
1. The use of non-invasive respiratory support such as CPAP in very preterm 
infants had become more established as standard practice at the trial site. 
CPAP was initiated in many infants who showed good respiratory effort 
shortly after birth, even in those infants born ≥27 weeks’ gestation. Many of 
these infants subsequently did not require mechanical ventilation. Of those 
infants that did require mechanical ventilation, some were intubated after 24 
hours of age. As such they were not eligible for the trial. 
2. More parents declined prospective consent than expected. Parents were not 
asked to give their reasons for declining consent. However, many did 
spontaneously volunteer their reasons. Some did not want their infants to 
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take part in a research study. However, for many, their reasons for declining 
were related to the consent process. Some of these reasons are listed here. 
• There was not enough time before the consent deadline in which parents 
could consider the trial information or make a decision. 
• Some mothers remained affected by sedative medications received 
before or at the time of delivery. Therefore they were not able to consider 
the trial information in order to make an informed decision. 
• Parents knew that randomisation may lead to a change in their infant’s 
mode of ventilation. Some parents did not want the ventilator mode to be 
changed on the basis of their decision to give consent to the trial. 
• Some parents of twins or triplets did not want their infants randomised to 
different modes of ventilation. 
3. Eight eligible infants admitted to the trial site during this time were outborn 
infants whose parents were not present at the trial site within 12 hours of 
intubation. These eight infants represented 33% of eligible infants admitted 
to the trial site at that time. Their parents had to travel from the hospital at 
which their infants were born to the trial site. It could take several hours for 
parents to travel or be transferred between hospitals. The mothers of these 
infants were usually still receiving postnatal inpatient care themselves, 
meaning that they could not be transferred between hospitals quickly. 
Therefore, one third of the parents of eligible infants could not be 
approached because they were not present prior to the consent deadline. 
It was therefore apparent that prospective consent was not an appropriate 
method of consent for this type of trial. Parents who may, under different 
circumstances, be willing to consider their infant’s participation in a trial were 
not able to do so when asked to consider the trial information within a narrow 
timeframe shortly after the birth of their preterm infant. The consent process 
was deterring many from being able to make a decision about their infant’s 
participation. 
Therefore the research team sought approval for a major amendment to the 
protocol so that deferred consent could be used. They also sought an extension 
to the recruitment period of 12 months. This extension was requested to aim to 
ensure that the trial recruited the planned sample size. 
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4.2.2 Change to the consent method 
On 18th November 2013, the North East-York regional ethics committee granted 
a favourable opinion for a protocol amendment involving the use of deferred 
consent. South Tees Hospitals NHS Foundation Trust Research and 
Development department also approved the amendment and deferred consent 
was used from that point onwards. A request to extend the recruitment period to 
June 2016 was also approved. 
As illustrated in Figure 4-2, the recruitment rate improved with 107 infants being 
recruited over the next 25 months. This equates to a recruitment rate of 4.28 
infants per month after the introduction of deferred consent. 
 
Figure 4-2 Graph demonstrating expected versus actual rates of ventilated 
infants and of enrolled infants.  
4.2.3 Recruitment during the entire recruitment period 
Recruitment continued for a total of 29 months and was completed in December 
2015 when 113 infants had been enrolled (although one infant had been 
withdrawn due to ineligibility). During the entire recruitment period, 172 infants 
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were ventilated, giving an overall mean of 5.9 potentially eligible infants 
admitted to the trial site per month. A mean of 3.9 infants per month were 
recruited.  
Table 4-1 shows the comparisons of data from the trial’s screening log. It shows 
that the change in the consent method improved the recruitment of eligible 
infants. There was a marked reduction in the number of parents declining 
consent, as well as the number of parents who were not present within the 
consent deadline because their infants were outborn infants.  
This table is specifically used to demonstrate the impact of deferred consent on 
recruitment. Therefore it includes the infant who was enrolled but later 
withdrawn.  
 Before the 
change in 
consent 
process 
After the 
change in 
consent 
process 
Total 
recruitment 
period 
Months of recruitment, n 4 25 29 
Infants born at <34 weeks’ 
gestation, n 
47 330 377 
Infants born at <34 weeks’ 
gestation and did not 
receive ventilation within 24 
hours of birth, n 
22 172 194 
Infants born at <34 weeks’ 
gestation and did receive 
ventilation within 24 hours 
of birth, n 
24 148 172 
Infants randomised, n (%)  6 (25) 136 (92) 142 (82.6) 
Infants enrolled, n (%)  6 (25) 107 (78.7)* 113 (65.7)* 
Parents declined consent, n 
(%) 
9 (37.5) 11 (7.4) 20 (11.6) 
Parents not present at the 
trial site before the consent 
deadline because infants 
were outborn, n (%) 
8 (33.3) 8 (5.4) 16 (9.3) 
Parents not approached, n 
(%)  
3 (12.5) 6 (4.1) 9 (5.2) 
Table 4-1 Comparisons of eligibility screening log data before and after the 
change in consent method 
n, number; %, proportion of the infants who did receive ventilation within 24 
hours of birth. To demonstrate the impact of deferred consent on recruitment 
the numbers of enrolled infants here also include the infant who was enrolled 
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and later withdrawn from the trial. Therefore these numbers appear different to 
those in the CONSORT diagram in Figure 4-1.  
4.2.4 Other challenges affecting recruitment 
Despite the improvement in recruitment rate after the change in the consent 
method, there were still fewer eligible infants and fewer recruited infants than 
had been anticipated. The reasons for this are listed here:  
• Infants who did not receive mechanical ventilation within the first 
24 hours of life: Figure 4-1  demonstrates that 205 infants were born 
at <34 weeks’ gestation but did not receive mechanical ventilation 
within the first 24 hours of life. These infants were therefore not eligible 
for the trial. They represent 51.4% of all infants born at <34 weeks’ 
gestation and screened for eligibility for the trial. Specific data on 
further clinical management of these infants were not collected for the 
purpose of this trial. However, the broad categories regarding the 
respiratory management included: 
• no respiratory support required at any time, 
• supplemental oxygen only required, 
• non-invasive respiratory support only required. 
• non-invasive respiratory support only required initially but 
mechanical ventilation was received at some time after 24 hours 
of age. 
As specific data on these infants were not collected for this trial, the 
proportions of infants managed in each category are not known. 
However, the use of non-invasive respiratory support in very preterm 
infants (infants born between 28 and 31+6 weeks’ gestation) had 
become more established as standard practice at the trial site over 
recent years. 
• Infants of parents who had not yet arrived at the trial site: 16 
infants were not enrolled because their parents were not present in the 
neonatal unit before the consent deadline. Eight of these infants were 
admitted before the introduction of deferred consent. At that time, the 
protocol stated that consent had to be sought within 12 hours of 
intubation. The other eight infants were admitted to the trial unit after 
the introduction of deferred consent at which point consent had to be 
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sought within 36 hours of intubation. All of these 16 infants were 
outborn infants.  
4.2.5 Reasons for randomisation but non-enrolment 
Twenty-nine infants were randomised but not enrolled into the trial. For most, 
this was because deferred parental consent was not sought or obtained. The 
specific reasons are given below.  
• Two infants ventilated after 24 hours of life were randomised in error. 
As they did not meet the eligibility criteria consent was not sought and 
they were not enrolled into the trial. Both infants had been randomised 
to receive VG. 
• Two infants were initially randomised appropriately to one of the trial 
modes of ventilation but were then diagnosed with major congenital 
anatomical anomalies affecting the respiratory system and potentially 
affecting life expectancy. As this was one of the exclusion criteria these 
infants’ parents were not approached for consent. One of these infants 
had been randomised to VG and one had been randomised to VCV. 
• Twenty-five infants were randomised appropriately but subsequently 
deferred consent was not obtained. They did not therefore meet the 
inclusion criteria and were not enrolled into the trial. Two of these 
infants died before consent could be sought; one had been randomised 
to VCV and the other had been randomised to VG. The CONSORT 
diagram shown in Figure 4-1 demonstrates that the reasons for not 
obtaining consent were balanced between the two groups.  
4.2.6 Infant withdrawn from the study  
One infant was randomised on the basis of meeting all the inclusion criteria 
after birth. This was confirmed prospectively by the clinical team and later by 
the research team. The infant was enrolled into the trial when deferred consent 
was obtained. However, several days later, this infant was diagnosed with a 
condition consistent with one of the exclusion criteria. This congenital condition 
had not been suspected previously and was one that substantially altered the 
infant’s intrinsic respiratory condition. In addition, over time, management of this 
infant within the trial protocol contributed to the infant’s clinical instability. The 
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treating clinician and research team agreed that the infant should be withdrawn 
from the study at that point to prevent further clinical instability. After that point, 
the infant was no longer managed according to the trial protocol. The infant had 
not reached the ‘success’ criteria by this point. The parents were informed of 
the decision to withdraw the infant from the trial. 
After careful consideration the research team decided that data from this infant 
should be excluded from the analysis. This judgement was made because this 
infant’s condition made him/her inherently different from the rest of the trial 
population. Inclusion of this infant’s data in the analysis would bias the results 
because the continued need for ventilation was due to the underlying condition 
and not primarily due to ongoing lung disease associated with prematurity. 
Therefore previously collected data on this infant were destroyed, no further 
data were collected and no data from this infant were analysed. The parents 
were informed of this decision. 
The SAP stated that data would be analysed on an intention-to-treat basis for 
all infants from whom consent was obtained. Therefore this was a protocol 
deviation (Abraha et al., 2010). However, this was a pilot trial aiming to 
investigate the effects of VTV on a target population that was representative of 
preterm infants with RDS. This infant was not representative of the target 
population and excluding his/her data was acceptable in the context of a pilot 
trial (Giangregorio et al., 2015). This is discussed further in Section 7.5.5 of 
Chapter 7 Discussion. 
Therefore, the analysis of data from this trial was done on a modified intention-
to-treat basis (Abraha et al., 2010) although it shall be referred to as intention-
to-treat during this thesis. A discussion of its strengths and limitations is 
included in Section 7.5.5 of Chapter 7 Discussion.   
4.2.7 Delays in randomisation 
In two eligible infants, there was a substantial delay in randomisation.  
1. In one case, because the unit was busy, the infant was initially started on 
VCV with a plan to randomise shortly afterwards. Due to an oversight, 
the clinical team did not realise that randomisation had not occurred. The 
infant remained on VCV for 13 hours and 55 minutes until randomisation. 
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The infant’s allocated mode of ventilation was VG therefore the mode of 
ventilation was changed to VG at the time of randomisation. The infant’s 
primary outcome was therefore measured as the duration of time from 
the point of randomisation until the time at which the ‘success criteria’ 
were met.  
2. In the second case, the team consisted of new medical personnel who 
misinterpreted the protocol and thought that only the research team 
could randomise the infant. The infant was born at night and received 
VCV for seven hours and 40 minutes until the research team became 
aware the following morning. The infant was then randomised to the 
allocated mode of VCV. All other care of the infant prior to randomisation 
had been in accordance with the protocol. The infant had not yet reached 
the success criteria. Therefore, for this infant, the primary outcome was 
measured as the duration of time from starting VCV (not from the time of 
randomisation) until the time at which the ‘success criteria’ were reached.  
For the first infant, randomisation led to a change in the mode of ventilation and 
therefore the delay in randomisation substantially affected the measurement of 
the primary outcome. For the second infant, because randomisation did not 
lead to a change in the mode of ventilation, the primary outcome was not 
affected. For both infants, the delays were recorded in the case record forms as 
protocol deviations. 
4.2.8 Co-enrolment 
In October 2015, an amendment was made to the IRAS form at the request of 
the trial’s sponsor during a monitoring visit. The IRAS form had originally been 
completed correctly to state that infants being enrolled were not already 
enrolled in other studies. However, the sponsor requested clarification in the 
IRAS form that infants enrolled into this trial may subsequently also participate 
in other studies. This did not require an amendment to the protocol. Due to the 
timeframes in which consent had to be sought, consent for this trial was always 
sought before that of any other.  
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4.2.9 Practical strategies regarding co-enrolment 
Prior to the introduction of any new study within the unit the research team, the 
Consultant Neonatologists and senior nursing team discussed the potential 
challenges regarding co-enrolment. Any studies that were deemed to risk 
introducing bias, safety concerns or protocol contamination to studies already 
underway were not undertaken at that time.  
Six other research studies were undertaken at the trial site during The VoluVent 
Trial’s recruitment period. Not all of these studies took place at the same time 
and not all infants were enrolled into all studies. These studies are listed below.  
1. A multi-centre RCT comparing different thresholds for platelet transfusion 
in preterm infants (The PLaNeT-2 Trial, ISRCTN registry number 
87736839, https://doi.org/10.1186/ISRCTN87736839). The primary 
outcome was the proportion of infants who die or experience a major 
bleed up to and including day 28 of life. 
2. A single centre RCT comparing methods of measuring blood pressure in 
preterm infants (The NiDOP study, ISRCTN registry number 36164200, 
https://doi.org/10.1186/ISRCTN36164200). The primary outcome was 
the correlation of blood pressure measurements between three different 
methods. 
3. A multi-centre RCT comparing speeds of increasing enteral feeds in 
preterm infants (The SiFT Study, ISRCTN registry number 76463425, 
https://doi.org/10.1186/ISRCTN76463425). The primary outcome was 
survival free from moderate or severe neurodisability at 24 months’ 
corrected gestational age. 
4. A multi-centre RCT comparing lactoferrin with a placebo in preterm 
infants (The ELFIN study, ISRCTN registry number 88261002, 
https://doi.org/10.1186/ISRCTN88261002). The primary outcome was 
the incidence of late-onset infection prior to discharge from hospital.  
5. A multi-centre RCT comparing ibuprofen with a placebo in preterm 
infants (The Baby-OSCAR Trial, ISRCTN registry number 84264977, 
https://doi.org/10.1186/ISRCTN84264977). The primary outcome was 
death or BPD at 36 weeks’ corrected gestational age. 
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The above studies were deemed to be compatible with The VoluVent Trial. An 
independent expert clinical researcher from The University of Melbourne was 
consulted regarding The Baby-OSCAR Trial. His advice was that recruitment to 
The Baby-Oscar Trial would not bias the results of The VoluVent Trial, which 
was already nearing the end of recruitment. Only one infant enrolled into The 
VoluVent Trial was also co-enrolled into The Baby-OSCAR Trial. 
Two RCTs were not undertaken at the trial site as the research team deemed 
that the protocols were not compatible with that of The VoluVent Trial. One trial 
involved the comparison of different modes of non-invasive respiratory support 
as primary respiratory support in preterm infants (Roberts et al., 2016). The 
other was a pilot RCT investigating the effects of low-dose dexamethasone in 
preterm infants (The MINIDEX trial, ISRCTN registry number 81191607, 
https://doi.org/10.1186/ISRCTN81191607). The protocols of both trials would 
have substantially changed the respiratory management of some infants in The 
VoluVent trial that may have introduced bias into its trial population and its 
primary outcome.  
4.2.10 Strategy for consent procedures regarding co-enrolment  
For several months during the recruitment period, this trial was one of four trials 
into which preterm infants could be co-enrolled. All four trials required parents to 
be approached within 72 hours of their infants’ births. The research team and 
Consultant Neonatologists met to discuss this as it raised certain challenges. 
The following four principles were discussed. 
1. Multiple concurrent trials should not impose a burden on parents of 
eligible infants. 
2. Only parents should make the decision as to whether they want to 
receive trial information. Researchers and clinicians should not decide 
this on behalf of the parents. 
3. The four trial protocols were all compatible. 
4. Co-enrolment would improve research efficiency and increase the 
likelihood of recruiting to time and target. 
During this meeting a strategy was agreed upon and documented formally as 
minutes of the meeting. This strategy provided specific details about consent 
practices whilst the trials were in their concurrent recruitment phases. Consent 
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for The VoluVent Trial was always sought first as this trial had the earliest 
deadline in which to seek consent. The aim was to ensure that, wherever 
possible and appropriate, all parents were offered information about the trials 
whilst aiming to minimise the burden that this may impose parents.  
The minutes of this meeting were compiled and included in the trial master file 
for The VoluVent Trial and in the relevant files for the other trials.  
4.3 Maternal characteristics 
Data on baseline maternal and antenatal characteristics that were routinely 
recorded in the infants’ medical records and the national electronic database 
were collected. The results are shown in Table 4-2. The randomised nature of 
the study meant that any differences that arose should have been due to 
chance and should not be analysed for significance. Therefore no statistical 
analyses were performed on maternal and antenatal characteristics. 
There were small differences in the proportions of mothers receiving antenatal 
steroids between the two groups. Fifty-four mothers (98%) of infants in the VG 
group received at least one dose of antenatal steroids compared with 49 (85%) 
mothers in the VCV group. Forty-three mothers (78%) of infants in the VG group 
received at least two doses of antenatal steroids, compared with 36 (63%) of 
mothers respectively in the VCV group. 
Exposure to antenatal steroids was analysed as a covariate for the primary 
outcome and is discussed in section 4.11. The trial site’s Annual Neonatal 
Reports published in 2013 and 2014 (Garg et al., 2013; Garg, 2014) state that 
the antenatal steroid administration rates for women who delivered infants 
between 24 and 34 weeks’ gestation in 2014 were 87% and 83% respectively. 
Therefore a greater proportion of infants in this trial were exposed to at least 
one dose of antenatal steroids prior to delivery than the overall population at the 
trial site. 
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Characteristics VG 
n = 55 
VCV 
n = 57 
Total 
population 
n = 112 
Maternal age, years, mean (SD) 29 (4.8) 28 (5.4) 28 (5) 
Maternal ethnicity 
White British, n (%) 
Asian Bangladeshi, n (%) 
White, other, n (%) 
 
49 (89.1) 
5 (9.1) 
1 (1.8) 
 
53 (93) 
3 (5.3) 
1 (1.7) 
 
102 (91.1) 
8 (7.1) 
2 (1.8) 
Multiple pregnancy 
Yes, n (%) 
No, n (%) 
 
18 (32.7) 
37 (67.3) 
 
22 (38.6) 
35 (61.4) 
 
40 (35.7) 
72 (64.3) 
At least one dose of antenatal steroids 
received 
Yes, n (%) 
No, n (%) 
                         
 
54 (98.2) 
1 (1.8) 
                   
                   
49 (86) 
8 (14) 
                    
                  
103 (92) 
9 (8) 
Doses of antenatal steroids received 
None, n (%) 
1 dose, n (%) 
≥2 doses, n (%) 
                         
1 (1.8) 
11 (20) 
43 (78.2) 
                        
8 (14) 
13 (22.8) 
36 (63.2) 
                      
9 (8) 
24 (21) 
79 (71) 
PPROM before 23 weeks’ gestation 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
2 (3.6) 
52 (94.5) 
1 (1.8) 
 
1 (1.8) 
56 (98.2) 
0 (0) 
 
3 (2.7) 
108 (96.4) 
1 (0.9) 
GBS isolated in this pregnancy 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
10 (18.2) 
43 (78.2) 
2 (3.6) 
 
12 (21.1) 
44 (77.2) 
1 (1.8) 
 
22 (19.6) 
87 (77.7) 
3 (2.7) 
Maternal chorioamnionitis 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
12 (21.8) 
38 (69.1) 
5 (9.1) 
 
13 (22.8) 
37 (64.9) 
7 (12.3) 
 
25 (22.3) 
75 (67) 
12 (10.7) 
Maternal fever ≥38 oC 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
5 (9.1) 
41 (74.5) 
9 (16.4) 
 
3 (5.3) 
45 (78.9) 
9 (15.8) 
 
8 (7.1) 
86 (76.8) 
18 (16.1) 
Antenatal antibiotics 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
12 (21.8) 
24 (43.6) 
19 (34.5) 
 
17 (29.8) 
17 (29.8) 
23 (40.4) 
 
29 (25.9) 
41 (36.6) 
42 (37.5) 
Intrapartum antibiotics received >4 hours 
before delivery 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
                      
                   
20 (36.4) 
29 (52.7) 
6 (10.9) 
                         
                    
15 (26.3) 
31 (54.4) 
11 (19.3) 
                      
                    
35 (31.3) 
60 (53.6) 
17 (15.2) 
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Any positive maternal culture 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
26 (47.3) 
26 (47.3) 
3 (5.5) 
 
23 (40.4) 
32 (56.1) 
2 (3.5) 
 
49 (43.8) 
58 (51.8) 
5 (4.5) 
Antepartum haemorrhage 
Yes, n (%) 
No, n (%) 
Missing data, n (%)  
 
15 (27.3) 
40 (72.7) 
0 (0) 
 
17 (29.8) 
38 (66.7) 
2 (3.5) 
 
32 (28.6) 
78 (69.6) 
2 (1.8) 
Pregnancy-induced hypertension 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
2 (3.6) 
53 (96.4) 
0 (0) 
 
3 (5.3) 
52 (91.2) 
2 (3.5) 
 
5 (4.5) 
105 (93.8) 
2 (1.8) 
Pre-eclampsia 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
3 (5.5) 
52 (94.5) 
0 (0) 
 
3 (5.3) 
52 (91.2) 
2 (3.5) 
 
6 (5.4) 
104 (92.9) 
2 (1.8) 
Eclampsia 
Yes, n (%) 
No, n (%) 
 
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
Maternal diabetes 
Yes, n (%) 
No, n (%) 
 
2 (3.6) 
53 (96.4) 
 
2 (3.5) 
55 (96.5) 
 
4 (3.6) 
108 (96.4) 
Table 4-2 Baseline maternal and antenatal characteristics 
SD, standard deviation; n, number.  
Missing data refer to variables for which the information was missing from the 
infants’ notes. Where missing data are not indicated these variables had 
complete data collection. 
4.4 Trial population 
The baseline characteristics of the trial population are described in Sections 4.4 
to 4.6. As with the maternal data, randomisation meant that any differences that 
arose should have been due to chance and should not be analysed for 
significance. Therefore no statistical analyses have been performed on the trial 
population’s baseline characteristics. 
4.4.1 Delivery details for all infants  
The characteristics of all infants at the time of delivery are summarised in Table 
4-3. The mean gestational age was 27.7 weeks’ gestation at birth. Similar 
values were seen when the two intervention groups were compared. The 
 80 
median birth weight was 1030g for the total population. Similar median weights 
were seen when the two intervention groups were compared.  
In both groups there were more male than female infants (57.1% male and 
42.9% female). The difference was slightly greater in the VCV group in which 
61.4% were male and 38.6% were female. However the absolute differences in 
numbers of infants is small.  
Table 4-3 demonstrates the following points. 
• The majority of infants was born at the trial site. 
• Almost two thirds of infants had been exposed to labour before delivery. 
• Approximately half were delivered by lower segment caesarian section 
(LSCS).  
• Approximately one third of the infants in the trial were part of a multiple 
pregnancy at delivery. 
• Almost two thirds of infants were intubated in the delivery room meaning 
that one third received NIV for some time in the delivery room and in the 
neonatal unit prior to intubation. 
• The median age of infants on admission to the unit was 29 minutes (IQR 
19.25 – 53 minutes), indicating that most infants received intensive care 
according to the trial protocol shortly after birth. 
Three infants were born unexpectedly at home. These infants were transferred 
from home to the trial site by ambulance. Given that these infants first received 
neonatal care at the trial site, they were designated as inborn infants for the 
purpose of data analysis. These infants were all randomised to the VCV arm of 
the trial. 
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Characteristics VG 
n = 55 
VCV 
n = 57 
Total 
population 
n = 112 
Completed weeks of gestation at 
the time of delivery, mean (SD) 
27.5 (2.89)                          27.8 (2.37)                         27.7 (2.63) 
Birth weight, g, median (IQR) 
 
1020 
(700 – 1530) 
1080 
(800-1395) 
1030 
(780-1475)  
Small for gestational age 
Yes, n (%) 
No, n (%) 
 
11 (20) 
44 (80) 
 
10 (17.5) 
47 (82.5) 
 
21 (18.8) 
91 (81.2) 
Gender 
Male, n (%) 
Female, n (%) 
 
29 (52.7) 
26 (47.3) 
 
35 (61.4) 
22 (38.6) 
 
64 (57.1) 
48 (42.9) 
Born at the trial site 
Inborn, n (%) 
Outborn, n (%) 
 
45 (81.8) 
10 (18.2) 
 
43 (75.4) 
14 (24.6) 
 
88 (78.6) 
24 (21.4) 
Labour before delivery 
Yes, n (%) 
No, n (%) 
 
34 (61.8) 
21 (38.2) 
 
37 (64.9) 
20 (35.1) 
 
71 (63.4) 
41 (36.6) 
Born by LSCS  
Yes, n (%) 
No, n (%) 
 
24 (43.6) 
31 (56.4) 
 
33 (57.9) 
24 (42.1) 
 
57 (50.9) 
55 (49.1) 
Breech presentation  
Yes, n (%)  
No, n (%) 
Missing data, n (%) 
 
20 (36.4) 
31 (56.4) 
4 (7.3) 
 
20 (35.1) 
28 (49.1) 
9 (15.8) 
 
40 (35.7) 
59 (52.7) 
13 (11.6) 
Multiple births 
Yes, n (%) 
No, n (%) 
 
19 (34.5) 
36 (65.5) 
 
21 (36.8) 
36 (63.2) 
 
40 (35.7) 
72 (64.3) 
Intubated in the delivery room 
Yes, n (%) 
No, n (%) 
 
34 (61.8) 
21 (38.2) 
 
37 (64.9) 
20 (35.1) 
 
71 (63.4) 
41 (36.6) 
Apgar score at five minutes, n, 
median (IQR) 
Missing data, n (%) 
 7              
(5.75 – 9) 
5 (9.1) 
8                  
(7 – 9) 
6 (10.5) 
  8                  
(6 – 9) 
11 (9.8) 
Age on admission to trial site, 
minutes, median (IQR) 
29 
(18 – 39) 
31 
(19.5–67.5) 
29 
(19.25 – 53) 
First recorded admission 
temperature, oC, mean (SD) 
Missing data, n (%)  
                              
37 (0.85)           
1 (1.8) 
              
36.9 (0.71)        
4 (7) 
                          
37 (0.78)        
4 (4.5) 
Table 4-3 Delivery details for all infants 
SD, standard deviation; g, grams; IQR, interquartile range; n, number; LSCS, 
lower segment caesarian section; oC, degrees Celsius. Missing data refer to 
variables for which the information was missing from the infants’ notes. Where 
missing data are not indicated these variables had complete data collection. 
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4.5 Comparison of the stratified groups according to gestational age 
Infants were stratified before randomisation into two groups, those born at <28 
weeks of gestation and those born at 28 – 33+6 weeks’ of gestation. This 
stratification was chosen because more mature preterm infants (28 – 33+6 
weeks’ gestation) are more likely to be ready for extubation earlier than 
extremely preterm infants (<28 week’s gestation). Therefore infants were 
stratified before randomisation in order to ensure a balance of randomisation 
across the trial population.  
The stratification achieved a good balance of randomisation across the two sub-
groups. There were 54 infants in the sub-group of infants born at <28 weeks’ 
gestation, 27 of whom were randomised to VG and 27 of whom were 
randomised to VCV. There were 58 infants in the 28 – 33+6 weeks’ gestation 
sub-group, 28 of whom were randomised to VG and 30 of whom were 
randomised to VCV.  
The characteristics of the two sub-groups are shown in Table 4-4 and Table 
4-5. These prognostic characteristics were well balanced between the two arms 
of the trial in both sub-groups. These characteristics can affect a preterm 
infant’s requirement for mechanical ventilation therefore the balance indicates 
effective randomisation. The absolute numbers of infants in these sub-groups 
are small but in a larger trial the effect of some of these characteristics could be 
investigated using regression analyses.  
4.5.1 Infants born at <28 weeks’ gestation 
In infants born at <28 weeks’ gestation, the mean (SD) gestational age was 
25.4 (1.29) weeks’ gestation. The median (IQR) birth weight was 775g (657 – 
916 g).  
Table 4-4 demonstrates the following points. 
• Just over half of the infants were male (53.7%). The proportion of male 
infants in the VCV group was slightly greater (59.3%) although the 
absolute numbers are small. 
• A greater proportion of infants in the VG group (88.9%) was born at the 
trial site compared with the VCV group (66.7%). However, the absolute 
numbers are small. 
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• Approximately three quarters of infants had been exposed to labour 
before delivery. 
• The proportion of infants born by LSCS was greater in the VCV group 
(48.1%) compared with the VG group (22.1%) although the absolute 
numbers are small. 
• The majority of infants (88.9%) was intubated in the delivery room. 
Similar proportions were seen in the VCV and the VG groups meaning 
that most infants received mechanical ventilation within the first few 
minutes of life. 
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Characteristics VG 
N = 27 
VCV 
N = 27 
Total 
population 
N = 54 
Completed weeks of gestation at 
the time of delivery, mean (SD) 
25 (1.43) 25.7 (1.07) 25.4 (1.29) 
Birth weight, g, median (IQR) 700 
(650 – 915) 
800 
(680 – 920) 
775 
(657 – 916) 
Small for gestational age 
Yes, n (%) 
No, n (%) 
 
7 (25.9) 
20 (74.1) 
 
6 (22.2) 
21 (77.8) 
 
13 (24.1) 
41 (75.9) 
Gender 
Male, n (%) 
Female, n %) 
 
13 (48.1) 
14 (51.9) 
 
16 (59.3) 
11 (40.7) 
 
29 (53.7) 
25 (46.3) 
Born at the trial site 
Inborn, n (%) 
Outborn, n (%) 
 
24 (88.9) 
3 (11.1) 
 
18 (66.7) 
9 (33.3) 
 
42 (77.8) 
12 (22.2) 
Labour before delivery 
Yes, n (%) 
No, n (%) 
 
21 (77.8) 
6 (22.2) 
 
20 (74.1) 
7 (25.9) 
 
41 (75.9) 
13 (24.1) 
Born by LSCS 
Yes, n (%) 
No, n (%) 
 
6 (22.2) 
21 (77.8) 
 
13 (48.1) 
14 (51.9) 
 
19 (35.2) 
35 (64.8) 
Breech presentation 
Yes, n (%) 
No, n (%) 
Missing data, n (%) 
 
11 (40.1) 
15 (55.6) 
1 (3.7) 
 
11 (40.7) 
12 (44.4) 
4 (14.8) 
 
22 (40.7) 
27 (50) 
5 (9.3) 
Multiple births 
Yes, n (%) 
No, n (%) 
 
8 (39.6) 
19 (70.4) 
 
9 (33.3) 
18 (66.7) 
 
17 (31.5) 
37 (68.5) 
Intubated in the delivery room 
Yes, n (%) 
No, n (%) 
 
23 (85.2) 
4 (14.8) 
 
25 (92.6) 
2 (7.4) 
 
48 (88.9) 
6 (11.1) 
Apgar score at five minutes, 
median (IQR) 
Missing data, n (%) 
 7                     
(5 – 8) 
2 (7.4) 
 7                     
(5 – 9) 
4 (14.8) 
 7                   
(5 – 8) 
6 (11.1) 
Age on admission to trial site, 
minutes, median (IQR) 
25 
(18 – 37) 
29 
(22 – 198) 
 28.5 
(19.5 – 43.5) 
First recorded admission 
temperature, oC, mean (SD) 
Missing data, n (%) 
36.9 (1.01)         
1 (3.7) 
36.9 (0.82)        
3 (11.1) 
36.9 (0.92)      
4 (7.4) 
Table 4-4 Delivery details of infants born at <28 weeks’ gestation 
SD, standard deviation; g, grams; IQR, interquartile range; n, number; LSCS, 
lower segment caesarian section; oC, degrees Celsius. Missing data refer to 
variables for which the information was missing from the infants’ notes. Where 
missing data are not indicated these variables had complete data collection. 
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4.5.2 Infants born at 28 – 33+6 weeks’ gestation 
In infants born at 28 – 33+6 weeks’ gestation, the mean (SD) gestational age 
was 30 (1.51) weeks’ gestation. The median (IQR) birth weight was 1415g 
(1164 – 1703g). When the two groups were compared the median birth weight 
in the VG group was slightly higher than in the VCV group (1525g and 1355g 
respectively).  
Table 4-5 demonstrates the following points. 
• Sixty per cent of infants were male. Similar proportions were seen in both 
the VCV and VG groups 
• Approximately three quarters of infants were born at the trial site and this 
proportion was similar in the VCV and VG groups. 
• When compared with the total population, and with the infants born at 
<28 weeks’ gestation, fewer infants in this group had been exposed to 
labour before delivery (51.7%) and a larger proportion (65.5%) were born 
by LSCS. 
• Only 39.7% of infants born in this gestational age group were intubated 
in the delivery room, meaning that most of these infants received NIV 
initially before receiving mechanical ventilation later on in the neonatal 
unit.  
Given the increased use of NIV as primary respiratory support for preterm 
infants (Schmölzer et al., 2013) the finding that most infants in this group 
received NIV initially was not surprising.  
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Characteristics VG 
N = 28 
VCV 
N = 30 
Total 
population 
N = 58 
Completed weeks of gestation at the 
time of delivery, mean (SD) 
30 (1.5) 30 (1.5) 30 (1.51) 
Birth weight, g, median (IQR) 1525 
(1116–1787) 
1355 
1167–1655) 
1415 
(1164-1703) 
Small for gestational age 
Yes, n (%) 
No, n (%) 
 
4 (14.3) 
24 (85.7) 
 
4 (13.3) 
26 (86.7) 
 
8 (13.8) 
50 (86.2) 
Gender 
Male, n (%) 
Female, n %) 
 
16 (57) 
12 (43) 
 
19 (63) 
11 (37) 
 
35 (60) 
23 (40) 
Born at the trial site 
Inborn, n (%) 
Outborn, n (%) 
 
21 (75) 
7 (25) 
 
22 (73.3) 
8 (26.7) 
 
43 (74.1) 
15 (25.9) 
Labour before delivery 
Yes, n (%) 
No, n (%) 
 
13 (46.4) 
15 (53.6) 
 
17 (56.7) 
13 (43.3) 
 
30 (51.7) 
28 (48.3) 
Born by LSCS 
Yes, n (%) 
No, n (%) 
 
18 (64.3) 
10 (35.7) 
 
20 (66.7) 
10 (33.3) 
 
38 (65.5) 
20 (34.5) 
Breech presentation,  
Yes, n (%) 
No, n (%)  
Missing data, n (%) 
 
9 (32.1) 
16 (57.1) 
3 (10.7) 
 
9 (30) 
16 (53.3) 
5 (16.7) 
 
18 (31) 
32 (55.2) 
8 (13.8) 
Multiple births 
Yes, n (%) 
No, n (%) 
 
11 (39.3) 
17 (60.7) 
 
12 (40) 
18 (60) 
 
23 (39.7) 
35 (60.3) 
Intubated in the delivery room 
Yes, n (%) 
No, n (%) 
 
11 (39.3) 
17 (60.7) 
 
12 (40) 
18 (60) 
 
23 (39.7) 
35 (60.3) 
Apgar score at five minutes, median 
(IQR) 
Missing data, n (%) 
 8                     
(6 – 9) 
3 (10.7) 
 8                   
(7 – 9) 
2 (6.7) 
8                 
(7 – 9) 
5 (8.6) 
Age on admission to trial site, 
minutes, median (IQR) 
30.5  
(21.3 – 270.5) 
34.5  
(16.8 – 56.5) 
31         
(18.5–56.5) 
First recorded admission 
temperature, oC, median (IQR) 
Missing data, n (%) 
37                    
(36.6 – 37.4) 
0 (0) 
37                  
(36.6 – 37.4) 
1 (3.3) 
37            
(36.6–37.4) 
1 (1.7) 
Table 4-5 Delivery details of infants born at 28 – 33-6 weeks’ gestation 
SD, standard deviation; g, grams; IQR, interquartile range; n, number; LSCS, 
lower segment caesarian segment; oC, degrees Celsius. Missing data refer to 
variables for which the information was missing from the infants’ notes. 
Variables without missing data had complete data collection. 
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4.6 Comparison of infants born at the trial site with those born in other 
hospitals 
Eighty-eight infants (79%) were recorded as inborn infants. These include three 
infants who were born at home and brought by ambulance to the trial site. 
These three infants first received hospital care at the trial site. Therefore they 
were recorded as inborn infants for the purpose of data collection and analysis. 
Twenty-four infants were born at other hospitals and transferred to the trial site 
for intensive care.  
Randomisation was balanced in the group of inborn infants with 45 infants 
randomised to VG and 43 randomised to VCV.  
Table 4-6 demonstrates the following points. 
• Equal proportions of inborn infants received non-invasive ventilation 
(NIV) prior to trial entry. The median duration of NIV prior to trial entry 
was longer in the VCV group than in the VG group.  
• Inborn infants in the VCV group did not receive any other modes of 
ventilation prior to trial entry because VCV was the standard mode of 
ventilation used in the trial unit. Any infant receiving ventilation before 
randomisation was ventilated using VCV. Therefore these infants did 
not require a change of ventilation if they were then randomised to 
VCV.  
• Thirteen (29%) of infants in the VG group received a different mode of 
ventilation prior to randomisation and trial entry. Ten infants received 
VCV before randomisation to VG. Four of these had been enrolled 
before the introduction of deferred consent. They were managed 
according to the protocol which stated that they should receive VCV 
prior to randomisation. Two infants received pressure-limited modes of 
ventilation. One infant initially received HFOV but was changed to VG 
at less than 24 hours of age.  
Therefore, the respiratory management of infants before enrolment was similar 
between groups. The only important difference between groups was that some 
infants in the VG group had received a difference mode of ventilation before 
randomisation. This was to be expected given the reasons stated above. 
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Characteristics VG 
n = 45 
VCV 
n = 43 
Total 
population 
n = 88 
Non-invasive ventilation used 
before intubation, n (%) 
9 (20) 9 (21) 18 (21) 
Duration of non-invasive ventilation 
before intubation, minutes, median 
(IQR) 
202 
(140 – 585) 
375 
(156 – 1055) 
233 
(148-710) 
Age at intubation, minutes, median 
(IQR)  
12 
(8 – 73) 
12.5 
(7 – 55) 
12 
(7 – 62) 
Doses of surfactant received 
before starting trial mode, n (%) 
No doses  
One dose  
                        
                      
0 (0) 
45 (100) 
                              
                       
4 (9.3) 
39 (90.7) 
                   
                  
4 (4.5) 
84 (95.5)  
Doses of surfactant received in 
total, n (%) 
One dose 
Two doses 
Three doses 
                     
                   
23 (51.1) 
17 (37.8) 
5 (11.1) 
                       
                       
22 (51.2)                       
17 (39.5) 
4 (9.3) 
              
                    
45 (51.1) 
34 (38.6) 
9 (10.3) 
Mechanically ventilated before 
starting trial mode, n (%) 
13 (29) 0 (0) 13 (15) 
Duration of mechanical ventilation 
prior to starting trial mode, minutes, 
median (IQR) 
195 
(66 – 525) 
N/A 195 
(66 – 525) 
Age when starting trial mode, 
minutes, median (IQR) 
50 
(29 – 202) 
40 
(25 – 75) 
44 
(27 – 136) 
Table 4-6 Respiratory management received by inborn infants before enrolment 
n, number; IQR, interquartile range  
Table 4-7 shows the respiratory management of outborn infants before 
enrolment. This sub-group was very small, consisting of only 24 infants. Ten 
infants were randomised to VG and 14 were randomised to VCV.  
All outborn infants received mechanical ventilation prior to trial entry. This may 
have affected the results of their outcome measures. For this reason a sub-
group analysis of the primary outcome was undertaken excluding outborn 
infants as planned a priori in the SAP (see Appendix 9.3). Although there was 
an imbalance between groups in the numbers of infants receiving NIV at the 
referring hospital, the absolute numbers are very small. The median duration of 
time spent on NIV prior to receiving ventilation was similar between the two 
groups.  
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Characteristics VG 
n = 10 
VCV 
n = 14 
Total 
population 
n = 24 
Level 1 referring unit, n (%) 8 (80) 10 (71) 18 (75) 
Non-invasive ventilation used at 
referring hospital, n (%) 
8 (80) 4 (29) 12 (50) 
Duration of non-invasive ventilation 
at referring hospital, minutes, 
median (IQR) 
205 
(165 – 285) 
200 
(153 – 494) 
205 
(165 – 285) 
Mechanically ventilated at referring 
hospital, n (%) 
10 (100) 14 (100) 24 (100) 
Age at intubation, minutes, median 
(IQR)  
185 
(81 – 317) 
36 
(4.5 – 182) 
109 
(5 – 222) 
Doses of surfactant received at 
referring hospital, n (%) 
No doses  
One dose  
Two doses  
Three doses  
                        
                      
0 (0) 
8 (80) 
2 (20) 
0 (0) 
                         
                      
0 (0) 
9 (64.3) 
4 (28.6) 
1 (7.1) 
                         
                      
0 (0) 
17 (70.8) 
6 (25) 
1 (4.2) 
Doses of surfactant received in 
total, n (%) 
One dose 
Two doses 
Three doses 
 
                        
7 (70) 
3 (30) 
0 (0) 
 
                       
7 (50) 
4 (28.6) 
3 (21.4) 
                        
                       
14 (58.3) 
7 (29.2) 
3 (12.5) 
Duration of ventilation prior to 
starting trial mode of ventilation, 
minutes, mean (SD) 
186 (82) 372 (146) 295 (153) 
Age on arrival at trial site, minutes, 
median (IQR) 
375 
(326 – 442) 
395 
(346 – 577) 
378 
(341 – 498) 
Age when starting trial mode, 
minutes, median (IQR) 
375 
(329 – 449) 
421 
(346 – 556) 
393 
(341 – 499) 
Table 4-7 Respiratory management of outborn infants before enrolment 
n, number; IQR, interquartile range; SD, standard deviation  
 
Table 4-8 shows a comparison between inborn and outborn infants in their 
characteristics and respiratory management before enrolment. They were 
similar in mean gestational ages and in birth weights. A larger proportion of 
outborn infants had received NIV prior to starting mechanical ventilation 
compared with inborn infants. Outborn infants were much older by the time they 
started the trial mode of ventilation (median age 393 minutes, IQR 341 – 499 
minutes) compared with the inborn infants (median age 44 minutes, IQR 27 – 
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136 minutes). This is not surprising and reflects the fact that outborn infants 
required transfer to the trial unit for intensive care.  
Characteristics Inborn infants 
n = 88 
Outborn 
infants 
n = 24 
Completed weeks of gestation at the time of 
delivery, mean (SD) 
28 (2.7) 28 (2.3) 
Birth weight, g, median (IQR) 1030 
(725 – 1465) 
1170 
(850 – 1490) 
Gender: 
Male, n (%) 
Female, n (%) 
 
48 (57) 
37 (43) 
 
16 (59) 
11 (41) 
Singleton, n (%) 55 (65) 17 (63) 
Received non-invasive ventilation before 
intubation, n (%) 
18 (21) 12 (50) 
Duration of non-invasive ventilation before 
intubation, minutes, median (IQR) 
233 
(148 – 710) 
205 
(165 – 285) 
Age at intubation, minutes, median (IQR) 12 
(7 – 62) 
109 
(5 – 222) 
Doses of surfactant received in total, n (%) 
One dose 
Two doses 
Three doses 
                         
45 (51.1) 
34 (38.6) 
9 (10.2) 
                          
14 (58.3) 
7 (29.2) 
3 (12.5) 
Duration of ventilation prior to starting trial 
mode of ventilation, minutes, median (IQR) 
195 
(66 – 525) 
275 
(197 – 374) 
Age at start of trial mode, minutes, median 
(IQR) 
44 
(27 – 136) 
393 
(341 – 499) 
Table 4-8 Characteristics of inborn infants compared to outborn infants 
SD, standard deviation; g, grams; IQR, interquartile range; n, number 
4.7 Assessment of radiological features of RDS  
The case record forms had been designed to collect data on the radiographic 
appearances of enrolled infants. A Consultant Paediatric Radiologist, who was 
blinded to allocation, initially reviewed the first chest x-rays of enrolled infants to 
ascribe a standardised score to the appearances of RDS. It was intended that 
this score would form part of the comparison of respiratory status between the 
two groups of infants.  
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However, it quickly became apparent that this information could not be collected 
consistently or accurately. Many infants had been intubated and given 
surfactant before their first chest x-ray, meaning that the radiological features of 
RDS were altered or completely absent. The x-rays of some outborn infants 
were not transferred from the local hospital to the trial site’s radiology computer 
system, despite repeated requests by the Principal Investigator. These x-rays 
could not be analysed. Therefore data collection of chest x-ray appearances 
was discontinued. 
4.8 Comparison of respiratory parameters and ventilatory requirements 
after starting the trial mode  
Table 4-9 shows a comparison of the respiratory parameters and ventilatory 
requirements of all infants randomised to VG and to VCV. These data were 
collected from the nursing observation charts in the infants’ medical records. In 
accordance with routine clinical practice they were recorded by the nurses as 
soon as possible after starting the trial mode.   
In both groups, the ventilatory support after starting the trial modes was similar. 
The mean and peak airway pressures, the expired tidal volumes and the FiO2 
were low in both groups. The median lung compliance for the total population 
was 0.34 mls/cmH2O/kg with similar values seen in both intervention groups. 
This is consistent with the reference value of 0.35 mls/cmH2O/kg (Van Kaam et 
al., 2015) for infants born at 27 – 28 weeks’ gestation who had received 
surfactant for RDS in the first three days of life. This is also consistent with the 
median gestational age of the trial population (28 weeks’ gestation).  
Therefore, these parameters demonstrate the following points.  
• The trial population had low ventilatory and oxygen requirements at the 
point of trial entry. This is common for preterm infants who have just 
received surfactant. 
• Their respiratory parameters were within acceptable ranges for ventilated 
preterm infants.   
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Parameters VG 
n = 55 
VCV 
n = 57 
Total 
population 
n = 112 
Mean airway pressure, cm 
H2O, median (IQR) 
9 
(8 – 11) 
9 
8 – 10) 
9 
(8 – 10) 
Peak inspiratory pressure, 
cm H2O, mean (SD) 
 
21 (6.8) 19 (4.1) 20 (5.6) 
Expired tidal volume, 
mls/kg, median (IQR) 
4.4 
(4 – 4.7) 
4.3 
(3.7 – 5.4) 
4.4 
(3.9 – 5) 
Minute volume, mls/minute, 
median (IQR) 
280 
(185 – 390) 
295 
(190 – 400) 
290 
(190 – 395) 
Fraction of inspired oxygen, 
median (IQR) 
0.23 
(0.21 – 0.32) 
0.23 
(0.21 – 0.39) 
0.23 
(0.21 – 0.35) 
Lung compliance, 
ml/cmH2O/kg, median (IQR) 
0.33 
(0.23 – 0.51) 
0.38 
(0.2 – 0.49) 
0.34 
(0.21 – 0.49) 
Table 4-9 Comparison of respiratory and ventilation parameters at trial entry 
IQR, interquartile range; SD, standard deviation; n, number; mls, millilitres; kg, 
kilogram 
4.9 Respiratory support and adjunctive weaning therapies received before 
and during the trial 
This sub-section discusses the respiratory support and adjunctive therapies 
received by enrolled infants before and during the trial. Much of these are 
descriptive data regarding compliance with the trial protocol. However, data 
from outborn infants are included and, before arriving at the trial site, they did 
not receive management according to the protocol. Table 4-10 presents a 
summary of these data.  
4.9.1 Presentation of data on infants enrolled before the introduction of 
deferred consent 
Before the introduction of deferred consent six infants were enrolled. They were 
randomised after consent had been obtained. They had all received VCV before 
randomisation. During that time their management whilst on VCV was in 
accordance with the trial protocol on ventilation of infants allocated to VCV. 
Four of these infants were randomised to VCV. Therefore, randomisation did 
not lead to a change in their ventilatory management. In Table 4-10 they are 
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included in the numbers of infants who received ventilation before 
randomisation. The duration of time that they received VCV before 
randomisation is included in the data on the ‘duration of ventilation before 
randomisation’. However, because they were managed according to the trial 
protocol before randomisation, this duration of time is also included in their 
primary outcome data (Section 4.10). 
Two infants were randomised to VG. They had received VCV before 
randomisation. The duration of time that they received VCV before 
randomisation is included in the data on the ‘duration of ventilation before 
randomisation’. 
4.9.2 Infants receiving mechanical ventilation before enrolment 
Twenty-three (42%) infants in the VG group received a different form of 
mechanical ventilation before trial entry compared with 16 (28%) of infants in 
the VCV group. This reflects the fact that some infants in the VG group initially 
received VCV as part of standard unit practice before randomisation to VG.  
4.9.3 Infants receiving only the trial modes of ventilation 
The trial protocol stated that infants should receive their randomised mode of 
ventilation with no cross-over between modes. They could receive high 
frequency oscillatory ventilation (HFOV) if their conditions deteriorated whilst on 
their trial mode.  
• There was no cross-over between modes during the trial.  
• The majority of infants (87%) received only their randomised mode of 
ventilation, excluding the use of HFOV also.  
• Nine infants (8%) received HFOV prior to reaching the primary 
outcome as part of the pragmatic trial protocol. The results of these 
infants were analysed on an intention-to-treat basis.  
This demonstrates excellent compliance with these elements of the protocol. 
4.9.4 Extubation of infants before reaching the ‘success’ criteria 
There were three reasons for extubation of infants before reaching the ‘success’ 
criteria. These included 
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• planned extubation due to hypocarbia, 
• planned extubation to avoid prolonged ventilation, 
• unplanned but successful extubation. 
These events were recorded as part of a process evaluation of the trial. They 
were accepted by the research team as part of ensuring safety of the 
participants whilst maintaining feasibility of the protocol. If these infants 
remained extubated for at least 24 hours they were recorded as having met the 
primary outcome. The time of extubation was used instead of the ‘success’ 
criteria. 
4.9.4.1 Planned extubation due to hypocarbia 
This was undertaken at the decision of the treating clinician in infants who were 
hypocarbic despite weaning of ventilation. This was done in order to prevent 
further hypocarbia which is associated with cause brain injury in preterm infants 
(Erickson et al., 2002).  
Three infants were extubated before reaching the ‘success’ criteria due to 
hypocarbia. Two were in the VCV group. One infant was extubated one hour 
before the SBT was due. The second infant had a MAP of 7-8 cmH2O but not 
consistently <8cmH2O for six consecutive hours. That infant had a SBT due to 
hypocarbia, despite the other ‘success’ criteria not being met. The SBT was 
successful and the infant was extubated. The third infant was in the VG group 
and was extubated three hours before the SBT was due. 
4.9.4.2 Planned extubation to prevent prolonged ventilation  
Seven infants were ventilated for prolonged periods. When their ventilation was 
able to be weaned, these infants reached a point whereby they appeared ready 
for extubation but were not generating mean airway pressures that were 
consistently <8cmH2O. In order to prevent further prolonged ventilation that 
would not provide benefit to these infants, the treating Consultant Neonatologist 
made the decision to extubate these infants despite the fact that they had not 
reached the ‘success’ criteria. This was accepted by the research team as part 
of ensuring safety of the participants. Two of the seven infants were in the VG 
group and five were in the VCV group.  
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4.9.4.3 Unplanned but successful extubation 
Six infants had unplanned but successful extubations, four in the VCV group 
and two in the VG group. These exubations occurred before reaching the 
‘success’ criteria. These infants were assessed as having good respiratory drive 
and the treating clinicians decided to support them with CPAP rather than 
reintubate them just for the purpose of the trial.  
4.9.5 Delay in performing the spontaneous breathing test 
Due to the busy and unpredictable nature of a neonatal unit, some of the SBTs 
were not performed immediately. If an SBT was delayed by more than one hour 
it was recorded as being delayed. The number of infants affected by a delayed 
SBT, and the reasons for delayed SBTs, were recorded as part of a process 
evaluation in assessing the feasibility of the trial. In most infants, the delay was 
due to clinical emergencies or priorities involving other infants in the unit. 
Delays that were due to protocol misinterpretation or oversight were discussed 
with clinical team members to aim to ensure that they did not occur again. 
In 23 infants the SBT was delayed but was subsequently successful when it 
was undertaken. Eleven infants were in the VG group. The median (IQR) delay 
in this group was 108 (80 – 168) minutes. Twelve infants were in the VCV 
group. The median (IQR) delay in this group was 114 (79 – 210) minutes. 
Therefore the difference in the median delays between groups was six minutes.  
These data demonstrate that the duration of delays, and the numbers of infants 
affected by them, were comparable between groups. The subsequent effects on 
the primary outcome results were balanced between groups. 
4.9.6 Spontaneous breathing test performed early 
In one infant, the SBT was performed one hour early in error. This infant was 
outborn and received ventilation during transfer from the birth hospital to the 
trial site. The infant was randomised to VG on arrival at the trial site. Over the 
next five hours the infant had a MAP <8 cmH2O and FiO2 ≤0.35 and the SBT 
was performed early in error. The infant was then extubated successfully. That 
infant’s primary outcome is recorded as five hours. 
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4.9.7 Use of volume SIMV 
As part of the trial protocol infants in the VCV group could receive volume 
synchronised intermittent mandatory ventilation (SIMV) with pressure support 
ventilation (PSV) as part of the weaning process.  
Twenty-three infants (40%) in the VCV group received volume SIMV with PSV 
before the ‘success’ criteria were reached. They spent a median of 12 hours 
(IQR 10 – 52 hours) on VCV before changing to SIMV plus PSV. They then 
received a median of four hours (3 – 12 hours) on SIMV plus PSV before 
reaching the ‘success’ criteria. 
Another six infants received volume SIMV after the primary outcome had been 
reached and before the infants were extubated. Twenty-eight infants (49%) did 
not receive volume SIMV with PSV at all. In these infants, ventilation was 
weaned using VCV alone.  
4.9.8 Infants receiving other modes of ventilation 
Before reaching the primary outcome, four infants received a mode of 
ventilation outwith the trial protocol. These infants all received pressure-limited 
ventilation as part of a clinical decision made at the time by the treating 
neonatologist due to concerns about the infant’s condition. Data from these 
infants were analysed on an intention-to-treat basis according to the groups to 
which they were randomised. 
A further four infants received a pressure mode of ventilation whilst still in the 
trial but after they had reached the primary outcome. In three of these four 
cases this was specifically due to a clinical decision made by the treating 
neonatologist. In the fourth case, this was due to an oversight by a member of 
the clinical team and their trial mode was restarted after 45 minutes. 
Therefore the number of protocol deviations regarding mode of ventilation was 
very low. This demonstrates very good compliance with the protocol in this 
regard. It shows that implementation of a protocol that excludes pressure-
limited modes of ventilation is feasible in a busy tertiary NICU.  
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4.9.9 Infants receiving pressure-limited ventilation for PDA surgery 
Nine infants received surgery for ligation of a patent ductus arteriosus (PDA). 
Six of these infants underwent this surgery before reaching the ‘success’ 
criteria. These infants had to be transferred to the regional cardiothoracic centre 
for surgery. All of these infants were ventilated at all times during transfer 
between the two sites and during surgery. During transfer they received 
pressure-limited ventilation using either a Globe-TrotterTM (Draeger) transport 
ventilator or a ProPaq (Welch Allyn) ventilator. During surgery they received 
pressure-limited ventilation using a Primus® (Draeger) ventilator.  
Of the six infants who underwent PDA ligation surgery before reaching the 
‘success’ criteria, two were in the VCV group and four were in the VG group. 
The mean (SD) duration of time spent on pressure-limited ventilation during 
transfer and surgery was 9.75 (1.7) hours in the VG group. The duration of time 
for both infants in the VCV group was nine hours each.  
These data were analysed on an intention-to-treat basis as pre-specified in the 
SAP. These periods of ventilation did not represent a protocol deviation. 
Therefore they are not included in the data showing the numbers of infants 
receiving pressure-limited ventilation at other times. 
4.9.10 Adjunctive therapies to facilitate extubation 
The therapies used to facilitate extubation were  
• caffeine citrate, 
• postnatal corticosteroid administration, 
• surgical ligation of a PDA. 
The protocol stated that all infants should receive caffeine citrate before 
reaching the ‘success’ criteria. Caffeine citrate is used as part of standard 
practice within the unit to increase the chance of successful extubation 
(Henderson-Smart D., 2010).  
Criteria for the use of postnatal corticosteroids or PDA ligation were not 
specified in the protocol. The treating Consultant Neonatologists made 
decisions on an individual case basis to give these therapies to infants whose 
ventilation was difficult to wean. As they could have affected the primary 
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outcome, the SAP specified that these therapies would be analysed as possible 
covariates using Cox proportional regression analyses (see Section 4.11).  
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Treatment received before and 
during the trial 
VG 
n = 55 
VCV 
n = 57 
Total 
population 
n = 112 
Received non-invasive ventilation 
before randomisation, n (%) 
17 (31) 13 (23) 30 (27) 
Duration of non-invasive ventilation 
before randomisation, minutes, 
median (IQR) 
204* 
(158 – 454)                    
240 
(165 – 724) 
215* 
(160 – 549)                         
Received mechanical ventilation 
before randomisation, n (%) 
23 (42) 16 (28) 39 (35) 
Duration of mechanical ventilation 
before randomisation, minutes, 
median (IQR) 
193 
(70 – 285) 
358 
(275 – 505) 
262 
(165 – 404) 
Received trial intervention only after 
randomisation and before reaching 
primary outcome, n (%) 
45 (82) 52 (91) 97 (87) 
Received HFOV as part of trial 
protocol before reaching primary 
outcome or before the data were 
censored, n (%) 
5 (9) 4 (7) 9 (8) 
Duration of time on trial mode of 
ventilation before changing to HFOV, 
hours, median (IQR) 
86  
(9 – 507) 
38.5 
(11 – 295) 
39 
(10 – 324) 
Duration of time on HFOV before 
primary outcome or before data were 
censored, hours, median (IQR) 
13 
(2.8 – 67) 
49 
(39 – 247) 
36  
(9 – 82) 
Received HFOV as part of trial 
protocol at any time, n (%) 
7 (13) 6 (11) 13 (12) 
Received pressure-limited ventilation 
after enrolment into trial and before 
reaching the primary outcome, n (%) 
2 (4) 
 
2 (4) 4 (4) 
Received pressure-limited ventilation 
after enrolment into trial but after 
reaching the primary outcome, n (%) 
0 (0) 4 (7) 4 (4) 
Did not reach ‘success’ criteria (data 
censored), n (%) 
Died 
Transferred to another 
hospital 
Total (died or transferred) 
                          
                        
3 (5) 
3 (5)                 
                       
6 (11) 
                               
                         
1 (2) 
2 (4)                 
                       
3 (5) 
                          
                        
4 (4) 
5 (4) 
                       
9 (8) 
Received more than one period of 
ventilation, n (%) 
At least two periods 
Two periods  
Three periods  
Four periods  
 
 
12 (22) 
8 (15) 
4 (7) 
0 (0) 
 
 
13 (23) 
10 (18) 
2 (4) 
1 (2) 
 
 
25 (22) 
18 (16) 
6 (5) 
1 (1) 
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Received postnatal steroid therapy 
to facilitate extubation before 
reaching primary outcome, n (%) 
4 (7) 2 (4) 6 (5) 
Received postnatal steroid therapy 
to facilitate extubation at any time, n 
(%) 
8 (15) 7 (12) 15 (13) 
Received surgical treatment of PDA 
before reaching primary outcome, n 
(%) 
4 (7) 2 (4) 6 (5) 
Table 4-10 Summary of respiratory support and adjunctive weaning therapies 
received by trial infants 
n, number; IQR, interquartile range; HFOV, high frequency oscillatory 
ventilation; PDA, patent ductus arteriosus 
*Data missing for one infant 
4.9.11 Summary of respiratory support and adjunctive therapies 
These data demonstrate that the trial protocol was implemented successfully 
with very few deviations. Eighty-seven per cent of infants received only the 
mode of ventilation to which they were randomised and very few required HFOV 
as part of the trial protocol. This represents very good protocol compliance. 
Very few infants received pressure-limited ventilation outwith the protocol and 
very few required additional therapies to facilitate extubation. 
This demonstrates that the protocol was feasible and sufficiently pragmatic for 
use within a neonatal intensive care setting.  
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4.10 Primary outcome results 
4.10.1 Presentation of data 
The primary outcome results are presented here. The reasons for censoring 
data are described first. Summaries of the primary outcome results for the 
whole population and for the pre-specified sub-groups are then presented.  
The data are presented as the duration of time in hours from starting the trial 
mode until reaching the ‘success’ criteria. The data were initially collected and 
recorded in minutes for precision. They were not normally distributed, with most 
infants reaching the ‘success’ criteria within 48 hours. Therefore, in order to 
analyse and present the data in a relevant format they were converted into 
hours before analysis and analysed as integers. Numbers with a proportion of 
an hour that was <0.5 of an hour were rounded down to the nearest integer. 
Numbers with a proportion of an hour that was ≥0.5 of an hour were rounded up 
to the nearest integer.  
For example, if, after conversion from minutes to hours, an infant’s primary 
outcome result was 18.3 hours, it was rounded down to 18 hours before 
analysis. If the result was 18.6 hours, it was rounded up to 19 hours before 
analysis. 
4.10.2 Censored data 
Nine infants did not reach the primary outcome because they died or were 
transferred to another hospital before reaching the primary outcome. The 
primary outcome data for these infants are therefore censored as part of the 
Kaplan Meier time-to-event analyses.  
Six infants in the VG group had censored data, of which three died and three 
were transferred to another hospital to receive further intensive care. Two of the 
three infants were transferred for surgery. The third was transferred to the 
surgical centre whilst ventilated in order to be closer to the family home.  
Three infants in the VCV group had censored data. Two died prior to reaching 
the primary outcome. One was transferred to the surgical centre for surgery. 
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4.10.3 Median time to ‘success’ criteria 
Table 4-11 shows the median times to ‘success’ criteria for the whole trial 
population and for the pre-specified sub-groups. The results are presented 
according to the infants’ randomised modes. As this trial was not powered to 
show statistical significance the results have been presented as medians and 
hazard ratios (HRs) with CIs. 
The HRs were calculated using the VCV group as the reference group and the 
VG group as the comparator group. In summary, HRs <1 favour the VCV group 
and HRs >1 favour the VG group. The closer a HR is to 1, the smaller the 
difference in the hazard rate (number of infants reaching the ‘success’ criteria at 
any time) between the two groups. The CIs reflect the degree of certainty 
around each HR. The wider the CI, the greater the degree of uncertainty and 
vice versa (Parmar et al., 1995).  
The results for each individual group or sub-group will be discussed in Sections 
4.10.5 to 4.10.7. The apparent discrepancy in favourable results between the 
median data and the HRs will be discussed in more detail in those sections.  
 
Group or sub-
group 
Median time to success criteria, 
hours, (95% CI) 
Hazard ratio 
(95% CI) VG VCV 
All infants 
n = 112 
23 
(10.78 – 35.22) 
36  
(18.0 – 53.97) 
0.93 
(0.63 – 1.37) 
Infants <28 
weeks’ gestation 
n = 54 
102 
(90.00 – 204.69) 
79 
(0.00 – 177.71) 
0.76 
(0.42 – 1.37) 
Infants 28 - 
33+6 weeks’ 
gestation 
n = 58 
19 
(16.48 – 21.52) 
24 
(11.92 – 36.08) 
1.6 
(0.92 – 2.82) 
Inborn infants 
n = 88 
32 
(13.46 – 50.54) 
25 
(12.6 – 37.4) 
0.75 
(0.47 – 1.19) 
Table 4-11 Comparison of median time to success criteria 
CI, confidence interval; n, number. 
4.10.4 Comparison of response rates using early phase trial methodology 
As explained in the SAP (version 11, dated 8th July 2016, Appendix 9.3) a 
review of the sample size calculation after the trial oversight review revealed 
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that a log-rank statistical comparison of the time-to-event analyses would be 
underpowered. Therefore, an alternative early phase trial methodology 
approach, amenable to pilot trials, was used to compare response rates 
between the two groups (Jung, 2008). This was pre-specified in Sections 6.2 
and 6.3 of the SAP. A ‘response’ was defined as an infant reaching the 
‘success’ criteria. The response rates were the numbers of infants reaching the 
‘success’ criteria in the VCV and VG groups. 
 
 
Time since starting 
trial mode 
(hours) 
Response rate (number of infants reaching 
‘success’ criteria) 
VG 
n = 55 
VCV 
n = 57 
48 34 (62%) 33 (58%) 
Table 4-12 Comparison of response rates using early phase trials methodology 
(Jung, 2008) 
Table 4-12 shows that, 48 hours after starting the trial mode, there was no 
difference in response rate between the two groups. The SAP had stated that a 
15% difference between groups would be considered potentially significant and 
that this would be one of the thresholds used to proceed to a larger trial. 
However, this difference as based on an expected response rate at 48 hours of 
80% in the VCV group and 95% in the VG group. As shown in Table 4-12, the 
response rates were lower at this time point in both groups. Therefore, in this 
trial, fewer infants than expected had reached the ‘success’ criteria by 48 hours. 
The decision to use 48 hours as the time point at which to measure response 
rates was based on previous trial data from the same trial site reported by Singh 
et al. (Singh et al., 2006). That trial compared VCV with PLV and used similar 
but not identical ‘success’ criteria. Those factors may explain the differences 
between that trial and this one in response rates seen at 48 hours in this trial. 
This is discussed further in Section 7.5.1 of Chapter 8 Discussion. 
Table 4-13 and Figure 4-4 show that the rates at which infants reached the 
‘success’ criteria were highest in the first 24 hours. When using this time point 
for comparison of response rates, the difference between groups is greater 
(11%). Therefore use of this time point might be a more appropriate end-point in 
future research. 
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Time since starting 
trial mode 
(hours) 
Response rate (number of infants reaching 
‘success’ criteria) 
VG 
n = 55 
VCV 
n = 57 
24 29 (53%) 23 (40%) 
48 34 (62%) 33 (58%) 
72 38 (69%) 36 (63%) 
96 40 (73%) 39 (68%) 
Table 4-13 Rates at which infants reached the ‘success’ criteria in the first 96 
hours. 
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4.10.5 Primary outcome results for the whole trial population 
Figure 4-3 and Figure 4-4 show the Kaplan-Meier curves for the time-to-event 
analyses for the whole trial population. Both curves represent the same data 
and analysis. Figure 4-3 shows the entire curves. Figure 4-4 focuses on the first 
240 hours. In doing so, Figure 4-4 demonstrates more clearly that that rates at 
which infants reached the ‘success’ criteria were highest within the first few 
days, and particularly within the first 24 hours.  
 
 
Figure 4-3 Kaplan-Meier curves of time to ‘success’ criteria for all infants 
 
Time	(hours)	 250	 500	 750	 1000	 1250	 1500	
Number	remaining	(VCV)		 6	 4	 3	 2	 1	 0	
Number	remaining	(VG)	 7	 6	 6	 3	 1	 1	
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Figure 4-4 Kaplan-Meier curves of time to ‘success’ criteria for all infants 
focusing on the first 240 hours 
In the VG group the time taken to reach the ‘success’ criteria ranged from five 
hours to 1663 hours. In the VCV group the time taken to reach the ‘success’ 
criteria ranged from six hours to 1484 hours. 
The median time to ‘success’ criteria in the VG group was 23 hours (95% CI 11 
– 35 hours). In the VCV group, the median time to ‘success’ criteria was 36 
hours (95% CI 18 – 54 hours). This result favours VG and represents a clinically 
relevant difference of 13 hours between groups in the time taken to be ready for 
extubation.  
Although the median time to ‘success’ criteria favours VG the HR of 0.93 (95% 
CI 0.63 – 1.37) just favours VCV. The HR is close to one, indicating that there is 
little overall difference between the groups in the time to reach the ‘success’ 
criteria. A HR of 0.93 means that, at any time during the trial, infants in the VCV 
group had a seven per cent increased chance of reaching the ‘success’ criteria 
compared with infants in the VG group.  
Time	(hours)	 24	 48	 72	 96	 120	 144	 168	 192	 216	 240	
Number	remaining	(VCV)		 33	 24	 21	 15	 13	 10	 8	 7	 6	 6	
Number	remaining	(VG)	 25	 19	 15	 12	 11	 9	 9	 9	 7	 7	
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This discrepancy may be explained by examining the curves in greater detail 
and considering the rates at which infants reached the ‘success’ criteria earlier 
in the trial compared with later in the trial. Figure 4-4 shows that infants in the 
VG group reached the ‘success’ criteria at a faster rate than those in the VCV 
group between approximately 20 hours and 130 hours. This explains why the 
median time to ‘success’ criteria favours the VG group. After approximately 130 
hours, infants in the VCV group reached the ‘success’ criteria at a faster rate 
than those in the VG group. In both groups very few infants had not yet reached 
the ‘success’ criteria by 160 hours. However, those infants account for the long 
‘tail ends’ of the curves in Figure 4-3. It is those infants that likely influence the 
overall HR which presumes that the hazard rate remains constant at all time 
points (Parmar et al., 1995).  
4.10.6 Effect of gestational age on the primary outcome  
4.10.6.1 Infants born at <28 weeks’ gestation 
There were 54 infants in this sub-group. Twenty-seven were randomised to 
VCV and 27 to VG. In this sub-group, the time taken to reach the ‘success’ 
criteria ranged from six to 1484 hours (62 days) in the VCV group and five 
hours to 1663 hours (69 days) in the VG group. 
Figure 4-5 shows the Kaplan-Meier curves of time to reach the ‘success’ criteria 
in infants born at <28 weeks’ gestation. The median time to ‘success’ criteria 
was 79 hours (95% CI 0.0 – 177.71) in the VCV group and 102 hours (95% CI 
0.0 – 204.69) in the VG group. This difference of 23 hours is clinically relevant. 
The HR was 0.76 (95% CI 0.42 – 1.37). This indicates that, at any time during 
the trial, infants in the VCV group had a 24% increased chance of reaching the 
‘success’ criteria than infants in the VG group. The median time to ‘success’ 
criteria and the HR appear to favour VCV in this gestational age group. 
However, the 95% CIs reflect the large degree of uncertainty associated with 
these results in this sub-group. 
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Figure 4-5 Kaplan-Meier curves of duration of time to ‘success’ criteria for 
infants born at <28 weeks’ gestation 
Infants born at <28 weeks’ gestation accounted for all of the infants in the trial 
who had not yet reached the ‘success’ criteria after one week (168 hours). 
Seventeen infants had not reached the ‘success’ criteria by 168 hours. Five 
infants had not reached the ‘success’ criteria by 1000 hours.  
Eight infants in this gestational age group had censored data. Three infants had 
been randomised to VCV; two died and one was transferred to another site 
before reaching the ‘success’ criteria. Five infants had been randomised to VG; 
two died and three were transferred to another site before reaching the 
‘success’ criteria. Therefore the censoring of data due to death was balanced 
between groups. No deaths were attributed to the mode of ventilation (see 
Section 4.15 Serious Adverse Events).  
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4.10.6.2 Infants born at 28 – 33+6 weeks’ gestation 
There were 58 infants in this sub-group. Thirty infants were randomised to VCV 
and 28 to VG. Figure 4-6 shows the Kaplan-Meier curves for the time-to-event 
analyses of these infants. In this sub-group, the time taken to reach the 
‘success’ criteria ranged from six to 161 hours in the VCV group and eight to 79 
hours in the VG group.  
 
Figure 4-6 Kaplan-Meier curves of time to ‘success’ criteria for infants born at 
28 – 33+6 weeks’ gestation 
The median time to ‘success’ criteria was 24 hours (95% CI 11.9 – 36.1) in the 
VCV group and 19 hours (95% CI 16.5 – 21.5) in the VG group. The clinical 
relevance of a difference of five hours is unknown. However the HR was 1.6 
(95% CI 0.92 – 2.82). This indicates that, at any time during the trial, infants in 
the VG group had a 60% increased chance of reaching the ‘success’ criteria 
than infants in the VCV group.  
These results strongly favour VG in infants born within this gestational age 
group. They demonstrate a bigger treatment effect when modes are compared 
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than the effect seen in infants born at <28 weeks’ gestation. In addition the 95% 
CIs are narrower and the lower CI is only just below one. These highlight the 
strength of the treatment effect of VG. 
Only one infant in this gestational age group had censored data. That infant had 
been randomised to VG but the death was not attributed to the mode of 
ventilation.  
4.10.7 Inborn infants 
There were 88 inborn infants. Forty-three infants were randomised to VCV and 
45 to VG. Figure 4-7 shows the Kaplan-Meier curves for the time-to-event 
analyses of these infants. In this sub-group, the time taken to reach the 
‘success’ criteria ranged from six to 964 hours in the VCV group and eight to 
1663 hours in the VG group.  
 
 
Figure 4-7 Kaplan-Meier curves of time to ‘success’ criteria for inborn infants  
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The median time to ‘success’ criteria was 25 hours (95% CI 12.6 – 37.4) in the 
VCV group and 32 hours (95% CI 13.5 – 50.5) in the VG group. The clinical 
relevance of a difference of seven hours is unknown. The HR was 0.76 (95% CI 
0.48 – 1.2).  
Therefore the median time to ‘success’ criteria and the HR appear to favour 
VCV in this gestational age group. However, the 95% CIs reflect the large 
degree of uncertainty associated with these results in this sub-group. 
4.11 Effects of covariates on the primary outcome 
A Cox proportional hazards model was used to investigate the effects of 
covariates on the primary outcome. Univariable analyses were undertaken to 
analyse the effect of these variables on the time to reach the ‘success’ criteria. 
Multivariable analyses were then undertaken to investigate their effect on the 
HR of primary outcome. The covariates are listed here. 
1. Gestational age (<28 weeks’ gestation and 28-33+6 weeks’ gestation) 
2. The administration of two doses of maternal antenatal corticosteroids 
before delivery.  
3. The administration of postnatal glucocorticosteroids (dexamethasone) 
to infants to facilitate extubation. 
4. Surgical ligation of a PDA to facilitate extubation. 
4.11.1 Gestational age as a covariate 
Gestational age had been predicted to be a covariate that may influence the 
primary outcome. As such, it was used as a stratification factor prior to 
randomisation. Its effect on the primary outcome is presented here.  
Figure 4-8 represents the Kaplan-Meier curves showing the effect of gestational 
age (either <28 weeks’ gestation or 28 – 33+6 weeks’ gestation) on the time to 
reach the ‘success’ criteria. The mode of ventilation has not been included in 
this curve. Therefore the dashed line represents the time to reach the ‘success’ 
criteria in all infants between 28 and 33+6 weeks’ gestation, regardless of their 
mode of ventilation. The solid line shows the same for infants born at <28 
weeks’ gestation. 
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Figure 4-8 Kaplan-Meier curves showing the effect of gestational age on time to 
‘success’ criteria 
This figure demonstrates that infants born at 28 – 33+6 weeks’ gestation reach 
the success criteria much quicker than infants born at <28 weeks’ gestation. As 
has been discussed previously this was not unexpected. This figure justifies the 
decision to use gestational age as a stratification factor before randomisation. 
Table 4-14 shows the results of univariable analysis investigating the effect of 
gestational age on the time to reach ‘success’ criteria. It demonstrates that 
gestational age had a strong effect on the primary outcome. There was a very 
large difference in the median time to reach the ‘success’ criteria. At any time 
during the trial, infants in the 28 - 33+6 weeks’ gestational age group had a 
three fold increase in the chance of reaching the ‘success’ criteria than those in 
the <28 weeks’ gestation group. The 95% CIs of the HR do not cross below 1. 
Therefore these results strongly favour the effect of the 28 – 33+6 weeks’ 
gestation variable on the primary outcome.  
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Factor Level Median time to ‘success’ 
criteria, hours (95% CI) 
HR 
(95% CI) 
Gestational 
age  
< 28 weeks 
(reference variable) 
93  
(9.75 – 176.25) 
1.00 
28 – 33+6 weeks 
(comparator variable) 
20  
(16.72 – 23.28) 
3.32  
(2.1 – 5.25) 
Table 4-14 Univariable analysis of the effect of gestational age on the time to 
reach the ‘success’ criteria using the Cox proportional hazards model 
CI, confidence interval; HR, hazard ratio 
The multivariable analysis is shown in Table 4-15. This table demonstrates that 
the chance of reaching the ‘success’ criteria (the hazard) according to the mode 
of ventilation was altered when gestational age was taken into account.  
Factor Level Adjusted HR (95% CI) 
Arm VCV (reference variable) 1.00 
 VG (comparator variable) 1.066 (0.72 – 1.59) 
Gestational 
age  
< 28 weeks  (reference variable) 1.00 
28 – 33+6 weeks (comparator variable) 3.36 (2.11 – 5.34) 
Table 4-15 Multivariable analysis of the effect of gestational age on the time to 
reach the ‘success’ criteria using the Cox proportional hazards model 
HR, hazard ratio; CI, confidence interval 
As discussed previously, when analysing the effect of trial mode alone, the HR 
for the whole population was 0.93. When adjusted for gestational age, the HR 
became 1.066. This indicates that infants had a 6% greater chance of reaching 
the ‘success’ criteria in the VG arm when the effects of gestational age were 
taken into account. The HR changed from one that originally appeared to favour 
VCV to one that favoured VG when adjusted for gestational age.  
These results demonstrate that, when accounting for gestational age, infants 
reached the ‘success’ criteria faster in the VG group. Gestational age has a 
strong effect on the time taken to be ready for extubation. Therefore these 
results strongly support further investigation of the effect of gestational age 
when designing a larger trial.  
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4.11.2 Exposure to antenatal corticosteroids as a covariate 
Administration of antenatal corticosteroids to women in preterm labour improves 
certain important outcomes in preterm infants, including a reduction in the 
incidence of RDS and in the need for mechanical ventilation (Roberts et al., 
2017). Therefore it was predicted to be a covariate that might reduce the time to 
reach ‘success’ criteria in infants who had been exposed to antenatal 
corticosteroids. 
A complete course of antenatal corticosteroids at the trial site consisted of two 
doses of betamethasone, with the second dose being given at least 24 hours 
and up to seven days before delivery of the infant. The medical records of both 
inborn and outborn infants in this trial commonly recorded the numbers of doses 
administered to mothers and the dates at which they were administered but not 
the timings. Therefore for the purpose of this trial, a complete course was 
considered to be two doses of maternal corticosteroids administered up to one 
week before the birth of the infant.  
Figure 4-9 and Figure 4-10 show the Kaplan-Meier curves for the time-to-event 
analyses according to exposure to maternal antenatal corticosteroids. Both 
curves represent the same data and analysis. Figure 4-9 shows the entire 
curves. Figure 4-10 focuses on the first 240 hours. 
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Figure 4-9 Kaplan-Meier curves showing the effect of two doses of antenatal 
corticosteroids on time to ‘success’ criteria 
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Figure 4-10 Kaplan-Meier curves showing the effect of two doses of antenatal 
corticosteroids on time to ‘success’ criteria focusing on the first 240 hours 
Seventy-nine infants were exposed to two doses of maternal antenatal 
corticosteroids. Thirty-three infants were not exposed to two doses. These 
Kaplan-Meier curves show that the administration of two doses of antenatal 
corticosteroids did not appear to effect the time to reach the ‘success’ criteria. 
However, Figure 4-10 shows that the Kaplan Meier curves cross each other 
several times, violating the assumption that the hazard risk remains constant 
over time.  
Table 4-16 shows that the median time to ‘success’ criteria when infants were 
exposed to two doses of antenatal corticosteroids was 25 hours. In infants not 
exposed to two doses, it was 40 hours. However, the HR favours the group who 
were not exposed to antenatal corticosteroids. This discrepancy may be related 
to the small number of infants in each sub-group. The wide CIs highlight the 
lack of certainty about these results.  
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Factor Level Median time to 
‘success’ criteria,  
hours (95% CI) 
HR  
(95% CI) 
Two doses of 
maternal 
antenatal 
corticosteroids 
No   
(reference variable) 
40  
(8.81 – 71.19) 
1.00 
Yes  
(comparator variable) 
25  
(13.12 – 36.88) 
0.89  
(0.57 – 1.38) 
Table 4-16 Univariable analysis of the effect of administration of maternal 
antenatal corticosteroids on the time to reach the ‘success’ criteria using the 
Cox proportional hazards model 
CI, confidence interval; HR, hazard ratio 
The multivariable analysis is shown in Table 4-17. This table demonstrates that 
the original HR comparing the trial modes was not altered when adjusted for 
exposure to two doses of antenatal corticosteroids. Therefore, a complete 
course of antenatal corticosteroids did not improve the chance of reaching the 
‘success’ criteria. This was unexpected, however there is a high degree of 
uncertainty related to these results as highlighted by the wide CIs that cross 1. It 
is also important to consider that antenatal corticosteroids are associated with 
improved lung function in the first week of life but not after that (McEvoy et al., 
2008). As some infants in this trial remained ventilated for many weeks, this is a 
possible reason for the apparent lack of benefit to infants in this trial  
Factor Level Adjusted HR (95% CI) 
Arm VCV (reference variable) 1.00 
VG (comparator variable) 0.95 (0.63 – 1.43) 
Two doses of 
antenatal steroids  
No (reference variable) 1.00 
Yes (comparator variable) 0.9 (0.57 – 1.43) 
Table 4-17 Multivariable analysis of the effect of two doses of maternal 
antenatal corticosteroids on the time to reach the ‘success’ criteria using the 
Cox proportional hazards model 
HR, hazard ratio; CI, confidence interval 
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4.11.3 Use of postnatal corticosteroids as a covariate 
Postnatal corticosteroids have benefits in weaning ventilation and facilitating 
extubation in ventilated infants (Doyle et al., 2017b). At the trial site they are 
used for infants who have severe lung disease associated with prematurity and 
have been ventilated for prolonged periods. At the trial site corticosteroids are 
not given for this purpose until infants have remained ventilated for over a 
week, and often longer than that (Doyle et al., 2017b).  
One potential effect in using them in this way is that they enable a ventilator-
dependent infant to be ready for extubation more quickly than might otherwise 
be the case. Therefore their use was considered to be a covariate that could 
potentially influence the primary outcome.  
Figure 4-11 shows the Kaplan-Meier curves showing the effect of postnatal 
corticosteroids on the time to reach the ‘success’ criteria. Only six infants 
received postnatal corticosteroids during the trial compared with 106 infants 
who did not. 
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Figure 4-11 Kaplan-Meier curves showing the effect of postnatal corticosteroids 
on time to ‘success’ criteria 
This figure appears to show that the use of postnatal corticosteroids does not 
favour the primary outcome. This is matched by the median times to ‘success’ 
criteria and HR shown in Table 4-18 that do not favour the use of postnatal 
corticosteroids on the primary outcome. However, very few infants received 
corticosteroids and the CIs are very wide, meaning that there is a high degree 
of uncertainty about these results.  
The results reflect the fact that postnatal corticosteroids were given to the 
infants who were ventilator-dependent for prolonged periods. The primary 
outcome for these infants ranged from 724 hours to 1662 hours. Therefore, 
these results demonstrate the effect of the severity of lung disease on the 
primary outcome rather than the effect of the postnatal corticosteroids on the 
primary outcome. As a result of this, and due to the very small numbers of 
infants exposed to this variable, a multivariable analysis was not undertaken. 
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Factor Level Median time to 
‘success’ criteria, 
hours (95% CI) 
HR  
(95% CI) 
Received 
postnatal 
steroids 
No  
(reference variable) 
24  
(13.99 – 34.01) 
1.00 
Yes  
(comparator variable) 
914  
(411.1 – 1416.91) 
0.127  
(0.04 – 0.42) 
Table 4-18 Univariable analysis of the effect of postnatal corticosteroids on the 
time to reach the ‘success’ criteria using the Cox proportional hazards model 
CI, confidence interval; HR, hazard ratio 
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4.11.4 Effect of surgical PDA ligation as a covariate 
A persistent PDA can prolong the need for mechanical ventilation (Clyman , 
2013). Six infants in the trial underwent cardiothoracic surgery to ligate their 
persistent PDAs. This surgery was considered necessary because the 
persistent PDAs were considered to be contributing to these infants’ need for 
prolonged ventilation. Therefore this was considered to be a covariate that may 
influence the primary outcome. 
Figure 4-12 shows the Kaplan-Meier curves showing the effect of PDA ligation 
on the time to reach the ‘success’ criteria. It appears to show that PDA ligation 
does not favour the primary outcome. This is matched by the median times to 
‘success’ criteria and HR shown in Table 4-19 that do not favour the effect of 
PDA ligation on the primary outcome.  
 
Figure 4-12 Kaplan-Meier curves showing the effect of PDA ligation on time to 
‘success’ criteria 
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However, the results again reflect the fact that PDA ligation was only used for 
infants who were ventilator-dependent for prolonged periods. The primary 
outcome for these infants ranged from 914 to 1662 hours. The results 
demonstrate the effect of the severity of lung disease on the primary outcome 
rather than PDA ligation as an influential covariate. As a result of this, and due 
to the very small numbers of infants exposed to this variable, a multivariable 
analysis was not undertaken.  
 
Factor Level Median time to 
‘success’ criteria, 
hours (95% CI) 
HR  
(95% CI) 
Received 
surgical 
PDA 
ligation 
No   
(reference variable) 
24  
(13.99 – 34.01) 
1.00 
Yes  
(comparator variable) 
1083  
(907.76 – 1258.24) 
0.162  
(0.061 – 0.432) 
Table 4-19 Univariable analysis of the effect of postnatal corticosteroids on the 
time to reach the ‘success’ criteria using the Cox proportional hazards model 
PDA, patent ductus arteriosus; CI, confidence interval; HR, hazard ratio 
  
 123 
4.12 Secondary outcome measures 
The results of analyses of secondary outcome measures are presented here. 
For all analyses involving HRs and ORs, VCV is the reference variable and VG 
is the comparator variable. 
4.12.1 Respiratory outcome measures 
 VG 
n = 55 
VCV 
n = 57 
HR / OR*  
(95% CI) 
Total duration of 
ventilation before first 
extubation, hours, 
median (95% CI) 
32 
(12.53 – 51.47) 
 
41 
(15.68 – 66.32) 
 
 HR 0.85  
(0.56 – 1.27) 
Reintubated within 72 
hours of first extubation, 
n (%) 
yes 
no 
data censored during 
first period of ventilation 
                              
                                                                  
                               
10 (18.2) 
38 (69.1) 
7 (12.7) 
                                          
           
                               
7 (12.3)           
44 (77.2)           
6 (10.5) 
 
OR 1.65 
(0.57 – 4.77) 
 
Total duration of 
mechanical ventilation 
before discharge, hours, 
median (95% CI)  
 
50 
(16.27 – 83.72) 
 
98 
(31.8 – 164.21) 
 
HR 0.86  
(0.57 – 1.29) 
Pulmonary air leak 
(pneumothorax or PIE) 
occurring whilst on trial 
mode of ventilation, n 
(%) 
 
5 (9) 
 
10 (18) 
 
OR 0.47 
(0.15 – 1.48) 
Pneumothorax occurring 
whilst on trial mode, n 
(%) 
1 (2) 7 (12) OR 0.13 
(0.02 – 1.11) 
PIE occurring whilst on 
trial mode, n (%) 
5 (9) 4 (7) OR 1.33 
(0.34 – 5.22) 
Number of episodes of 
hypocarbia (pCO2 
<4.0kPa) at any time  
median (IQR) 
0 episodes (%) 
≥1 episode (%) 
                               
        
                           
0 (0 – 2)** 
25 (46.2)** 
29 (53.7)** 
                                     
                                      
                                
0 (0 – 2) 
30 (52.6) 
27 (47.4) 
                       
    
                      
OR 0.88     
(0.62 – 1.28) 
Number of episodes of 
hypocarbia whilst on the 
trial mode  
median (IQR) 
0 episodes (%) 
≥1 episode (%) 
                          
                          
                            
0 (0 – 2)** 
27 (50)**            
27 (50)** 
                           
                                
                               
0 (0 – 2) 
33 (57.9)           
24 (42.1) 
                       
                         
                       
OR 0.84   
(0.56 – 1.26) 
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Number of infants 
requiring HFOV, n (%) 
7 (13) 6 (11) OR 1.24 
(0.39 – 3.95) 
Duration of NIV in infants 
who received it, days, 
median (IQR) 
12  
(4.2 – 19.8) 
 
(49 survivors) 
19  
(11.7 – 26.3) 
 
(51 survivors)  
HR 0.95 
(0.63 – 1.43) 
Need for respiratory 
support or supplemental 
at 28 days of life 
(survivors only), n (%) 
 
35 (70) 
 
(50 survivors) 
 
36 (67.9) 
 
(53 survivors) 
 
OR 1.1 
(0.48 – 2.54) 
Need for respiratory 
support or supplemental 
oxygen at 36 weeks’ 
CGA (survivors only), n 
(%) 
 
30 (60) 
 
(50 survivors) 
 
28 (52.8) 
 
(53 survivors) 
 
OR 1.34 
(0.61 – 2.93) 
Chronic lung disease 
requiring home oxygen 
therapy (survivors only), 
n (%) 
20 (40.8) 
 
(49 survivors) 
20 (37.7) 
 
(53 survivors) 
OR 1.14 
(0.51 – 2.52) 
Need for positive 
pressure respiratory 
support at home, n (%) 
 
0 
 
0 
 
N/A 
Table 4-20 Comparison of data on respiratory outcomes 
HR, hazard ratio; OR, odds ratio; CI, confidence interval; n, number; NICU, 
neonatal intensive care unit; PIE, pulmonary interstitial emphysema; IQR, 
interquartile range; N/A, not applicable; kPA, kilopascals; NIV, non-invasive 
ventilation; HFOV, high frequency oscillatory ventilation; CGA, corrected 
gestational age;  
*Hazard ratios are used for time-to-event data. Odds ratios are used for binary 
data. ** Data missing for one patient 
4.12.2 Duration of ventilation 
There were no obvious differences between groups in the total duration of 
ventilation until first extubation, and the total duration of ventilation before 
discharge. The HRs favoured VCV but the median values favoured VG. 
However the CIs for these outcome measures are wide and cross 1, 
highlighting the lack of certainty regarding these results. During any period of 
ventilation the data from 15 infants were censored due to death of transfer to 
another hospital whilst ventilated. Eleven of these infants were in the VCV 
group and four were in the VG group. Similar numbers of infants required HFOV 
at any time during the trial. 
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4.12.3 Pulmonary air leak 
There were no statistically significant differences between groups in the 
pulmonary air leak data. However, absolute differences were apparent. Twice 
as many infants in the VCV group (18%) developed either PIE or a 
pneumothorax whilst on the trial mode compared with those in the VG group 
(9%). When analysed further, the difference can be attributed to the data on 
pneumothoraces. Eight infants developed a pneumothorax whilst on the trial 
mode and, of these, seven were in the VCV group and one was in the VG 
group. The wide CIs are probably due to the small numbers of these outcomes.  
Of the seven infants in the VCV group who developed a pneumothorax, four 
were born at <28 weeks’ gestation and three were born at ≥28 weeks’ 
gestation. The infant in the VG group who developed a pneumothorax was born 
at <28 weeks’ gestation. All infants who developed PIE were born at <28 
weeks’ gestation. 
These numbers are small but this is an important finding in a trial of VTV 
modes. The aim of using VTV is to avoid volutrauma which contributes to VALI. 
A pneumothorax has been referred to as macroscopic evidence of barotrauma. 
However, excessive expansion of the lungs due to excessive tidal volumes may 
also cause pneumothoraces. Therefore this is an important outcome measure 
to explore further in a larger trial. 
4.12.4 Hypocarbia 
Hypocarbia, defined in this trial as a pCO2 of <4kPa measured on blood gas 
analysis, can be a side effect of ventilation. It can represent excessive 
expansion of the lungs due to excessive tidal volumes. In preterm infants, 
hypocarbia has been associated with brain injury (Okumura et al., 2001; 
Erickson et al., 2002). This is a serious side effect in infants whose brains are 
already at risk of injury due to antenatal, perinatal and postnatal events. 
Therefore it is important to avoid hypocarbia when ventilating preterm infants.  
In this trial there were no differences between groups in the numbers of 
documented episodes of hypocarbia. Fifty-four per cent of infants in the trial did 
not have any documented episodes of hypocarbia. The protocol did not 
mandate the timings of blood gas analyses and the treating clinical teams 
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decided on their timings as part of individualised patient care. Therefore the 
number and frequency of blood gas analyses varied with each patient.  
VTV has been shown to reduce the frequency of hypocarbia when compared 
with PLV (Keszler et al., 2004; Cheema et al., 2007). It is reassuring that no 
differences were seen between two modes of VTV in this trial. However as 
hypocarbia can reflect excessive tidal volume delivery it would need to be 
investigated further as a secondary outcome measure in a larger trial.  
4.13 Secondary outcomes: mortality and neurological outcomes 
The numbers of infants who died or developed severe IVH or PVL were small 
and were similar between groups. The overall mortality rate was similar to that 
of the trial site (Garg, 2014). 
 VCV 
n = 57 
VG 
n = 55 
OR 
(95% CI) 
Death before discharge from 
hospital, n (%) 
4 (7) 6 (10.9) 1.62 
(0.43 – 6.09) 
Severe IVH (Papile grades 3-4), 
n (%) 
7 (12.3) 3 (5.5)* 0.42 
(0.1 – 1.71) 
PVL, n (%) 3 (5.3) 4 (7.3)* 1.44 
(0.31 – 6.76) 
Table 4-21 Comparison of data on mortality and neurological outcomes 
n, number; OR, odds ratio; IVH, intraventricular haemorrhage; PVL 
periventricular leukomalacia 
* Data missing for one infant 
4.14 Secondary outcomes: other important outcomes of prematurity 
There were similar numbers of infants developing other important outcomes of 
prematurity. There were three additional infants requiring PDA ligation in the VG 
group. The proportion of infants requiring laser therapy for ROP is similar to that 
reported from the trial site in 2014 (Garg, 2014). 
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 VCV 
n = 57 
VG 
n = 55 
OR 
(95% CI) 
ROP requiring laser therapy 
(survivors only), n (%) 
6 (11.3)* 
(53 survivors) 
10 (20) § 
(50 survivors) 
2.02 
(0.67 – 6.06) 
PDA requiring medical or 
surgical treatment, n (%) 
14 (24.6) 15 (27.3) § 1.21 
(0.52 – 2.83) 
PDA requiring surgical 
treatment, n (%) 
3 (5.3) 6 (10.9) § 2.3 
(0.54 – 9.7) 
NEC (modified Bell’s stage 2 
or greater), n (%)  
4 (7) 4 (7.3) 1.04 
(0.25 – 4.38) 
Intestinal perforation without 
NEC, n (%) 
1 (1.8) 0 (0) 0.0 
 
Confirmed infection, (n (%) 15 (26.3) 16 (29.1) 1.15 
(0.5 – 2.63) 
Table 4-22 Comparison of data on other outcomes of prematurity 
N, number; OR, odds ratio; ROP, retinopathy of prematurity; PDA, patent 
ductus arteriosus; NEC, necrotising enterocolitis. 
* Data missing for one infant; § Data missing for two infants 
4.15 Serious adverse events 
The expected serious adverse events (SAEs) are outlined in Table 4-23. There 
were no suspected unexpected serious adverse events (SUSARs).  
The rates of chronic lung disease are calculated according to the numbers of 
infants who survived to 36 weeks’ gestational age. In the VG group, six infants 
died but one of those survived beyond 36 weeks’ corrected gestational age. 
Therefore the denominator number in that group is 50. In the VCV group, four 
infants died, all of whom died within the first two weeks of life. Therefore, the 
denominator number in that group is 53. 
The rates of retinopathy of prematurity (ROP) were calculated according to the 
numbers of infants who survived to receive ROP screening. This was the same 
as the numbers of infants who survived until 36 weeks’ corrected gestational 
age. Therefore the denominator numbers are 50 for the VG group and 53 for 
the VCV group.  
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Serious expected adverse 
events 
VG                    
n = 55 
VCV                  
n = 57 
Total population 
n = 112 
Death before discharge from 
hospital, n (%) 
Yes 
No 
                                 
                             
6 (10.9) 
49 (89.1) 
                                
                                 
4 (7) 
53 (93) 
                           
                            
10 (8.9) 
102 (91.1)  
Chronic lung disease 
(survivors only), n (%) 
Yes 
No 
 
                                                
                                   
30 (60) 
20 (40) 
(50 survivors) 
                 
                       
28 (52.8) 
25 (47.2) 
(53 survivors) 
                         
                            
58 (56.3) 
45 (43.7 
(103 survivors) 
Reintubation after initial 
extubation, n (%) 
Yes 
No 
Data censored during first 
period of ventilation 
                                         
                                  
10 (18.2) 
38 (69.1) 
7 (12.7) 
                                   
                          
7 (12.3) 
44 (77.2)           
6 (10.5) 
                         
                              
17 (15.2) 
82 (73.2) 
13 (11.6) 
Pulmonary air leak after 
enrolment into trial, n (%) 
Yes 
No 
                                    
                                  
2 (3.6) 
53 (96.4) 
                            
                          
9 (15.8) 
48 (84.2) 
                           
                             
11 (9.8) 
101 (90.2) 
Episodes of hypocarbia (pCO2 
<4.0kPa) per infant on any 
mode of ventilation after 
randomisation into trial, n (%) 
No episodes 
One episodes 
Two episodes 
Three episodes 
Four episodes 
Five episodes 
Six episodes 
Seven episodes 
Eight episodes 
Fourteen episodes 
Missing data  
                                                                         
                                        
                                         
                                
25 (45.5) 
12 (22.2) 
7 (12.7) 
4 (7.4) 
2 (3.7) 
2 (3.7) 
1 (1.9) 
0 (0) 
1 (1.9) 
0 (0) 
1 (1.9) 
        
                         
                  
                             
30 (52.6)  
6 (10.5) 
7 (12.3) 
2 (3.5) 
5 (8.8) 
2 (3.5) 
2 (3.5) 
2 (3.5) 
0 (0) 
1 (1.8) 
0 (0) 
       
                        
                              
                          
55 (49.1) 
18 (16.1) 
14 (12.5) 
6 (5.4) 
7 (6.2) 
4 (3.6) 
3 (2.7) 
2 (1.8) 
1 (0.9) 
1 (0.9) 
1 (0.9) 
Episodes of hypocarbia (pCO2 
<4.0kPa) per infant on trial 
mode of ventilation only after 
randomisation into trial, n, (%) 
No episodes 
One episode 
Two episodes 
Three episodes 
Four episodes 
Five episodes 
Six episodes  
                                            
                               
                                   
                                
27 (49.1) 
12 (21.8) 
7 (12.7) 
3 (5.5) 
3 (5.5) 
1 (1.8)             
0 (0) 
                 
                                 
                                                   
                      
33 (57.9) 
6 (10.5) 
6 (10.5) 
3 (5.3) 
5 (8.8) 
0 (0)                
1 (1.8) 
                            
                           
  
                                  
60 (53.6) 
18 (16.1) 
13 (11.6) 
6 (5.4) 
8 (7.1) 
1 (0.9)               
1 (0.9) 
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Seven episodes 
Eight episodes 
Missing data  
0 (0) 
1 (1.8) 
1 (1.8) 
3 (5.3) 
0 (0) 
0 (0) 
3 (2.7) 
1 (0.9) 
1 (0.9) 
Episodes of pulmonary 
haemorrhage after 
randomisation, n, (%) 
No episodes 
One episode 
Two episodes 
                              
                           
                           
50 (91) 
3 (5.4) 
2 (3.6) 
                         
                          
                        
52 (91.2) 
4 (7) 
1 (1.8) 
                       
                         
                       
102 (9.1) 
7 (6.3) 
3 (2.6) 
NEC, (≥ Bell’s Stage 2) n, (%) 
Yes 
No 
 
4 (7.3) 
51 (92.7) 
 
4 (7) 
53 (93) 
 
8 (7.1) 
104 (92.9) 
Intestinal perforation without 
NEC, n (%) 
Yes 
No 
                                              
                                    
0 (0) 
0 (0) 
                      
                         
2 (3.5) 
55 (96.5) 
                           
                             
2 (1.8) 
110 (98.2) 
Intracranial haemorrhage or 
white matter damage seen on 
cranial ultrasound scan, n (%) 
Yes 
No 
Missing data  
                                  
                                
                                
6 (10.9) 
48 (87.3) 
1 (1.8) 
                                         
                              
                             
9 (15.8) 
48 (84.2) 
0 (0) 
                 
                           
                             
15 (13.4) 
96 (85.7) 
1 (0.9) 
PDA treated medically, n (%) 
Yes 
No 
Missing data 
 
9 (16.4) 
45 (81.8) 
1 (1.8) 
 
11 (19.3) 
46 (80.7) 
0 (0) 
 
20 (17.9) 
91(81.3) 
1(0.9) 
PDA treated surgically, n (%) 
Yes 
No 
Missing data 
                                      
6 (10.9) 
47 (85.5) 
2 (3.6) 
                           
3 (5.3) 
54 (94.7) 
0 (0) 
                                  
9 (8) 
101 (90.2) 
2 (1.8) 
Any ROP, (survivors only), n 
(%) 
Yes 
No 
Missing data 
 
                         
20 (40) 
27 (54) 
3 (6) 
(50 survivors) 
 
                        
24 (45.3) 
28 (52.8) 
1 (1.9) 
(53 survivors) 
 
                           
44 (42.7) 
55 (53.4) 
4 (3.9) 
(103 survivors) 
ROP requiring treatment 
(survivors only), n (%) 
Yes 
No 
Missing data 
                               
                                  
10 (20) 
37 (74) 
3 (6) 
(50 survivors) 
                                  
                              
6 (11.3) 
46 (86.8) 
1 (1.9) 
(53 survivors) 
                          
                              
16 (15.5) 
83 (80.6) 
4 (3.9) 
(103 survivors) 
Table 4-23 Expected serious adverse events (SAEs) 
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4.16 Comparison of SAE rates in the trial with the population at the trial 
site 
There were no major differences between groups in rates of SAEs. In the VG 
group, 42 infants (76.4%) had at least one SAE although in another three 
infants data on one SAE were missing. Forty-five infants (78.9%) in the VCV 
group had at least one SAE. There were no safety concerns raised in relation to 
the interventions or trial protocol.  
The trial site produces an annual report on important clinical outcomes of 
infants admitted to the site. The annual report published in 2014 stated that, 
from 2012 – 2014, 90% of infants born at ≤31 weeks’ gestation survived to 
discharge home (Garg, 2014). In this trial, 91.1% of infants survived to 
discharge home. Therefore the mortality rate for infants in this trial was no 
different to that reported by the unit.  
In 2014, 14.2% of infants born ≤30 weeks’ gestation and admitted to the trial 
site received laser therapy for ROP (Garg, 2014). The rate in this trial over a 
period of 29 months was similar (15.5%). The annual report also states that 
14% of infants born at <30 weeks’ gestation underwent PDA ligation in 2014, 
compared with only 8% of infants in this trial. In 2014, 9% of infants at the trial 
site developed NEC, similar to the proportion of 7.1% in this trial. 
The annual report also states that 30% of infants born at <32 weeks’ gestation 
were diagnosed with chronic lung disease (oxygen requirement at 36 weeks’ 
corrected gestational age). In this trial, 56.3% of infants had this diagnosis. This 
difference may be explained by the fact that this trial included infants born 
between 32 and 33+6 weeks’ gestation. Many infants in this trial were 
transferred to other hospitals for ongoing care after their initial period of 
intensive care. Data on these infants were requested from these other sites as 
stated in the trial protocol. Other units have differing practices regarding 
respiratory care which may have contributed to the higher rates of chronic lung 
disease. As this is such an important diagnosis in preterm infants, further 
investigation of this outcome would be essential in a larger trial.  
These data demonstrate that the rates of SAEs were balanced between groups 
and were mostly similar to overall rates reported at the trial site. 
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4.17 Duration of ventilation for non-enrolled infants 
During the trial period from July 2013 to December 2015, 47 infants were born 
at <34 weeks’ gestation, were ventilated for RDS, and remained at the trial site 
for ongoing intensive care. These infants were not enrolled into the trial. They 
included the 46 infants for whom consent was not obtained and one infant who 
had been enrolled but was subsequently withdrawn due to the postnatal 
diagnosis of an underlying congenital condition. 
The trial unit, The James Cook University Hospital Neonatal Unit, uses an 
electronic platform, BadgerNet Neonatal (Clevermed Ltd), to routinely record 
clinical data on all infants both prospectively and retrospectively. This is done as 
part of the UK Neonatal Collaborative. Data on all infants admitted to the unit 
are recorded in this platform as part of standard neonatal care. 
Data on infants not enrolled into the trial were not collected by the research 
team for the purposes of the trial. However, data on the duration of the first 
period of ventilation for non-enrolled infants ventilated during the trial period 
were obtained from the BadgerNet Neonatal platform. These data were used to 
provide a degree of comparison with enrolled infants in order to ascertain 
whether the enrolled infants were representative of the unit population as a 
whole.  
It was not possible to obtain information on the type of ventilation that each of 
the non-enrolled infants received but most would have received either VCV or 
VG. This is because the standard mode of ventilation in the neonatal unit at the 
time was VCV, and because, after the change in the consent process, infants 
were randomised to either VCV or VG before deferred consent was sought. 
There were some important differences between the data on enrolled infants 
collected specifically for the trial and the routinely recorded data on non-
enrolled infants held in the BadgerNet Neonatal platform. These are listed 
below. 
• The primary outcome on enrolled infants was the time taken to reach the 
‘success’ criteria. This was used as an objective measure to represent 
‘readiness for extubation’ rather than the subjective measure of duration 
of ventilation until extubation. Data on non-enrolled infants were only 
available as duration of initial period of ventilation until extubation. 
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Therefore, to compare the two groups, duration of ventilation was used 
rather than time to ‘success’ criteria.  
• The data on duration of ventilation for enrolled infants were recorded in 
hours whereas data on duration of ventilation for non-enrolled infants 
were only available in days. Therefore, to compare the two groups, the 
duration of ventilation for enrolled infants was converted from hours to 
days. Enrolled infants who were ventilated for ≤24 hours had their 
duration of ventilation converted to one day; enrolled infants who were 
ventilated for ≤48 hours had their duration of ventilation converted to two 
days, and so on. 
• The primary outcome data on enrolled infants were analysed as survival 
data because censored data were known and documented accordingly. 
This was not possible using routinely held data from the BadgerNet 
Neonatal platform as information on censoring was not available. 
Therefore data on duration of ventilation for non-enrolled infants could 
only be analysed using descriptive analyses (such as medians) rather 
than survival analysis.  
Therefore, the data on non-enrolled infants were not directly comparable to 
those on enrolled infants. However, they did provide some approximation on 
whether the enrolled infants were representative of the unit population. 
Comparisons of the data are shown in Table 4-24.  
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Group/Sub-group Duration of initial 
episode of ventilation in 
enrolled infants, days, 
median (IQR)  
Duration of initial 
episode of ventilation 
in non-enrolled 
infants, days, median 
(IQR) 
All infants 2 
(1 – 5.8) 
3 
(2 – 11) 
Infants born at <28 
weeks’ gestation 
4 
(1 – 19) 
8 
(3 – 34.8) 
Infants born at 28 – 33+6 
weeks’ gestation 
1 
(1 – 2.3) 
2 
(2 – 3) 
Table 4-24 Comparison of duration of initial episode of ventilation in enrolled 
and non-enrolled infants 
These comparisons show that there was a trend towards shorter periods of 
ventilation in enrolled infants compared with non-enrolled infants. These are 
exploratory data. When designing a larger trial, it would be useful to consider 
how to collect data on non-enrolled infants in order to ascertain whether the trial 
population are truly representative of the denominator population. 
4.18 Summary 
There was a clinically relevant difference between groups in the median time 
taken to be ready for extubation. The median time taken to reach the ‘success’ 
criteria was 13 hours sooner in the VG group compared to the VCV group. The 
majority of infants reached the ‘success’ criteria within the first 48 hours. There 
was a difference between the groups in infants born at 28-33+6 weeks’ 
gestation, with those in the VG group reaching the ‘success’ criteria faster. 
Gestational age had a marked effect on the time to be ready for extubation, with 
those born at 28-33+6 weeks’ gestation reaching the ‘success’ criteria much 
faster than those born at <28 weeks’ gestation. This validates the use of 
gestational age as a stratification factor.   
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Chapter 5 Ancillary Study 
5.1 Introduction 
This ancillary study was undertaken as part of a process evaluation of The 
VoluVent Trial to test the validity of the primary outcome (Oakley et al., 2006). 
This is good practice in trials of complex interventions (Craig et al., 2008; Moore 
et al., 2015) 
The primary outcome measure of The VoluVent Trial was the duration of time 
taken from starting the trial mode until reaching the ‘success’ criteria. These 
‘success’ criteria consisted of three objective criteria that represented ‘readiness 
for extubation’. Use of objective criteria removed the subjectivity of clinicians’ 
opinions regarding ‘readiness for extubation’ in order to reduce the possibility of 
bias.  
The three objective criteria were: 
• a mean airway pressure of <8 cmH2O and a fractional inspired oxygen 
concentration (FiO2) ≤0.35, both maintained for six consecutive hours 
• followed by successful completion of a SBT.  
An enrolled infant who reached these criteria had therefore met the primary 
outcome of the trial. 
5.2 Collection and recording of primary outcome data during The 
VoluVent Trial 
As part of routine clinical care in the trial unit neonatal staff frequently observed 
the MAP and FiO2 values displayed on the ventilator screen. Every hour the 
displayed values were recorded on nursing observation charts that are part of 
each infant’s medical records. These values were recorded by the neonatal 
nurses at approximately the start of every hour and, if possible and appropriate, 
at a time when the infant was in a resting state in accordance with routine unit 
practice. In accordance with The VoluVent Trial protocol, these data were also 
recorded on specifically designed trial data collection sheets by nursing staff 
caring for enrolled infants (Figure 5-1).  
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Figure 5-1 Example of a specifically designed trial data collection form for 
prospective collection of primary outcome data 
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However, given that the MAP values displayed on the screen can vary from 
breath to breath, the values that are recorded may have been influenced by 
clinical factors related to the infants, by human behavioural factors related to 
the nursing staff, and by electromechanical aspects of the ventilators.  
Examples of clinical factors affecting the displayed value of an infant’s MAP 
include: 
• respiratory rate, 
• lung compliance. 
The exact time at which the value is observed and recorded by nursing staff 
may be affected by human behavioural factors. Nurses aim to record the values 
that are displayed on the ventilator at the start of every hour but the precise 
timing can vary due to: 
• the nurse’s workload and possible need to care for other infants, 
• clinical emergencies related to the enrolled infant or to other infants, 
• the previous clinical experience of the nurse caring for the enrolled infant, 
• the inter-observer variability that arises when the nurse responsible for the 
enrolled infant takes his or her rest break and another nurse is temporarily 
responsible for the enrolled infant. 
The electromechanical aspect that may affect the value recorded by nursing 
staff relates to the analogue-to-digital conversion of the MAP. Personal 
correspondence with the company (Carefusion, Yorba Linda, CA) revealed that 
the MAP value displayed on the ventilator screen is a moving average value 
averaged over 60 seconds. Therefore, the MAP value may change slightly from 
one moment to the next and the value recorded by the nurse will depend on the 
moving average value displayed on the screen at any one time. 
Therefore this ancillary study was undertaken to test the validity of data 
collection used for the primary outcome. A flow chart summarising the study is 
shown in Figure 5-2. 
5.3 Objective 
To compare the MAP value that is recorded manually every hour by neonatal 
nurses, and used as part of the primary outcome for The VoluVent Trial, with 
electronically sampled MAP values generated with each breath.  
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Figure 5-2 Flow chart summarising data collection methods for this ancillary 
study 
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5.4 Methods 
5.4.1 Inclusion and exclusion criteria  
Infants were included in this ancillary study if they had been enrolled into The 
The VoluVent Trial but had not yet met the primary outcome. Selection of 
infants depended on the availability of the Principal Investigator and therefore 
infants were not randomly selected for this study. Infants were excluded from 
this study if the Principal Investigator was not available to set up the device 
used to sample continuous data produced by the ventilator. 
5.4.2 Devices used 
Data were downloaded from the ventilators in real time using the VOXP 
Research Data Collector (Applied Biosignals, GmbH, Germany) software 
programme installed onto an encrypted laptop computer. This software 
programme allows researchers to download and store real-time numerical and 
waveform pulmonary data from AVEA® ventilators. The license for use of the 
software was provided by Applied Biosignals (GmbH, Germany). For this study, 
the numerical values of MAP generated with every breath were downloaded in 
real time into Excel spreadsheets generated by the software and stored within 
the laptop.  
MATLAB (MATLAB 2012a, The MathWorks, Inc., Natick, Massachusetts, 
United States) was used to calculate a ‘moving average’ of the airway pressure 
based on the sampled airway pressure data obtained using the VOXP 
Research Data Collector.  
5.4.3 Sampling techniques and data acquisition 
Figure 5-3 shows a simplified diagram demonstrating how the infant’s airway 
pressure is detected as a signal by the flow sensor (which contains a hot-wire 
anemometer) attached to the ETT, transduced and transferred to the ventilator, 
and displayed on the ventilator screen as a numerical value. 
The VOXP Research Data Collector software was used to download data from 
the AVEA® ventilators via a Medical Information Bus (MIB) interface. This 
allowed continuous airway pressure signals to be sampled and transferred to 
the software as discrete numerical data within the encrypted laptop computer. 
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As shown in Figure 5-3, the airway pressure signal (detected by the flow sensor 
as waveforms) underwent analogue-to-digital conversion before being 
processed and combined with other variables, and then displayed on the screen 
as a numerical mean airway pressure value (a moving average over 60 
seconds).  
Prior to being converted from an analogue to a digital signal the airway 
pressure signal was sampled by the VOXP Research Data Collector software at 
an analogue-to-digital rate of 100Hz using a baud rate of 115200. This meant 
that infant’s continuous airway pressure signal was sampled and converted to a 
discrete numerical value at a rate of 100 times per second.  
The software also allows researchers to set the interval at which the variable of 
interest is downloaded as a numerical value. For this ancillary study an interval 
of ‘every breath’ was set so that the software downloaded the MAP with every 
breath. This ‘breath-by-breath’ interval was chosen because it ensured that 
MAP values were sampled as accurately as possible in infants who were 
spontaneously breathing with variable respiratory rates.  
5.4.4 Manual data recording and storage 
Values of MAP recorded manually by nursing staff were recorded on nursing 
observation charts and on specifically designed trial data collection sheets 
(Figure 5-1). One value was recorded every hour. The nurses used a clock 
within the neonatal unit to document the time at which the value was recorded. 
The time was documented in hours and minutes (for example, 10:12, 09:58, 
14:06, etc). 
5.4.5 Continuous data recording and storage 
Data on individual patients were downloaded into Microsoft Excel spreadsheets 
generated by the VOXP Research Data Collector. Each spreadsheet was saved 
under each infant’s VoluVent Trial number. The electronic data were stored in 
accordance with South Tees Hospitals NHS Foundation Trust’s standard 
operating procedures (South Tees Hospitals NHS Foundation Trust Information 
Governance Department, 2007).  
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Figure 5-3 Flow chart demonstrating the detection and processing of the airway 
pressure signal and the sampling and recording of the mean airway pressure 
values 
 141 
5.4.6 Time periods of data collection 
The focus of this study was to test the validity of the primary outcome by means 
of comparing two methods of clinical measurement. Therefore data sampled 
from the ventilator and manual data were collected simultaneously for each 
infant in this ancillary study. Data were collected at a time when the Principal 
Investigator was available to set up and close down the VOXP Research Data 
Collector. The time periods were chosen if the following criteria were met:  
• the infant was in a stable clinical condition,  
• there were no planned invasive procedures or routine changes of 
equipment, 
• there were no plans to temporarily remove the infant from the incubator. 
Routine nursing procedures, including nappy changes and ETT suction, were 
undertaken according to clinical need.  
5.5 Planned statistical analysis  
5.5.1 Defining the measurements for comparison of MAP values 
M1 value: an MAP value was recorded manually by a nurse once every hour. 
The time at which this value was recorded was also documented. This was 
referred to as measurement 1 (M1). The time was recorded as the hour and 
minute at which the value was documented on the trial data collection sheets 
(Figure 5-1).  
M2 value: MAP values were downloaded by the VOXP Research Data 
Collector on a breath-by-breath interval. Therefore there were many MAP 
values that corresponded to the hour and minute at which the M1 value was 
recorded. The median of all the values downloaded by the VOXP Research 
Data Collector within the same minute as M1 was calculated and referred to as 
M2. Initially the SAP stated that the mean value of all MAP values downloaded 
at breath-by-breath intervals was planned for use as the M2 measurement. 
However, calculating mean values produced M2 values with decimal points 
whereas all M1 values were integers. Therefore, the median value was used as 
the M2 value when compared with M1.  
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However, several M3 values had decimal places. Therefore, when M2 data 
were compared with M3 data, the mean values were calculated and compared. 
M3 value: sampling the continuous airway pressure signal at 100Hz provided 
6,000 airway pressure values per minute. These values were retrospectively 
converted back to airway pressure waveforms using MATLAB software. A 
‘moving average’ MAP value was calculated from these data. This was done to 
provide a third measurement (M3) in order to verify the ‘breath-by-breath’ data 
(M2). This was done as part of process evaluation of this ancillary study (Moore 
et al., 2015). 
5.5.2 Statistical methods for comparing the two measurements of mean 
airway pressure 
M1 and M2 were compared using the statistical methods for assessing 
agreement between two methods of clinical measurement described by Bland 
et al. (Bland et al., 1986). M2 and M3 values were then compared using the 
same methods in order to verify the M2 measurement. 
5.5.3 Comparison of M1 and M2 for one infant only: 
The differences between M1 and M2 at each time point were calculated. The 
overall mean difference +/- two standard deviations (SD) were then calculated 
(see Table 5-1). As described by Bland et al. (Bland et al., 1986) the upper limit 
of agreement reflected the mean difference plus two SDs. The lower limit of 
agreement was the mean difference minus 2 SDs.  
Using a Bland Altman plot the difference between M1 and M2 for each time 
point were plotted against the overall mean difference and the upper and lower 
limits of agreement. The standard errors (SE) and CIs of the limits of agreement 
between M1 and M2 were calculated to demonstrate the precision of the limits 
of agreement. 
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Hour of 
data 
collection 
Time 
(hours 
and 
minutes) 
MAP value 
recorded 
manually 
every hour 
(M1),       
cmH2O 
Median MAP 
value 
downloaded 
with every 
breath (M2), 
cmH2O 
M1 – M2, 
cmH2O 
Mean of 
M1 plus 
M2, 
cmH2O 
1      
2      
3      
4      
5      
6      
7      
8      
Sum of 
M1 – M2, 
cmH2O 
     
Mean of 
M1 – M2, 
cmH2O  
     
Mean of 
M1 – M2 
plus 2SD, 
cmH2O 
     
Mean of 
M1 – M2 
minus 
2SD,     
cmH2O 
     
Table 5-1 Example of table comparing repeated values of M1 and M2 for one 
infant 
5.5.4 Comparison of M1 and M2 for several infants 
The methods described above were used to compare repeated measurements 
from several infants. The median value of all of the M1 values from an individual 
infant was referred to as MedianM1. The median value of all of the M2 values 
from an individual infant was referred to as MedianM2. The differences between 
MedianM1 and MedianM2 were plotted against their mean and corrected SD 
(see Table 5-2). Ninety five per cent of the differences should be between the 
two corrected SDs to show a good level of agreement between the two 
methods of measurement (M1 and M2) (Bland et al., 1986). 
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Participating 
infant 
Median of 
M1 
(MedianM1), 
cmH2O 
Median of 
M2 
(MedianM2), 
cmH2O 
MedianM1 –  
Median M2, 
cmH2O 
Mean of 
MedianM1 
plus 
MedianM2, 
cmH2O 
1     
2     
3     
4     
5     
6     
7     
…14     
Total of 
(MedianM1 – 
MedianM2), 
cmH2O 
    
Mean of 
(MedianM1 – 
MedianM2), 
cmH2O  
    
Mean of 
(MedianM1 – 
MedianM2) plus 
2SD, cmH2O 
    
Mean of 
(MedianM1 – 
MedianM2) 
minus 2SD, 
cmH2O 
    
Table 5-2 Example of table comparing repeated median values of M1 and M2 
for 14 infants 
5.5.5 Verification of M2 
The value of M2 was verified using the airway pressure values sampled at 
100Hz. Twelve thousand airway pressure values (6000 per minute or 100 times 
per second, corresponding to 100Hz) were obtained during the minute 
preceding, and the minute corresponding to, the time at which the nurse 
recorded the M1 measurement. MATLAB (MATLAB 2012a, The MathWorks, 
Inc., Natick, Massachusetts, United States) was used to calculate the average 
value of the 12,000 airway pressure values. This average value was then 
plotted for every 100th of a second to create a ‘moving average’. This also had 
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the effect of filtering the data to remove artifacts. The mean value of these 
filtered data was then calculated and referred to as M3. It was compared with 
M2 using the Bland Altman analysis (Bland et al., 1986).  
5.5.6 Recording the timing of the data 
At the start of the data collection period for each infant the Principal Investigator 
recorded the time in hours and minutes using a clock in the neonatal unit. The 
nurses used the same clock to record the timings of their M1 values in hours 
and minutes on the specifically designed data collection sheets. The start time 
documented by the Principal Investigator corresponded to time 00:00, the time 
recorded in the VOXP Research Data Collector software programme at the start 
of data collection.  
The software programme then continuously recorded the time in hours, 
minutes, seconds and one tenth of each second (eg: 00:44:29.5 for 44 minutes, 
29.5 seconds) throughout the entire period of data collection. The timings 
documented by the nurses were retrospectively matched to the corresponding 
time (in hours and minutes) in the Microsoft Excel spreadsheets produced by 
the software programme. In that way, the MAP values that comprised the M2 
and M3 measurements could be matched to the M1 value documented at the 
same hour and minute by the nurse. 
For example, if the start time of the data collection period was recorded as 
13:30 and the nurse documented the first M1 value at 13:51, this M1 value was 
therefore documented 21 minutes after the start of the data collection. This 
corresponded to data downloaded by the VOXP Research Data Collector 21 
minutes after time 00:00. The MAP values downloaded within the 21st minute of 
data collection (ie: from 00:21.0 to 00:21.9) comprised the M2 values. 
5.6 Results 
In total, data from 15 infants were collected using the VOXP Research Data 
Collector. Data from one infant were not subsequently analysed because an M1 
value was found to be missing for the 10th hour of data collection. This M1 value 
had not been documented by the nurse. Therefore, this infant’s dataset was not 
complete. As this ancillary study was an observational study, this infant’s data 
were not analysed. 
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Of the remaining 14 infants, five were female and nine were male. Six had been 
randomised to VG and eight to VCV. Their gestational ages ranged from 23 to 
28 completed weeks of gestation and their birth weights ranged from 620g to 
1317g 
The duration of data collection for each of these 14 infants varied from four 
hours to 15 hours. This variation was primarily due to the availability of the 
Principal Investigator. Data were collected both during the day and at night. 
Table 5-4 shows the variation in the duration of data collection for the 14 
infants. 
 
 
Figure 5-4 Number of hours of data collection for each infant 
This graph shows the duration of time over which data were collected for this 
ancillary study. The shortest duration was four hours and the longest was 15 
hours. The most frequent duration was eight hours (three infants). 
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5.6.1 Example of the Comparison of M1 and M2 (Infant 12) 
An example of the data for comparison of M1 and M2 from one of the 14 infants 
is shown in Table 5-3. For the purpose of this ancillary study this infant is 
referred to as Infant 12 although that was not his/her actual trial number. 
Hour of 
data 
collection 
Time 
(hours 
and 
minutes) 
Value 
recorded 
manually 
every 
hour (M1), 
cmH2O 
Median 
value 
sampled 
with every 
breath 
(M2),       
cmH2O 
M1 – M2, 
cmH2O 
Mean of 
M1 plus 
M2,       
cmH2O 
1 09:55 9 9 0 9 
2 11:10 8 8 0 8 
3 12:00 8 10 -2 9 
4 13:10 10 11 -1 10.5 
5 14:05 10 11 -1 10.5 
6 15:10 8 9 -1 8.5 
7 16:10 9 9 0 9 
8 17:15 8 7 1 7.5 
Sum of 
M1 – M2, 
cm H2O 
   -4  
Mean of 
M1 – M2, 
cm H2O 
   -0.5  
Mean of 
M1 – M2 
plus 2SD, 
cm H2O 
   1.352  
Mean of 
M1 – M2 
minus 
2SD,      
cm H2O 
   -2.352  
Table 5-3 Example of comparison of M1 and M2 data for Infant 12 
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5.6.2 Bland Altman plot for Infant 12 
 
 
 
 
Figure 5-5 Bland Altman plot showing the differences between M1 and M2 and 
their variance from the overall mean difference over eight consecutive time 
points for Infant 12.  
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5.6.3 Description of the Bland Altman plot comparing M1 and M2 for Infant 
12  
• The mean difference between M1 and M2 for this infant was -0.5 cmH2O.  
• The upper limit of agreement was the mean of M1 and M2 plus 2 SDs. In 
this case, this upper limit of agreement was 1.352 cmH2O.  
• The lower limit of agreement was the mean of M1 and M2 minus 2 SDs, 
which, for this infant, was -2.352 cmH2O.  
• The standard error of the mean difference +/- two SDs was 0.567. Therefore 
the 95% CIs of the upper limit of agreement were 0.486 to 2.218 cmH2O. 
The 95% CIs of the lower limit of agreement were -1.486 to -3.218 cmH2O. 
M1 was used as the reference against which M2 was compared. For this infant, 
there were no differences between three of the eight measurements at hours 1, 
2 and 7. At the eighth hour the MAP value documented by the nurse (M1) was 1 
cmH2O higher than the median MAP value downloaded with every breath (M2) 
at the same time period. At hours 4, 5 and 6, M1 was 1 cmH2O lower than M2. 
At the third hour, M1 was 2 cmH2O lower than M2. This created a negative 
overall mean difference of -0.5 cmH2O.  
5.6.4 Explanation of the Bland Altman plot comparing M1 and M2 for Infant 
12 
For Infant 12, the mean difference between the MAP value documented by the 
nurse every hour (M1) and the median MAP value downloaded from the 
ventilator with every breath (M2) at the same time point was -0.5 cmH2O. The 
value documented by the nurse tended to be lower than the value downloaded 
by the VOXP Research Data Collector, giving the mean difference a negative 
value. 
At each time point, the difference between the values of M1 and M2 falls within 
the upper and lower limits of agreement (the mean difference +/- two SDs). 
Therefore, for Infant 12, this indicates good agreement between the two 
measurements.  
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5.6.5 Comparison of M1 and M2 for all 14 infants 
Infant Median of 
M1 
(MedianM1), 
cmH2O 
Median of 
M2 
(MedianM2), 
cmH2O 
MedianM1 –  
MedianM2, 
cmH2O 
Mean of 
MedianM1 
plus 
MedianM2, 
cmH2O 
1 9 9 0 9 
2 7 7 0 7 
3 7 7 0 7 
4 6 6.5 -0.5 6.25 
5 8 8 0 8 
6 9 9 0 9 
7 6.5 7 -0.5 7.75 
8 8 8 0 8 
9 8 8 0 8 
10 9 9 0 9 
11 9 9 0 9 
12 8.5 9 -0.5 8.75 
13 8 8 0 8 
14 7 7 0 7 
Total of 
(MedianM1 – 
MedianM2), 
cm H2O 
  -1.5  
Mean of 
(MedianM1 – 
MedianM2), 
cm H2O  
  -0.11  
Mean of 
(MedianM1 – 
MedianM2) 
plus 2SD,    
cm H2O 
  0.316  
Mean of 
(MedianM1 – 
MedianM2) 
minus 2SD, 
cm H2O 
  -0.536  
Table 5-4 Comparison of M1 and M2 data for 14 infants 
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5.6.6 Bland Altman plot for the comparison of M1 and M2 for all 14 infants 
 
 
 
Figure 5-6 Bland Altman plot showing how the differences between MedianM1 
and MedianM2 differ from the overall mean difference for all 14 infants. 
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5.6.7 Description of the Bland Altman plot comparing M1 and M2 for all 14 
infants  
• The mean difference between MedianM1 and MedianM2 for all infants was -
0.11 cmH2O.  
• The upper limit of agreement was the mean of MedianM1 and MedianM2 
plus 2 SDs. The upper limit of agreement was calculated as 0.316 cmH2O 
for all 14 infants.  
• The lower limit of agreement was the mean of MedianM1 and MedianM2 
minus 2 SDs, which, for all infants, was -0.536 cmH2O.  
• The standard error of the mean difference +/- two SDs was 0.099. Therefore 
the 95% CIs of the upper limit of agreement were 0.13 to 0.502 cmH2O. The 
95% CIs of the lower limit of agreement were -0.722 to -0.35 cmH2O. 
For 11 of the 14 infants, there was no difference between the MedianM1 and 
MedianM2 values. For three of the infants, the MedianM1 value was 0.5 cmH2O 
lower than the MedianM2 value.  
5.6.8 Explanation of the Bland Altman plot comparing M1 and M2 for all 14 
infants  
For all 14 infants, the mean difference between the median M1 values 
(MedianM1) and the median M2 values (MedianM2) at the same time points 
was -0.11 cmH2O. For three infants, the value documented by the nurse was 
0.5 cmH2O lower than the value downloaded by the VOXP Research Data 
Collector, resulting in this negative mean difference. 
The differences between the values of MedianM1 and MedianM2 all fell within 
the upper and lower limits of agreement (the mean difference +/- two SDs) and 
well within the 95% CIs of these limits of agreement. Therefore this 
demonstrates very good agreement between the two measurements when the 
median values for all 14 infants are compared. 
5.6.9 Verification of M2 
Two sets of data obtained using the VOXP Research Data Collector were 
analysed for this study. One set comprised the mean airway pressure values 
sampled with every breath (M2), as analysed above. The other set comprised 
more sensitive data used to verify the M2 data. These other data consisted of 
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the airway pressure values sampled 100 times per second and downloaded into 
a separate Microsoft Excel file created by the VOXP Research Data Collector. 
The VOXP Research Data Collector downloaded these data, as well as the M2 
data, simultaneously.  
These data were used to create a visual display of the 12,000 airway pressure 
data values downloaded during the minute preceding, and the minute 
corresponding to, the M1 value. An average airway pressure value was also 
calculated and referred to as M3. This was done using MATLAB software 
(MATLAB 2012a, The MathWorks, Inc., Natick, Massachusetts, United States). 
As shown in Figure 5-7, the visual display resembled the airway pressure 
graphic waveforms commonly displayed on modern ventilators. 
In Figure 5-7 the time of the data collection is on the x-axis and the airway 
pressure is on the y-axis. The 12,000 data points obtained using the VOXP 
Research Data Collector were used to create the airway pressure waveform 
graphic shown in blue in the figure. The red line represents the ‘moving 
average’ of all of these data points. The red number on the right side of the 
figure represents the mean value of all of these data points. This value is the 
M3 value and, for this infant, was 7 cmH2O 
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Figure 5-7 Output from MATLAB software when analysing M3 data for one 
infant (analysed and produced by Ms Audrey Wilkinson, Northern Medical 
Physics and Clinical Engineering) 
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5.6.10 Results of comparison of M2 and M3 values 
Data from 12 of the 14 infants in this study were used to verify the M2 data. M3 
data on two infants were not available for comparison. M2 was used as the 
comparison against which M3 was compared. Table 5-5 shows an example of 
these data from Infant 12.  
Hour of 
data 
collection 
Time 
(hours 
and 
minutes) 
Mean of M2, 
cmH2O 
Mean of M3, 
cmH2O 
M2 – M3, 
cmH2O 
Mean of 
M2 plus 
M3, 
cmH2O 
1 09:55 9 9 0 9 
2 11:10 8 8.2 -0.2 8.1 
3 12:00 10 10.1 -0.1 10.05 
4 13:10 10.68 10.4 0.28 10.54 
5 14:05 10.45 10 0.45 10.225 
6 15:10 9.05 9 0.05 9.025 
7 16:10 9.18 9 0.18 9.09 
8 17:15 7 7 0 7 
Sum of 
M2 – M3, 
cmH2O 
   0.66  
Mean of 
M2 – M3, 
cmH2O  
   0.083  
Mean of 
M2 – M3 
plus 2SD, 
cmH2O 
   0.505  
Mean of 
M2 – M3 
minus 
2SD,     
cmH2O 
   -0.339  
Table 5-5 Example of comparison of M2 and M3 data from Infant 12 
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Figure 5-8 Bland Altman plot showing the comparison of M2 and M3 data for 
Infant 12 
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5.6.11 Description of the Bland Altman plot comparing M2 and M3 for 
Infant 12  
• The mean difference between M2 and M3 for this infant was 0.083 cmH2O.  
• The upper limit of agreement was the mean of M2 and M3 plus 2 SDs. In 
this case, this upper limit of agreement was 0.505 cmH2O.  
• The lower limit of agreement was the mean of M2 and M3 minus 2 SDs, 
which, for this infant, was -0.339 cmH2O.  
• The standard error of the mean difference +/- two SDs was 0.567. Therefore 
the 95% CIs of the upper limit of agreement were 0.362 to 0.648 cmH2O. 
The 95% CIs of the lower limit of agreement were -0.196 to -0.482 cmH2O. 
M2 was used as the reference against which M3 was compared. For this infant, 
there was no difference between two of the eight measurements at hours 1 and 
8. The biggest difference between the two measurements occurred at hour 5 
when the M2 value was 0.45 cmH2O higher than that of M3. At hours 4 to 7, the 
M2 value was higher than that of M3. At hours 2 and 3, the M3 value was 
higher than that of M2. Therefore, more of the differences were positive than 
negative. 
5.6.12 Explanation of the Bland Altman plot comparing M2 and M3 for 
Infant 12 
For Infant 12, the mean difference between M2 and M3 was 0.083 cmH2O. At 
each time point, the difference between the values of M2 and M3 fell within the 
upper and lower limits of agreement (the mean difference +/- two SDs). 
Therefore, for Infant 12, this indicates good agreement between the two 
measurements.  
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5.6.13 Comparison of MeanM2 and MeanM3 for 12 of the 14 infants 
Table 5-6 shows the comparison of the mean values of M2 and M3 for 12 of the 
14 infants, with M2 as the reference value. M3 data on Infants 1 and 8 were not 
available. 
Subject Mean of 
M2 
(MeanM2), 
cmH2O 
Mean of M3 
(MeanM3), 
cmH2O 
MeanM2 –  
MeanM3, 
cmH2O 
Mean of 
MeanM2 plus 
MeanM3, 
cmH2O 
2  6.93 6.86 0.07 6.895 
3 7.18 7.22 -0.04 7.2 
4 6.37 6.36 0.01 6.365 
5  7.8 7.82 -0.02 7.81 
6 8.88 8.86 0.02 8.87 
7 6.74 6.55 0.19 6.645 
9 7.65 7.64 0.01 7.645 
10 8.9 8.84 0.06 8.87 
11 8.71 8.81 -0.1 8.76 
12 9.17 9.09 0.08 9.13 
13  7.84 7.84 0 7.84 
14  7.07 7.14 -0.07 7.055 
Total of (MeanM2 – 
MeanM3), cmH2O 
  0.21  
Mean of (MeanM2 – 
MeanM3), cmH2O  
  0.018  
Mean of (MeanM2 – 
MeanM3) plus 2SD, 
cmH2O 
  0.172  
Mean of (MeanM2 – 
MeanM3) minus 
2SD, cmH2O 
  -0.136  
Table 5-6 Comparison of MeanM2 and MeanM3 data for 12 infants 
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5.6.14 Bland Altman plot for the comparison of M2 and M3 for 12 of the 14 
infants 
 
 
 
Figure 5-9 Bland Altman plot for the comparison of MeanM2 and MeanM3 
values for 12 infants 
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5.6.15 Description of the Bland Altman plot comparing M2 and M3 for 12 
infants 
• The mean difference between MeanM2 and MeanM3 for 12 infants was 
0.018 cmH2O.  
• The upper limit of agreement was the mean of MeanM2 and MeanM3 plus 2 
SDs. The upper limit of agreement was calculated as 0.172 cmH2O for 12 
infants.  
• The lower limit of agreement was the mean of MeanM2 and MeanM3 minus 
2 SDs, which, for these 12 infants, was -0.136 cmH2O.  
• The standard error of the mean difference +/- two SDs was 0.039. Therefore 
the 95% CIs of the upper limit of agreement were 0.142 to 0.202 cmH2O. 
The 95% CIs of the lower limit of agreement were -0.106 to -0.166 cmH2O. 
For one of the 12 infants, there was no difference between the MeanM2 and 
MeanM3 values. The largest difference between M2 and M3 was 0.19 cmH2O 
(Infant 7). All other differences were ≤0.07 cmH2O. 
5.6.16 Explanation of the Bland Altman plot comparing M2 and M3 for 13 
infants 
The Bland Altman plot demonstrates good agreement between the two 
measurements when the mean values for 12 infants were compared. The only 
difference that fell outside the limits of agreement for the mean difference was 
that of Infant 7. However, this mean difference was still within the upper 95% CI 
of the upper limit of agreement.  
Therefore, based on these data, M2 values were verified with the M3 
measurements.    
5.7 Strengths and limitations of this ancillary study 
There are several strengths and limitations of this ancillary study. These are 
discussed below. 
5.7.1 Strengths 
• The aim of this ancillary study was to validate one of the three ‘success 
criteria’ used as the primary outcome for The VoluVent Trial. This is an 
important part of complex interventions research, particularly in a trial such 
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as this in which the primary outcome measure is documented by a variety of 
nurses in a busy intensive care unit. The M1 and M2 measurements showed 
good agreement, demonstrating that the MAP values documented by 
nursing staff once every hour were representative of the MAP values 
generated with every breath.  
• In this ancillary study two methods of clinical measurement were compared, 
the manual recording of MAP once every hour (M1) and the sampling of an 
MAP value with every breath using computer software (M2). M2 was also 
verified by M3 data. This is the first study to make these comparisons in 
ventilated infants. It validated the primary outcome and also provided useful 
information for routine clinical care in NICU. It demonstrated that hourly 
documentation of MAP by nursing staff is a good reflection of the MAP 
values generated throughout each hour. This indicates that manual 
recordings are as good as electronic data.  
• The VOXP Research Data Collector uses software that samples a signal at 
100Hz. This meant that the airway pressure was sampled 100 times per 
second. In order to sample a continuous signal at an adequate rate to detect 
changes in that signal, Nyquist sampling theorem states that the sampling 
frequency should be twice as high as the frequency in the signal 
(Olshausen, 2000). The frequency of an airway pressure signal is complex 
and should be sampled many times per second to obtain adequately 
sensitive data. A sampling rate of 100Hz was sufficient to obtain digital data 
(airway pressure values every 100th of a second) and use it to recreate the 
airway pressure waveforms graphically. This sampling rate produced data 
that provided sensitive M3 values which were not difficult to store 
electronically. The software was also used on a standard laptop computer. 
This approach to a study involving signal analysis, nested within an intensive 
care RCT, is a useful part of process evaluation in a complex interventions 
trial (Moore et al., 2015).  
5.7.2 Limitations 
• Data could only be collected when the Principal Investigator was available to 
set up the VOXP Research Data Collector to collect data from the ventilators 
in ‘real time’. Therefore infants were not selected in a truly randomised 
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fashion. However, the only determinant of infant selection was the 
availability of the Principal Investigator. No other aspect of the infant’s care, 
condition or participation in The VoluVent Trial was taken into account. The 
Principal Investigator was not required to be present during the period of 
data collection. Data collection was continued for as long as possible. 
However availability of the Principal Investigator did determine the duration 
of data collection for each infant because she also had to be available to 
stop the data collection.  
• The use of a clock to record the timings of data collection may have limited 
the data. The nurses recorded the times at which M1 values were 
documented as accurately as possible to the nearest minute. The use of a 
clock may have introduced an element of subjectivity in these timings. The 
VOXP Research Data Collector used a timer built into its software. The 
Principal Investigator retrospectively matched the M1 data with those 
comprising the M2 and M3 data. Although this was done as accurately as 
possible, the use of two different timers may have affected the reliability of 
matching the data. A means of improving this would be to use a timer that 
the nurses can use for the M1 data that is calibrated before each use and 
synchronised with the timer in the VOXP Research Data Collector. This 
would improve the accuracy of the matching of data.   
• The duration of data collection may have affected the reliability of the data 
obtained for some of the infants. Data for Infant 8 was collected over four 
hours. Therefore there were only four time points for use during the analysis 
for this infant. This may explain why this infant appears as a possible outlier 
in the Bland Altman plot for comparison of M2 and M3 values for 13 infants. 
However, in the analysis comparing M1 and M2 values this infant does not 
appear to be an outlier. Therefore, it is not clear from this study whether the 
duration of data collection affects the reliability of the data.  
• Fourteen infants were originally included in this ancillary study and 
contributed data for the comparison of M1 and M2. However, M3 data from 
only 12 infants was available for analysis to verify the M2 data. This may 
have affected the validity of the comparison of M2 and M3 values.  
• Data were collected on all 14 infants during routine periods of care within the 
NICU. The criteria for inclusion of an infant in this ancillary study were:  
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a. the infant had to have stable clinical conditions,  
b. no invasive procedures or routine changes of equipment were 
planned, 
c. temporary removal of the infant from the incubator was not 
planned. 
Whilst these criteria were adhered to, routine care may still have involved 
some periods of handling or movement of these infants. This may have 
affected the MAP of these infants at times. During handling the MAP is likely 
to be more variable than during periods of rest. When infants are awake the 
MAP may be more variable than during periods of sleep as infants may 
make more vigorous movements when awake. If the study had been 
planned so that data were only collected when infants were asleep and not 
being handled, the variability in MAP data may have been less. However, 
this can also be considered a strength of the study in that the data collected 
are a true representation of the MAP generated in ventilated infants in NICU.  
• The design of this study meant that the nurses had to know when the data 
collection periods were taking place. They also had to record the time of 
documentation of MAP in hours and minutes. This is a deviation from routine 
practice during which they record the MAP to the nearest hour only. The 
nurses were also aware of the presence of a laptop connected to the infants’ 
ventilators during the data collection periods. These issues may have 
introduced observer bias into the study by affecting the nurses’ behaviour 
regarding observation of the MAP on the ventilator screen, documentation of 
the MAP value, and documentation of timings to the nearest minute. 
5.7.3 Conclusion 
This ancillary study was undertaken as part of process evaluation of The 
VoluVent Trial to validate one of the elements of the primary outcome measure. 
This element was the MAP value documented by nursing staff every hour and 
used as part of the primary outcome. Although the primary outcome is 
considered to be a subjective measure, the MAP values can be affected by 
clinical, human and electromechanical factors. 
This study compared the median MAP values manually recorded by nurses 
every hour during data collection with the median MAP values sampled and 
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downloaded with every breath at the same time points. Comparison of these 
two measurements using Bland Altman analysis showed good agreement 
between the two measurements. This means that the MAP values documented 
once an hour by the nurses are a good representation of the MAP values being 
generated with every breath.  
According to the SAP for this ancillary study, written prior to data analysis, the 
proportion of M2 and M3 values between the two corrected SDs was high 
enough to indicate a good level of agreement between M2 and M3. This means 
that the M2 measurement was verified by M3.  
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Chapter 6 Consent for Neonatal Emergency Care Trials 
6.1 Introduction 
Informed consent forms the cornerstone of research ethics (World Medical 
Association, 2013). The justification for informed consent in research arose from 
the Nuremburg Trials, from which the ten ethical principles forming the 
Nuremburg Code (Doyal et al., 2001a) were created. The fundamental elements 
of informed consent (Beauchamp et al., 2001) include:  
• capacity (on behalf of the person giving consent) 
• disclosure (of information about the research study by the researcher 
or clinician) 
• understanding (of that information) 
• voluntariness (in giving consent without coercion)  
• consent  
 However, the form that informed consent should take continues to be debated 
(Doyal et al., 2001b).  
The most commonly recognised form of informed consent for research is 
prospective consent obtained from the eligible individuals themselves 
(Beauchamp et al., 2001). However, as demonstrated in The VoluVent Trial, 
prospective consent may not be suitable for all research studies. Deferred 
consent for research is becoming more widely accepted in the emergency care 
setting (Crash-2 trial collaborators, 2010; Perkins et al., 2016; Lyttle et al., 
2017). However there are still gaps in knowledge about the use of deferred 
consent in neonatal research. The VoluVent Trial highlighted some of these 
gaps. They relate to the ethical principles and the practical implementation of 
deferred consent in a neonatal trial. They also relate to the impact that deferred 
consent has on the consent procedure and the design of a neonatal trial. 
The gaps in knowledge are linked to the unique differences between obtaining 
consent for research involving adults or older children, and for research 
involving infants. These differences shall be discussed first, followed by a 
summary of the impact of deferred consent on The VoluVent Trial with 
reference to published literature. 
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6.2 Informed consent in neonatal research 
There are many similarities between the elements of informed consent 
procedures for neonatal and paediatric research, and for adult research. 
However, there is a fundamental difference between newborn infants and older 
children or adults. By virtue of their age and physical, cognitive and emotional 
developmental status, newborn infants lack the capacity to give informed 
consent. The four components of capacity, as described in the Mental Capacity 
Act of 2005 (Mental Capacity Act, 2005) are the abilities to: 
• understand the information given, 
• retain the information given, 
• make a decision based on the information given, 
• communicate that decision.  
None of these components can apply to seeking consent for the participation of 
newborn infants in research studies. They can apply to older children 
depending on the age of the child and the circumstances (General Medical 
Council, 2007). Therefore, in neonatal research, informed consent must always 
be sought from someone other than the eligible infant. The decision to 
participate in the neonatal research study is never made by the participant. This 
is known as proxy consent (Montgomery, 2001). It adds another level of 
complexity to the informed consent process in neonatal research studies.  
6.2.1 Proxy consent 
In the United Kingdom, proxy consent can be given by the person or persons 
with parental responsibility for an infant (Foex, 2001). Other than in exceptional 
circumstances a newborn infant’s mother always has parental responsibility. 
She can give proxy consent for research at any time provided she has the 
capacity to give consent (General Medical Council, 2007). An infant’s father has 
parental responsibility if he is married to the infant’s mother at the time of birth. 
Therefore a married father can also give proxy consent for an infant to 
participate in research. 
However an unmarried father only assumes parental responsibility after being 
named as the infant’s father on the birth certificate (Children Act, 2004). 
Therefore an unmarried father cannot provide consent for neonatal research. In 
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practice, an unmarried father could sign a consent form for his infant but the 
mother must also agree to the study and sign the form as she is the only one 
with parental responsibility at that time. In the United Kingdom same-sex 
couples both have parental responsibility if they are married or in a civil 
partnership at the time of conception. If they are not married or in a civil 
partnership, the parent who did not give birth to the child gains parental 
responsibility if named on the birth certificate or if a parental responsibility 
agreement is made (Parental Rights and Responsibilities, gov.uk).  
Therefore the law regarding parental responsibility is one of the ways in which 
seeking consent for neonatal research involves unique challenges. Many 
infants are now born to unmarried couples. Despite it being good practice to 
involve both parents in a discussion and decision about neonatal research, only 
the mother can provide written consent if they are not married.   
In The VoluVent Trial an infant was enrolled only if written consent had been 
obtained from someone with parental responsibility. Mothers and married 
fathers could give proxy consent provided they had the capacity to do so 
(Mental Capacity Act, 2005). Unmarried fathers could not give proxy consent as 
the infants’ births had not been registered within the required timeframe.  
Throughout this thesis, the term ‘consent’ refers to proxy consent when it is 
used in reference to consent from parents (or someone with parental 
responsibility) on behalf of the newborn infant. 
6.2.2 Prospective consent 
In research, prospective consent refers to consent obtained before the patient is 
exposed to any part of a trial protocol. This includes randomisation and 
exposure to interventions. This is a commonly used form of consent in neonatal 
research. 
6.2.3 Advantages of prospective consent 
An important advantage of prospective consent is that it aims to preserve 
autonomy. In neonatal research, it is parental autonomy that is preserved 
because it is the parents, not the infant, who are providing consent (Beauchamp 
and Childress, 2001). It enables parents to make decisions about all aspects of 
their infant’s management in relation to research. Prospective consent is 
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suitable for any type of non-emergency research. It should be used in non-
emergency neonatal research so that parents have the opportunity to make 
decisions about research at all stages.  
6.2.4 Disadvantages of prospective consent 
Prospective consent has been, and continues to be, used for emergency 
interventions research (Azzopardi et al., 2008; Singh et al., 2006). However, it 
can lead to difficulties with obtaining informed consent that then impact on 
recruitment rates. These were demonstrated well during the first four months of 
The VoluVent Trial and will be discussed here. 
6.2.4.1 Initial use of prospective consent in The VoluVent Trial 
Between July and November 2013, prospective written parental consent was 
sought according to the original trial protocol (version 7, dated 18th July 2013). 
Verbal and written information was offered to parents before the birth of their 
infant if it was possible and appropriate to do so. If not, information was offered 
after a potentially eligible infant’s birth, again only if it was possible and 
appropriate to do so. Written parental consent had to be obtained within 12 
hours of intubation before an infant could be randomised.  
Therefore, before obtaining consent, a potentially eligible infant initially received 
VCV. If parental consent was obtained within 12 hours of intubation the infant 
was then randomised within the appropriate stratification group. If that infant 
was randomised to VCV, no changes were made to his or her ventilation. If the 
infant was randomised to VG, the mode of ventilation was therefore changed to 
VG. 
Obtaining prospective consent for the trial was difficult for a number of reasons. 
Seventeen sets of parents either declined consent or, in the case of outborn 
infants, were not present in the hospital within 12 hours of intubation. Although 
they were not asked for their reasons for declining, several parents voluntarily 
explained their reasons. Many of these were similar to those reported recently 
by authors of another neonatal emergency interventions trial (Songstad et al., 
2017). These included 
• feeling unable to make a decision within 12 hours, 
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• feeling uncomfortable with the prospect that randomisation may lead to 
a change in their infant’s ventilation,  
• feeling unable to consider the information due to fatigue, worry or the 
effects of medications,  
• in the cases of outborn infants, feeling unable to consider the 
information within the very narrow timeframe because they had only 
just arrived at the trial site. 
On some occasions, members of the clinical or research teams did not 
approach parents because they felt that the timing was not appropriate. As a 
result, recruitment was affected with only six infants recruited being in four 
months.  
The challenges described by parents demonstrate clearly that parents are often 
not in a position to give fully informed consent shortly after the birth of a sick or 
preterm infant. These challenges, highlighted by the attempted use of 
prospective consent in an emergency interventions trial, are discussed in more 
detail below. Some of them are unique to neonatal research. 
6.2.4.2 Challenges in using prospective consent in neonatal emergency 
interventions research 
One commonly occurring challenge in neonatal research is that mothers have 
often received sedation or anaesthesia shortly before the birth of their infants. 
This may affect their capacity to give consent (Mental Capacity Act, 2005). In 
The VoluVent Trial half of the trial population were born by caesarean section, 
meaning that at least half of the mothers would have received anaesthesia or 
potent analgesia at the time of delivery. In this regard, the context of consent in 
neonatal emergency interventions research differs from that of non-emergency 
interventions research. It also differs from paediatric research because most 
parents of older children are not themselves recovering from childbirth or a 
major operation.  
Therefore the physical effects of labour and childbirth on the mother create a 
unique challenge in seeking consent for neonatal emergency interventions 
research. Fatigue, anxiety or distress may also impact on both parents’ abilities 
to give informed consent in the first few hours after their infant’s birth (Mason, 
1997; Manning, 2000). If the father does not have parental responsibility, this 
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creates an additional challenge unique to neonatal emergency interventions 
research. 
As highlighted by The VoluVent Trial, parents may feel uncomfortable with the 
prospect that their decision to give consent may lead to a change in their 
infant’s management through randomisation. This is consistent with published 
literature (Harron et al., 2015) and emphasises the burden of responsibility that 
parents may feel in this situation. It is possible that parents would not have the 
same concerns regarding their own participation in an adult study. In neonatal 
research, parents have had a shorter relationship with their infants compared 
with parents of older children eligible for paediatric research. Whilst the duration 
of this relationship does not determine the strength of parent-infant bond it may 
impact on parents’ decisions regarding consent for neonatal research. These 
factors all highlight the complex and often unique challenges that arise when 
considering consent for neonatal emergency interventions research. 
One methodological disadvantage with prospective consent in emergency 
interventions research is that initial management of participants prior to protocol 
implementation may affect the scientific validity of the trial results. Initially a 
potential participant may receive one particular type of intervention before 
consent is obtained. After consent is obtained and randomisation occurs they 
may then receive a different intervention. Depending on the trial design and the 
intention-to-treat definition used in the protocol this can impact on the validity 
and reliability of the results. 
These examples demonstrate that, in neonatal emergency interventions 
research, prospective consent may not be an appropriate method for seeking 
informed consent.  
6.3 Deferred consent 
Deferred consent refers to consent given by a patient or a proxy after part of the 
protocol has already been implemented. The person giving consent therefore 
gives permission for the intervention or protocol to continue and for the 
researchers to use the participant’s data for the study (Woolfall et al., 2013). 
Deferred consent has been permissible for children’s research studies in the UK 
since the Clinical Trials Regulations were updated in 2008 (The Medicines for 
Human Use (Clinical Trials) and Blood Safety and Quality (Amendment) 
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Regulations, 2008). The regulations specify that certain conditions must exist 
that render fully informed prospective consent prior to starting the trial protocol 
impossible. These conditions are that: 
• “the minor requires urgent treatment,  
• urgent action is required for the purposes of the trial, 
• meeting the requirements [in obtaining informed consent] is not 
reasonably practicable, 
• an ethics committee has given its approval”.  
Deferred consent is not suitable for all studies but does make good quality 
research into emergency interventions possible. If deferred consent is declined 
the participant takes no further part in the study and no data related to that 
participant are used for purpose of the study.  
Deferred consent has been used in neonatal and paediatric research studies in 
several countries including the United Kingdom (Gilbert et al., 2016; Lyttle et al., 
2017), Australia and New Zealand (Franklin et al., 2015; Dalziel et al., 2017; 
Songstad et al., 2017). It has enabled the investigation of emergency 
interventions that would otherwise have no evidence base. Some authors use 
different terms such as ‘retrospective consent’ (Songstad et al., 2017) or 
‘research without prior consent’ (Woolfall et al., 2015; Woolfall et al., 2016). 
‘Research without prior consent’ has been proposed because it takes account 
of the fact that the parents do not give consent to the initial trial procedures but 
only to continuation in the trial (Woolfall et al., 2016). However, in this thesis the 
term ‘deferred consent’ will be used in order to maintain consistency with The 
VoluVent Trial protocol (version 9, 21st August 2014). 
6.4 Making a change to the method of consent during The VoluVent Trial 
In order to improve the consent procedure used in The VoluVent Trial, the use 
of deferred consent was considered. This was discussed with parents who had 
previously declined or agreed to research studies in the unit. They indicated 
that deferred consent would be acceptable to them. 
On 18th November 2013 the North East-York ethics committee gave a 
favourable opinion for a substantial protocol amendment for this trial to allow 
the use of deferred consent. The South Tees Hospitals NHS Foundation Trust 
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Research and Development department also approved the amendment. As a 
result, more parents gave consent for their infants to participate in the trial. The 
recruitment rate improved immediately, with an average of four infants per 
month recruited since the change of protocol. 
6.5 The impact of deferred consent on the consent procedure 
The use of deferred consent in The VoluVent Trial changed the consent 
procedure in several ways. Giving deferred consent meant that parents agreed 
to their infants’ ongoing participation in the trial. It also meant that they agreed 
to the collection and use of data from their infants’ medical records for the 
purpose of the trial. Declining deferred consent meant that such data would not 
be collected and that infants would no longer be managed according to the trial 
protocol. As the research and clinical teams were in equipoise about the two 
modes of ventilation, the infants of parents who declined deferred consent 
remained on their allocated mode of ventilation unless their clinical conditions 
dictated otherwise.  
This meant that, regardless of their parents’ decisions, the management of 
these infants did not change substantially. This appeared to be acceptable to 
parents. Many expressed relief that their decision either to give or decline 
consent would not lead to a change in their infants’ modes of ventilation. 
Several stated that, because the mode of ventilation would not change and 
because the main purpose of giving consent was to give permission for data 
collection, they were willing to give consent.  
However, deferred consent did affect parents’ autonomy. Randomisation and 
initial management according to protocol had already occurred before parents 
were able to make a decision about the trial. This is an important disadvantage 
of deferred consent and is discussed further in Section 6.7.  
6.6 The impact of deferred consent on this trial 
The use of deferred consent had several advantages during this trial. These are 
consistent with published literature (Manning, 2000; Woolfall et al., 2014; Furyk 
et al, 2017; Songstad et al., 2017). 
• Parents had more time in which to consider the trial information before 
making a decision. 
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• Mothers who had received sedatives or anaesthesia were offered 
information only once the effects of medication had worn off. 
• In most cases, there was time for the parents of outborn infants to 
consider the trial information after they had arrived at the hospital. 
Therefore more outborn infants could be enrolled, making the results 
more generalisable and reducing selection bias. 
• The parents’ decisions to give or decline consent did not lead to a 
change in their infants’ ventilation. This addressed a specific concern 
raised by parents when prospective consent was sought. 
• Clinicians or researchers seeking consent were usually able to offer 
information at a time that better suited the parents which removed 
some of their reservations about approaching parents. 
• The randomised mode of ventilation could be initiated immediately. 
This improved the scientific validity of the trial by reducing the number 
of infants who received a different mode of ventilation prior to 
randomisation. 
• The recruitment rate improved after the introduction of deferred 
consent. The trial was therefore completed to time and target, fulfilling 
the research team’s ethical obligation to complete the study. 
6.7 Ethical considerations when using deferred consent 
Deferred consent enables researchers to study interventions in emergency 
settings that otherwise could not be investigated. This is important in neonatal 
and paediatric research. It is vital that emergency interventions are based on 
evidence from well-conducted research rather than anecdote. Recent updates 
in international neonatal resuscitation guidelines (Wyllie et al., 2015) are based 
on evidence from trials using deferred consent or waivers of consent. 
However, there are ethical aspects that must be considered before using 
deferred consent for emergency interventions research. These should be 
deliberated carefully to determine whether deferred consent is appropriate for 
the participants and families, the research question and the trial design. The 
criteria specified in the Clinical Trials Regulations (The Medicines for Human 
Use (Clinical Trials) and Blood Safety and Quality (Amendment) Regulations, 
2008) must be adhered to.  
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6.8 Autonomy 
Of the four ethical principles, autonomy is the principle challenged by deferred 
consent. Personal autonomy is the ability to self-govern (Beauchamp et al., 
2001) in the context of being “free from both controlling interference by others 
and from limitations, such as inadequate understanding, that prevent 
meaningful choice” (Beauchamp et al., 2001, p.58). Therefore, informed 
consent is closely linked to autonomy. Clinicians and researchers have an 
obligation to respect a patient’s autonomy and a patient has a right to make an 
autonomous choice about research.  
Those who argue that prospective consent for research should always be 
obtained highlight that deferred consent overrides the participants’ (or parents’) 
autonomy (Manning, 2000). They have autonomy to decide on ongoing 
participation but were not given autonomy to decide about initial randomisation 
and protocol implementation.  
However, individual patients’ interests must be balanced with the responsibility 
to society to produce a rigorous evidence base for emergency interventions. 
This is vital in neonatal medicine in which many treatments are used without 
license or without a strong evidence base. Deferred consent allows emergency 
interventions to be researched appropriately and adequately. Therefore, it can 
be argued that it would be unethical towards the wider society not to use 
deferred consent as part of good trial design (Jansen-van der Weide et al., 
2015; Rebers et al., 2016). Currently many unproven emergency treatments are 
given as part of ‘standard’ practice without consent ever being sought 
(Stephenson, 2006). If this is considered acceptable then implementing 
emergency interventions as part of an approved trial protocol that includes 
deferred consent should also be acceptable. 
The ethical arguments either way are valid and reasonable. In the era of 
evidence-based medicine it would seem appropriate to use deferred consent 
within the regulations in order to determine the evidence. However, it is vital that 
the evidence for the use of deferred consent is also determined so that it can be 
used most appropriately and efficiently.  
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6.9 Current evidence regarding the use of deferred consent in neonatal 
and paediatric research 
Deferred consent has been used in trials involving adult patients for some time 
(CRASH-2 trial collaborators, 2010; Perkins et al., 2016). However, it has only 
recently been used in paediatric trials in the UK (Gilbert et al., 2016; Lyttle et al., 
2017). 
Parental opinions and experiences of giving consent for research involving their 
children have previously been explored (Mason et al., 2000; Allmark et al., 
2005; Culbert et al., 2005). In recent years, the use of deferred consent in 
paediatric populations has been specifically investigated (Woolfall et al., 2014; 
Furyk et al., 2017). The views of parents, clinicians and researchers have been 
obtained through qualitative research (Woolfall et al., 2013; Woolfall et al., 
2014). These studies have sought qualitative data on hypothetical scenarios, 
retrospective data on actual trials, and nested studies undertaken prior to or 
during RCTs. Some researchers have assessed the impact of deferred consent 
on the validity of trials by reporting its effect on recruitment and the children that 
were included or excluded as a result of deferred consent (Harron et al., 2015; 
Songstad et al., 2017). 
The CATCH trial (Gilbert et al. 2016) was undertaken in paediatric intensive 
care centres in the UK to investigate three different types of central venous 
catheter in children. It involved the use of prospective consent and deferred 
consent, and was one of the first UK trials to use deferred consent in a 
paediatric population. Prospective consent was used when children required 
central venous catheters for elective procedures. Deferred consent was used 
when the catheters were required as emergency interventions. The recruitment 
rate was higher when deferred consent was used than when prospective 
consent was used. A substantial proportion of parents declined prospective 
consent due to parental distress or preference for standard treatment (Harron et 
al., 2015). The authors highlighted the fact that most of the children who died in 
PICU could not be recruited. This was because parents declined consent, were 
not approached because researchers felt it was inappropriate to do so, or did 
not respond to approach by researchers after the death of their children. As 
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understandable as these reasons are, the authors highlight the inability to 
recruit these children limited the validity of the trial results.  
The way in which deferred consent alters trial methodology and procedures can 
affect prognostic factors and trial outcomes. The introduction of deferred 
consent altered the intention-to-treat analysis in The VoluVent Trial. Initially, 
when prospective consent was used, analysis of data from all randomised 
infants was planned. When deferred consent was used, data from some 
randomised infants could not be analysed as consent was not obtained for all of 
them. This may have affected the balance of prognostic factors between the 
two groups which could then have affected the results. This is discussed further 
in Section 7.5.5 of Chapter 7 Discussion.    
Songstad et al. (Songstad et al., 2017) reported the impact of deferred consent 
on a neonatal emergency interventions RCT comparing two types of NIV in 
preterm infants. They found that deferred consent led to higher recruitment 
rates. Interestingly, in their study, making a change from prospective to deferred 
consent was associated with a change in maternal and infant demographics. 
After the introduction of deferred consent, fewer mothers of enrolled infants had 
been exposed to antenatal steroids and more had received intrapartum 
antibiotics. The authors postulate that this may be because deferred consent 
enabled the enrolment of more infants from unexpected deliveries. This requires 
further evaluation and is an example of the impact of deferred consent on trial 
population demographics.   
The CRASH-2 trial collaborators (CRASH 2 trial collaborators, 2010) reported 
on an RCT investigating the use of tranexamic acid in adult trauma patients. 
This large multi-centre trial used a variety of different consent procedures at 
different sites, including deferred, waived and proxy consent. A logistic 
regression analysis was performed exploring ‘time to treatment’ as an 
explanatory variable on the outcome of mortality due to bleeding. They 
estimated that a delay of one hour in administering the trial treatment reduced 
the proportion of people who benefitted from the treatment from 63% to 49% 
(Roberts et al., 2011). The authors argue that, in emergency interventions 
research, a delay in starting a trial treatment due to the need to obtain 
prospective consent may increase mortality in the trial population. Secondly, a 
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delay may also conceal the true treatment effect that may then affect translation 
of a trial’s findings into clinical care. The delay caused by the need to seek 
consent may dilute the effect of an emergency intervention on the trial 
population. A stronger or positive effect may be seen in clinical practice during 
which the same emergency intervention would be given immediately without 
seeking consent. 
6.9.1 Parents’ experiences of deferred consent 
Parents have indicated that deferred consent is acceptable to them when used 
in trials comparing standard treatments (Woolfall et al., 2014). There is less 
evidence to suggest that they consider it to be acceptable when a novel 
treatment or placebo is being used. However, two trials are currently underway 
in the UK and Australia comparing the use of a standard drug for the 
emergency treatment of childhood status epilepticus (phenytoin) with a non-
standard drug (levetiracitam) (Dalziel et al., 2017; Lyttle et al., 2017;). The 
EcLiPSE trial is being undertaken in the UK (Lyttle et al., 2017). This is the first 
time deferred consent has been used in a paediatric emergency interventions 
trial involving a non-standard intervention. Prior to commencing the EcLiPSE 
trial, qualitative research was undertaken exploring parents’ views on the use of 
deferred consent in such a trial. Parents were initially uncomfortable with the 
prospect of deferred consent. However when parents were informed of the 
rationale for the trial, including the fact that the standard treatment has 
important side effects, the majority indicated that the use of deferred consent 
would be acceptable (Woolfall et al., 2014). These data informed the design of 
the EcLiPSE trial that now includes a nested study investigating the 
experiences of parents approached for consent for this trial (Lyttle et al., 2017).  
A similar qualitative study was undertaken prior to the Australian trial comparing 
phenytoin and levetiracitam for the treatment of childhood status epilepticus 
(Dalziel et al., 2017). This study was slightly different in that the parents 
interviewed had experience of children receiving emergency care for minor 
illnesses in the Emergency Department rather than more serious conditions 
such as status epilepticus. As a result, they were asked about hypothetical 
scenarios regarding children needing higher levels of care than their children 
has received. Parents in this study had mixed views on the use of deferred 
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consent. The majority did find it acceptable provided that the interventions were 
both used as standard care. In keeping with the findings by Woolfall et al. 
(Woolfall et al., 2014) parents were less comfortable with the idea of deferred 
consent for a trial of a novel or high-risk intervention. 
Similar data were obtained by O’Hara et al. (O’Hara et al., 2018). They explored 
the views of bereaved and non-bereaved parents on ‘research without prior 
consent’. This was part of a feasibility study to inform a pilot emergency 
interventions trial on the use of fluid boluses for children with septic shock. 
Twenty-one parents were interviewed for this trial, including seven bereaved 
parents, and all had had children who had recently been admitted to UK 
hospitals with severe infection. After they had discussed the need to establish 
an evidence base for the use of fluid boluses and the need to administer the 
interventions without delay in an emergency, all 21 parents stated that they 
would have given consent for such a trial.  
Much of the qualitative research done on parental views of the use of deferred 
consent in the paediatric population has focused on children and young people, 
with less emphasis on the neonatal population. Therefore this is an area that 
requires further explanation. Seeking consent for neonatal trials is unique. 
Proxy consent is always required. Parents of newborn infants are in a uniquely 
vulnerable position. The mother may be physically and mentally vulnerable due 
to the effects of labour and interventions at delivery. The father may be anxious 
about the condition of the mother as well as the infant. Both parents may be 
fatigued and emotionally vulnerable. Many parents are unmarried, meaning 
that, in the first few days of life, only the mother has parental responsibility. In 
addition to all of these factors, parents have to make a decision based on what 
they think is best for an infant that they have potentially only just met. 
The use of deferred consent in The VoluVent Trial appeared to be acceptable to 
the majority of parents and this is manifest by the fact that most parents gave 
consent for the trial and did not raise objections to the fact that their infant had 
already been managed according to a trial protocol. However, it would be 
dangerous to assume that it was acceptable to all parents and that they did not 
have any objections. At the time that consent was sought they may not have 
been able to raise objections, either because any objections that they had arose 
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at a later date or because their concerns about other aspects of the infant’s 
condition took precedence over any concerns about research. They may also 
have felt unable to raise concerns about the consent process because of fear 
about the effect on their relationship with their child’s clinical team. These are 
possibilities but parental experiences of deferred consent in this trial need to be 
investigated before a larger trial can be undertaken.  
6.9.2 Clinicians’ and researchers’ experiences of deferred consent 
Published literature on the use of deferred consent reveals themes that relate to 
the experiences of clinicians and researchers in its use in paediatric and 
neonatal settings. The majority of those who had not used deferred consent for 
paediatric research thought that it would have a negative impact on the parent-
practitioner relationship whereas the majority of those who had used it before 
thought that it had no impact on the relationship (Woolfall et al., 2013).  
Foglia et al. (Foglia et al., 2017) studied a different group of researchers but 
also identified differing responses depending on prior experience of deferred 
consent. They surveyed participants at the Fourth International Neonatal 
Resuscitation Research Workshop in 2015. Their sample of 47 respondents 
consisted of neonatal researchers, some of whom were on national and 
international neonatal resuscitation committees. The survey questions related to 
research in the delivery room immediately after the birth of an infant. Half of the 
participants had prior experience of using deferred consent and half did not. 
The levels of comfort regarding deferred consent for minimal risk or 
comparative effectiveness delivery room studies were similar between groups. 
However, prior experience of using deferred consent was associated with a 
greater proportion of respondents feeling comfortable with using it to investigate 
novel treatments in the delivery room. Only 33% of those with prior experience 
of deferred consent stated that it is possible to produce scientifically valid 
delivery room research using antenatal prospective consent, compared with 
50% of those without experience of it. Compared to the study by Woolfall et al. 
(Woolfall et al., 2013), the respondents were concerned about the 
methodological limitations in using prospective antenatal consent. Given the 
target population of this survey, that is to be expected. 
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Clinicians and researchers working in the neonatal unit at The James Cook 
University Hospital had little or no experience of using deferred consent prior to 
its introduction during this trial. The ethical reasons for changing the consent 
method were discussed with all those authorised to take consent before the 
protocol amendment was made. Extra training sessions were undertaken and 
written guidance produced so that those seeking deferred consent were aware 
of the practical and theoretical differences of using this method compared to 
prospective consent.  
When deferred consent had been used for almost two years as part of this trial, 
a formal meeting was held to discuss approaches to consent for all of the 
neonatal research studies that were active in the unit at that time. The research 
team, the unit’s Consultant Neonatologists and senior nurses attended the 
meeting. By then it was clear that the use of deferred consent had led to a 
process of “experiential learning” (Woolfall et al., 2013) through which clinicians 
and researchers seeking consent had learnt how to better judge the time at 
which to approach parents. The team had developed a collaborative approach 
to seeking consent, following patterns of approach agreed by all team members 
but tailored to each individual infant. These patterns of approach facilitated the 
consent process for each study and therefore facilitated co-enrolment into 
multiple studies.  
The experience of the Principal Investigator for The VoluVent Trial was that, 
when compared with prospective consent, deferred consent requires a more 
detailed discussion with parents. In response to parents’ questions, and in order 
to be open and transparent, this discussion usually included the topics of 
consent methodology and the ethical issues in seeking consent for research 
studies. In the neonatal intensive care setting, in the hours after a preterm infant 
eligible for an emergency interventions trial has been born, deferred consent 
allows the parents more time to consider information. It also enables the 
research team to approach them at a time that is appropriate for the parents.  
Deferred consent appears to have been acceptable to all of those authorised to 
seek consent for this trial but their views and experiences have not been 
studied. If a similar ventilation trial were to be undertaken on a larger scale, this 
is an important area of qualitative research that would need to be embedded 
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into the design of that larger trial. This would ensure that the appropriate 
regulations, guidance and training could be provided to the clinicians and 
researchers who would be required to seek consent. This would aim to ensure 
similar standards and quality of practice if deferred consent were to be sought in 
multiple centres.  
6.10 Deferred consent in the context of a complex interventions trial 
The VoluVent Trial demonstrated that seeking prospective consent from parents 
of newly born preterm infants for enrolment into a complex interventions trial 
was neither appropriate nor practical. The use of deferred consent 
• appeared to be more acceptable to both parents and to those seeking 
consent, 
• improved the scientific validity and generalisability of the results and 
• improved the recruitment rate. 
The use of deferred consent in this trial appeared to be acceptable to the 
majority of parents but, as discussed above, this observation needs to be 
formally investigated. Investigating parental views on its use in a complex 
interventions trial could also be considered. As discussed earlier, changing 
consent method from prospective to deferred consent changed one of the 
reasons for asking parental consent. They were not being asked to decide 
whether their infant should be randomised and a trial intervention initiated. They 
were being asked to give permission for the trial protocol to continue and for the 
collection of data. Did this change the amount of information that the parents 
wanted regarding the complexity of the interventions in order to make an 
informed decision? If so, did they need more or less information to make a 
decision and would the decision have been easier or harder if prospective 
consent had been used? Did it, as Manning suggests (Manning, 2000), actually 
alleviate them of the burden of having to consider complex information in the 
first few hours after the birth of their premature infants? It is possible that the 
use of deferred consent in this particular complex interventions trial may have 
made the decision-making process easier for parents. However, although 
clinicians and researchers have raised these possibilities (Manning, 2000), only 
parents can provide the answers and researchers should not presume that they 
know the answers to these questions.  
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The need to change the method of consent during this trial highlighted the 
importance of using qualitative research to choose the most appropriate method 
of consent during the design stage of a study. Whilst designing this trial, advice 
was sought from parents about the content of the participant information sheet 
but their input on the most appropriate method of consent was not sought. 
When designing this trial on a larger, multi-centre scale it would be necessary to 
embed a nested qualitative study to investigate parents’ experiences of consent 
for neonatal emergency interventions research. 
6.11 Future directions 
The use of deferred consent is now being used more widely and facilitates 
research into emergency interventions. When used judiciously by researchers 
experienced in seeking deferred consent, well versed in its ethical benefits and 
challenges, and knowledgeable of the scientific basis of a particular trial, 
deferred consent appears to be acceptable to most parents and clinicians. 
There are still gaps in knowledge about its use, particularly as to the best 
method of seeking deferred consent from parents whose child has died 
(Woolfall et al., 2015).  
Therefore further qualitative research is needed into the use of deferred 
consent in neonatal research studies. Areas that should be considered include 
whether parents feel relieved about not having to decide on initiation of a trial 
protocol and whether they would feel the same about a study comparing two 
‘standard treatments’ and a study investigating a novel treatment.  
  
 183 
Chapter 7 Discussion 
7.1 Introduction 
This is the first randomised controlled trial to compare two types of VTV in 
preterm infants. The results provide new data with which to plan a larger study. 
This pilot trial also provides important information on how to approach 
challenges in designing and implementing a trial of complex interventions in a 
neonatal intensive care setting. This information will be crucial to the design of a 
larger trial comparing VTV modes in preterm infants and is also applicable to 
the design of other neonatal emergency interventions trials. 
This chapter discusses some of the important outcomes from this trial, how they 
can be used to develop a larger trial, and the strengths and limitations of the 
trial. 
7.2 Effect of two VTV modes on readiness for extubation in preterm 
infants 
The trial results demonstrated a clinically relevant difference between VCV and 
VG in the primary outcome. In the VG group the median duration of time taken 
for an infant to be ready for extubation was 23 hours (95% CI 10.8 – 35.2 
hours). In the VCV group the median duration was 36 hours (95% CI 18 – 54 
hours).  
A difference of 13 hours of ventilation represents a potentially important 
difference in ventilation-associated lung injury (VALI) between the two groups. 
The results suggest that it is possible that VG has the potential to reduce 
exposure to volutrauma. However, this single centre trial was not designed to 
confirm lung injury although this is an appropriate outcome measure for 
neonatal trials. Indirect measures of VALI, such as a clinical diagnosis of 
chronic lung disease, could be used in a future trial but would require a much 
larger sample size and detailed statistical techniques to adjust for covariates. A 
difference of 13 hours may also have a health economic benefit. 
More than half (62%) of the trial population had reached the ’success’ criteria by 
48 hours. Three quarters (76%) had reached the ‘success’ criteria by 96 hours. 
The majority of infants requiring ventilation beyond this time point were the 
extremely preterm infants (<28 weeks’ gestation). This is not surprising given 
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their greater immaturity. However it demonstrates another important research 
question as to whether one mode of VTV is more beneficial than another for 
different gestational age groups.    
7.3 Effect of two VTV modes of different gestational age groups 
Regardless of the mode of ventilation used, infants in this trial reached the 
‘success’ criteria much quicker in the 28 – 33+6 weeks’ gestation group 
compared with the <28 weeks’ gestation group (median time 20 hours, 95% CI 
16.7 – 23.3 hours, and 93 hours, 95% CI 9.8 – 176.3 hours respectively). The 
unadjusted HR was 3.32 (95% CI 2.1 – 5.3). This strongly indicates a three-fold 
increase in the risk of meeting the ‘success’ criteria at any time point in the 28 – 
33+6 weeks’ gestation group. This is not surprising given that more mature 
preterm infants usually require shorter periods of ventilation than extremely 
preterm infants. It justifies the use of stratification according to these gestational 
age groups when designing this trial and is an important strength of the trial.  
The pre-specified sub-group analyses were planned as exploratory analyses 
and were not powered to show significant differences between groups. 
However, the results demonstrate potentially important differences between 
VCV and VG in the sub-groups. These differences could be evaluated further in 
a larger trial powered to show any differences in treatment effect across sub-
groups.  
7.3.1 Effect of VCV and VG in infants born at <28 weeks’ gestation 
In the extremely preterm infants (those born at <28 weeks’ gestation), the 
median time to ‘success’ criteria was shorter in the VCV group (79 hours, 95% 
CI 0 – 177.7 hours) compared with the VG group (102 hours, 95% CI 90 – 
204.7 hours). This is an average difference of 23 hours between groups. The 
wide CIs associated with these results reflect the high degree of uncertainty 
about these results. However, 23 hours is a clinically relevant difference and 
worth investigating with a larger trial. Although almost two thirds (59%) of 
infants in this group had reached the ‘success’ criteria by 96 hours this group 
also accounted for most of the infants who required ventilation for longer than 
this.     
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7.3.2 Effect of VCV and VG in infants born at 28 – 33+6 weeks’ gestation 
In the 28 – 33+6 weeks’ gestation group, there was a shorter median time to 
‘success’ criteria in the VG group (19 hours, 95% CI 16.5 – 21.5 hours) 
compared with the VCV group (24 hours, 95% CI 11.9 – 36.1 hours). The 
difference between groups here was an average of only five hours. This is not a 
strikingly relevant difference clinically but, as stated previously, the histological 
effects are unknown and it is possible that five more hours of ventilation in the 
VCV group may contribute to greater VALI in that group. The results of this trial 
cannot address this.  
7.3.3 Frequency of pneumothorax 
The overall incidence of pneumothorax occurring whilst on the trial mode was 
low (7%). However, there was an imbalance between the two groups. Only one 
infant in the VG group developed a pneumothorax whilst receiving VG, 
compared with seven in the VCV group. The numbers of infants are too small to 
draw any conclusions about this. However, pneumothorax is an important short-
term complication of mechanical ventilation and can have serious sequelae 
(Jarreau, 2015a). It represents macroscopic evidence of VALI. Therefore, in this 
regard, these results provide important information regarding choice of 
secondary outcomes measures in a larger trial. With a larger sample size, 
regression analyses could determine whether the mode of VTV independently 
increases the risk of developing a pneumothorax.    
7.4 Strengths of the study 
7.4.1 Study design: comparison of two modes of VTV 
This randomised controlled trial is the first study to compare two types of VTV in 
newborn infants using clinically relevant outcomes. It was undertaken following 
the Cochrane review comparing PLV with VTV published in 2010 (Wheeler et 
al., 2010). The authors recommended that further research should include 
comparisons of different volume-targeting modes and strategies. The updated 
Cochrane review in 2017 (Klingenberg et al., 2017), which included analyses of 
more recent research studies, still contains the same recommendation that 
volume-targeting strategies be researched. Therefore this trial contributes 
unique data to the field of research of using VTV in newborn infants. 
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7.4.2 Study design: methodology 
The VoluVent Trial is an example of a trial of complex interventions (Craig et al., 
2008). These interventions (modes of ventilation) were studied in a complex 
environment (an intensive care unit) involving complex patients (preterm 
infants) and complex operators (neonatal nurses and doctors). Therefore it was 
necessary to design a protocol that was rigorous enough to produce 
scientifically valid results but flexible enough to be successfully implemented 
and completed in a busy neonatal intensive care unit (NICU).  
The points below describe some of the ways in which this was achieved. 
7.4.2.1 Designing the trial 
When designing the trial the protocol was drafted by the Principal Investigator 
with oversight from senior Co-Investigators. It was then discussed with all 
Consultant Neonatologists and with senior nurses in the unit. Their feedback on 
certain practical aspects of the protocol contributed to re-drafted and updated 
versions. It was then produced as the final document and was then submitted to 
the ethics committee and regulatory body for approvals.  
This engagement with the clinical team ensured that the protocol was 
acceptable to, and supported by, senior team members. The protocol was 
implemented thoroughly and achieved good fidelity (Craig et al., 2008). The trial 
recruited to time and target. These aspects demonstrate that the trial, whilst 
using standardised outcome measures and follow up, was feasible and 
practical.  
7.4.2.2 Implementation of training packages 
Volume guarantee had not been used in routine practice in the unit prior to the 
design of the trial. Five months before recruitment started the Principal 
Investigator implemented a training package for all team members caring for 
ventilated infants in the unit. The training consisted of seminars, practical 
workshops and bedside teaching on the use of VG, VCV and the trial protocol. 
Ad hoc training sessions were also provided. The Principal Investigator also 
delivered these training sessions to all new starters within the team, including 
new groups of junior doctors, on a routine and ad hoc basis. The Principal 
Investigator was employed as the unit’s Clinical Research Fellow in 
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Neonatology and always contactable in person or by telephone to provide 
additional guidance throughout the course of the trial. These measures aimed 
to ensure that there was good fidelity with the trial protocol (Hasson, 2015). 
7.4.2.3 Randomisation 
Preparation of the randomisation sequences was undertaken by the Deputy 
Director of the Clinical Effectiveness Unit at South Tees Hospitals NHS 
Foundation Trust. He remained independent of the trial throughout and was the 
only person who knew the randomisation sequence. Block randomisation was 
computer-generated. Two separate block randomisation sequences were 
prepared, one for each stratification group. The randomised allocations were 
sealed within sequentially numbered opaque envelopes. This is a standard 
randomisation procedure recommended by the MHRA (Medicines and 
Healthcare products Regulatory Agency, 2012). The research and clinical 
teams had no knowledge of, or access to, the randomisation sequences during 
the trial. A record of these sequences was kept by the Deputy Director of the 
Clinical Trials Unit until the trial had finished. 
The research team, clinical team and parents did not know which mode of 
ventilation an infant would receive until the infant had been randomised. Once 
the envelope had been opened they could not be blinded to the allocation 
because this is not currently possible in a ventilation trial. After randomisation, 
the envelopes and the allocations within them were kept by the Principal 
Investigator in a locked cabinet. This complies with good practice as outlined by 
the Medicines and Healthcare products Regulatory Agency (Medicines and 
Healthcare products Regulatory Agency, 2012).  
Compliance with MHRA guidance about randomisation is another area of 
strength in this trial. It prevented selection bias and achieved a good balance 
across treatment groups and with prognostic factors.  
The CONSORT diagram (Figure 4-1)  shows that 73 infants were randomised to 
receive VCV and 69 infants were randomised to receive VG. This reduced 
allocation bias because the randomisation procedure ensured almost equal 
allocation of infants between the two arms of the trial. In addition equal numbers 
of infants in either arm of the trial were excluded after randomisation because 
deferred consent was not obtained. This reflects the absence of sampling bias 
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and the maintenance of equipoise by the research and clinical teams 
throughout the trial. Finally, the results tables in Table 4-4 and Table 4-5 show 
that there were similar numbers of infants randomised to either mode of 
ventilation in both of the stratification groups. Again, this reflects that 
randomisation minimised bias by achieving an excellent balance of the two 
modes of ventilation within the trial population. 
7.4.2.4 The primary outcome measure 
Definition: The primary outcome measure was the duration of time, in hours, 
from starting the allocated mode of ventilation until reaching the pre-defined 
‘success criteria’. These criteria consisted of maintenance of a MAP <8 cmH2O 
and FiO2 of ≤0.35 for six consecutive hours, followed by a successful SBT 
(Kamlin et al., 2006). Use of these criteria ensured that the primary outcome 
was objective and standardised for all infants in the trial. These pre-defined 
‘success criteria’ were chosen to reflect ‘readiness for extubation’. Use of these 
criteria removed the subjective bias that would have occurred if the outcome 
had been dependent on clinicians’ opinions regarding readiness for extubation.  
Clinical relevance: The primary outcome measure was chosen to reflect the 
duration of time taken from starting the allocated mode of ventilation to being 
‘ready for extubation’. This outcome measure is relevant when using VTV in 
newborn infants. Ventilator-associated lung injury  (VALI) is a side effect of 
ventilation (Jobe et al., 1998). The earlier an infant is ready for extubation, the 
shorter the duration of exposure to mechanical ventilation and to volutrauma. 
This outcome measure is of clinical importance in the management of infants at 
risk of VALI. Therefore, for this single centre trial, the chosen primary outcome 
measure was relevant for a comparison of ventilator modes aimed at controlling 
tidal volumes. 
Pragmatic actions: Some infants were extubated without having met the 
‘success criteria’.  
Six infants had unplanned extubations but had good respiratory drive and were 
not re-intubated. This had been pre-determined in the trial protocol because it 
would not have been appropriate to re-intubate these infants just for the 
purpose of the trial. In practice these infants were recorded as having met the 
primary outcome if they remained extubated for at least 24 hours.  
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Ten infants had a planned extubation before reaching the ‘success criteria’. 
These infants fell into two groups. The first group consisted of three infants who 
became hypocarbic despite maximal weaning of ventilation but who continued 
to have a MAP of at least 8cmH2O. As hypocarbia is a risk factor for brain injury 
in infants (Okumura et al., 2001; Erickson et al, 2002) the clinical team deemed 
it necessary to extubate these infants without delay in order to avoid ongoing 
hypocarbia. This was considered by the clinical and research teams to be in 
those infants’ best interests. Therefore planned extubations due to hypocarbia 
were not deemed to be major protocol deviations. The infants were recorded as 
having had the primary outcome if they remained extubated for 24 hours. 
The second group of seven infants consisted of those who had been ventilated 
for a prolonged period of time but appeared ready for extubation despite not 
having reaching the ‘success’ criteria. Attempted extubation was deemed 
necessary by the treating Consultant Neonatologist in order to avoid prolonged, 
unnecessary ventilation. These infants had not reached the ‘success’ criteria 
because either the MAP remained ≥8 cmH2O or the FiO2 remained >0.35, or 
both. These planned extubations were not deemed to be major protocol 
deviations. The infants were recorded as having had the primary outcome if 
they remained extubated for at least 24 hours.    
These sixteen infants did not reach the defined ‘success’ criteria. However the 
decisions to extubate them were acceptable and pragmatic within this particular 
trial. These actions revealed necessary adjustments that would need to be 
applied to a protocol for a larger trial (Richards, 2015) 
Cost implications: Although a health economic evaluation was not planned, 
the primary outcome measure also has possible cost implications. A ventilated 
infant is defined as an infant requiring intensive care (Craig et al., 2011). In the 
UK the definition of one intensive care day is “any day where a baby receives 
any form of mechanical respiratory support via a tracheal tube” (Craig et al., 
2011). It is important to investigate whether one particular mode of VTV enables 
infants to be ready for extubation sooner than another mode. Being ready for 
extubation sooner implies the need for a shorter duration of mechanical 
ventilation. This may then translate into a possible reduction in the cost of 
providing intensive care for ventilated infants.  
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In this trial, the median time to ‘success’ criteria in infants in the VG group was 
23 hours (median time to ‘success criteria’, 95% CI 10.78 – 35.22 hours). In 
those who received VCV the median time was 36 hours (95% CI 18.03 – 53.97 
hours). The limitations of the trial’s sample size are discussed in Section 7.5.1. 
However if this difference were seen in a larger trial, it would indicate a potential 
cost benefit in using VG in that the cost of intensive care provision would be 
reduced from 2-3 to 1-2 days. 
However, health economic evaluations are more complex than this. For 
example, it is also possible that earlier extubation may lead to higher rates of re-
intubation. Rates of re-intubation were reported as part of this trial and no 
difference was seen between the two groups. However this was a secondary 
outcome measure for which the trial was not powered. A longer-term health 
economic analysis planned as part of a larger trial would provide important 
information on the cost of these modes in the context of this secondary 
outcome. 
7.4.2.5 Evaluation of the primary outcome measure 
An ancillary study was undertaken to assess the validity of one of the chosen 
‘success criteria’ forming part of the primary outcome measure. The strengths 
and limitations of that ancillary study have been discussed in detail in Chapter 
Five. This ancillary study contributed substantially to the strengths of The 
VoluVent Trial because it tested the validity of the primary outcome measure. 
There are no other published studies comparing manually recorded MAP values 
with those recorded electronically at much higher sampling rates. Therefore the 
ancillary study provides unique data as well as validating the trial’s primary 
outcome measure. 
The ancillary study showed that the MAP values documented once every hour 
by a nurse closely reflect the values recorded electronically with every breath 
during that same minute. These were also validated by measurements being 
sampled at 100Hz. This strengthens the validity of the primary outcome 
measure. It demonstrates that one MAP value documented manually by a nurse 
once an hour is representative of the MAP values being generated continuously 
during VG and VCV ventilation.  
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The ancillary study also provides data that are useful for routine clinical 
practice. The use of electronically recorded data as part of routine practice is 
gaining popularity in UK NICUs. However manually recorded physiological and 
ventilatory data still form part of standard practice in many units. The results of 
this ancillary study show that manually recorded MAP values show a high level 
of agreement with those sampled more frequently using computer software. 
Therefore, these data show that manual recording of MAP measurements is 
valid and reliable. 
7.4.3 Inclusion of a statistical analysis plan 
A major strength of this study was the use of a pre-determined SAP. There is 
increasing recognition of the importance of SAPs (Chen, 2013) by funders, 
regulators and journals. In accordance with Good Clinical Practice guidance 
(Medicines and Healthcare products Regulatory Agency, 2012) a SAP was 
compiled for this trial by the Principal Investigator. During its compilation the 
SAP underwent several version-controlled revisions under the supervision of a 
senior statistician from Newcastle University’s Institute of Health and Society’s 
Biostatistics Group.  
The sixth version of the SAP was used by another statistician from the Institute 
of Health and Society’s Biostatistics Group at Newcastle University. This 
statistician used it to undertake an independent, blinded analysis of interim data 
from 50 infants as part of the trial oversight review. This demonstrated that the 
SAP was clear and comprehensive enough that independent analyses of data 
on demographics, characteristics and the primary outcome could be performed.  
The blinded analyses were used by an independent clinical reviewer to create 
the trial oversight report. The SAP was updated on the basis of that report. The 
Principal Investigator remained blinded to that interim analysis until full 
recruitment had completed. The Principal Investigator undertook analysis of the 
full dataset only after the final version of the SAP (version 11, dated 8th July 
2016) had been completed.  
The use of a SAP, and adherence with the procedures described above, 
demonstrate a thorough and transparent approach to statistical planning and 
data analysis (Gamble et al., 2017). The SAP ensured that the trial’s statistical 
approach could be updated on the recommendation of the trial oversight 
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reviewer. This was done to ensure that the statistical approach reflected the 
distribution of the primary outcome data. This 2-stage analysis has been 
identified as good practice in recent published guidance on SAPs (Gamble et 
al., 2017). It did not require a protocol amendment because the original 
statistical approach was undertaken. However, it did allow the data to be 
presented in a descriptive manner that was appropriate for the sample size. It 
also allowed incorporation of early phase trials methodology (Jung, 2008) into 
the statistical approach which was relevant for a pilot trial.  
This approach, as described in the final version of the SAP, enabled effective 
use of the results and data generated by this pilot trial. Use of HRs and CIs for 
the time-to-event analyses encouraged a greater emphasis on the descriptions 
of the data, and their merits and uncertainties (Kyriacou, 2016). Incorporation of 
the early phase trials methodological approach enabled the identification of a 
‘response threshold’ that could allow the development of a larger trial. The SAP 
enabled an exploratory approach that would inform the design and statistical 
approach of a larger trial. Analysis and presentation of data in this way is 
appropriate for pilot trials (Lancaster et al., 2004; Lee et al., 2014).  
The use of a detailed SAP for this trial also ensured that the validity of its results 
can be tested in future by independent researchers. The statistical methods can 
be checked thoroughly by clinicians, researchers, peer-reviewers, editors, and 
parent or patient groups. This allows transparency regarding the data 
derivation, statistical methods and interpretation of the results. It will also 
improve the ability of those interested parties to determine whether the results 
are applicable to them.   
7.4.4 Statistical approach using early phase trials methodology 
The use of early phase trials methodology described by Jung (Jung, 2008) was 
appropriate for this pilot trial. No difference was seen between the two groups in 
the event rates (number of infants reaching the ‘success’ criteria) at 48 hours. 
This may be because the choice of 48 hours as a time point was made using 
data from a previous trial (Singh et al., 2006). The plan to use this time point 
was based on the proportion of events seen in the previous trial by Singh et al 
(Singh et al., 2006). They compared VCV with PLV and showed a substantial 
difference in events at 48 hours.  
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However, such a difference was not apparent in The VoluVent Trial. This may 
have been because VG and VCV are both modes of VTV and therefore it is 
more difficult to show such a striking difference. Figure 4-4 shows the time-to-
event analysis for the first 240 hours of The VoluVent Trial. Table 4-13 shows 
the event rates for both groups at every 24 hour time period for the first 96 
hours after enrolment. A greater difference was seen between the two groups at 
24 hours after enrolment. This indicates that the first 24 hours of ventilation may 
be a more appropriate focus for this primary outcome in a larger trial.   
7.4.5 Use of deferred consent 
The use of deferred consent is a major strength of this trial. After a protocol 
amendment it led to a marked improvement in recruitment. In doing so, it 
ensured that recruitment was completed to time and target. It also appeared to 
be more acceptable to parents. Some parents volunteered opinions that they 
were comfortable with the fact that deferred consent did not lead to a change in 
their infant’s treatment. Deferred consent also ensured that infants could 
receive their allocated mode of ventilation as soon as possible. This improved 
the ethical and scientific validity of the trial and also allowed parents more time 
in which to make a decision about participation. 
The amendment in consent method and subsequent improvement in 
recruitment demonstrate the value of a pilot trial in identifying and addressing 
challenges in undertaking complex interventions research (Ukoumunne et al., 
2015). A previous trial led by the same unit compared two modes of mechanical 
ventilation and recruited 109 infants over a period of 29 months (Singh et al., 
2006). That trial involved two participating centres. Ninety infants in that trial 
were recruited at the same centre as The VoluVent Trial. The authors of the 
previous trial did not report difficulties in recruitment using prospective parental 
consent obtained within six hours of starting mechanical ventilation. Two 
decades later, it is not clear why it was more difficult to obtain prospective 
consent for The VoluVent Trial. Recent research has reported qualitative data 
on parental experiences of different consent methods in paediatric emergency 
care trials (Harron et al., 2015). However there is still a gap in knowledge 
regarding parents’ experiences of different consent methods in the neonatal 
intensive care setting.  
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The VoluVent Trial has therefore highlighted an area for further qualitative 
research. This could involve nested qualitative research before and within a 
larger trial comparing modes of VTV. 
7.4.6 Co-enrolment 
This trial site has been a research-active unit for many years. Like many such 
units, co-enrolment of infants into more than one research study is supported at 
the trial site provided that the burden on parents is minimised and 
contamination of simultaneous protocols does not occur. Many infants in this 
trial were eligible for other concurrent trials ongoing in the unit at the same time. 
Some were co-enrolled into these trials after enrolment into The VoluVent Trial. 
Published literature suggests that most parents are willing to allow their infants 
to be enrolled into more than one study. Morley et al. (Morley et al., 2005) 
asked 98 parents in a large tertiary NICU for their opinions regarding co-
enrolment. These parents had previously been asked to join at least two studies 
although not all had agreed to do so. Seventy six per cent of respondents 
stated that they would be prepared to allow their infant to be enrolled into more 
than one study. Harron et al. (Harron et al., 2012) described the co-enrolment 
process in two trials involving emergency and elective interventions in two 
paediatric intensive care units (PICUs). Data from one unit were limited but data 
from the other showed that all but one of the children enrolled into the first trial 
were also enrolled into the second (with the second trial using a deferred 
consent process). However, there is little published qualitative data on this 
subject. Qualitative research investigating parents’ views on co-enrolment on 
both a broader and a more focused scale could inform the design of future 
studies. 
Practical and ethical issues regarding co-enrolment did arise during this trial. 
The strategy undertaken to address these issues are described in Section 4.2.9 
of Chapter 4 Results. This strategy demonstrated a considered and ethical 
approach to co-enrolment. The aim was to balance the obligations of minimising 
the burden on parents whilst ensuring that parents had access to information 
about all studies and could make their own decisions about co-enrolment. The 
strategy also demonstrated an approach that aimed to minimise selection bias 
in the trial populations of the concurrent studies. Enabling co-enrolment with full 
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parental consent ensured that infants were not excluded from some studies just 
because they had been enrolled into another study previously. This increased 
the generalisability of the results of all of the concurrent trials. 
However, despite the ethos of aiming to facilitate co-enrolment to prevent bias, 
the research team also had to ensure that concurrent studies did not lead to 
protocol contamination. Therefore two trials were not introduced at the trial site 
during the recruitment period for The VoluVent Trial. The protocols for these 
trials were discussed by the research team and were deemed to be 
incompatible with that of The VoluVent Trial.  
One of those two trials, The HIPSTER trial, was a non-inferiority trial comparing 
two methods of NIV as primary respiratory support in preterm infants (Roberts 
et al., 2016). The target population was infants who had never received 
surfactant or mechanical ventilation. The VoluVent Trial protocol specified that 
all preterm infants should receive CPAP after birth if they required NIV. This 
standardised the mode of NIV for infants who may subsequently become 
eligible for The VoluVent Trial. The HIPSTER trial protocol (Roberts et al., 2015) 
would have prevented this standardisation of NIV. This could have potentially 
affected The VoluVent Trial’s population characteristics. Use of two different 
modes of NIV may have lead to differences in the infants’ lung disease at the 
time of intubation. This may have then affected The VoluVent Trial’s primary 
outcome result. 
The second trial was a randomised controlled pilot trial investigating use of a 
low dose corticosteroid to facilitate extubation in ventilator-dependent preterm 
infants (Yates et al., 2016). This double-blind placebo controlled trial would 
have altered the respiratory management of some infants already enrolled in 
The VoluVent trial. It too could have substantially affected the primary outcome 
result.  
The challenges of co-enrolment that arose during this trial highlighted the way 
in which the themes of ethical obligations, patient involvement and good trial 
conduct can affect any aspect of any research study. They also emphasise the 
need to balance the obligations of clinical and research teams towards 
individual infants and parents with the wider obligations of ensuring that 
research studies can complete recruitment with generalisable patient 
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populations. These issues were described by Brocklehurst in 1997 
(Brocklehurst, 1997) and remain relevant today. 
7.4.7 Trial monitoring 
As part of research governance procedures the South Tees Hospitals NHS 
Foundation Trust’s Research and Development department undertook two 
monitoring visits to scrutinise the conduct of the trial. A favourable report was 
given on both occasions.  
As advised by the sponsor, this study did not require a formal Data Monitoring 
and Safety Committee. However, in line with Good Clinical Practice guidance 
(Medicines and Healthcare products Regulatory Agency, 2012), we did request 
a trial oversight review of data from the first 50 infants to be enrolled (see 
Appendix 9.8). This review was undertaken by an independent statistician and 
clinical reviewer. They were blinded to the interventions allocated to infants.  
These monitoring exercises were a major strength of this trial. They 
demonstrated awareness of, and practice consistent with, Good Clinical 
Practice guidance (Medicines and Healthcare products Regulatory Agency, 
2012). In light of the trial oversight review report we reviewed the sample size 
calculation because the review had indicated that the data were unlikely to be 
normally distributed. A retrospective calculation using non-parametric tests 
showed that a larger sample size would be needed to show a statistically 
significant difference between the two groups with a power of 80%.  
Therefore the decision was made to present the results as summary statistics 
rather than being hypothesis testing. The SAP was updated prior to analysing 
the data.  
7.5 Limitations of the study 
7.5.1 Sample size 
The sample size for this trial had been calculated using parametric tests based 
on the results of a previous ventilation trial done at the same trial site (Singh et 
al., 2006). Parametric tests were used because the previously published 
primary outcome data had been presented using mean values. However, the 
data from The VoluVent Trial were not normally distributed. Therefore Kaplan-
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Meier time-to-event analyses with Cox proportional hazards ratios were used to 
analyse the primary outcome data.  
A retrospective sample size calculation using a non-parametric log-rank test 
showed that 178 infants would be needed to show a statistically significant 
difference between the two groups in the number of infants reaching the 
‘success’ criteria at 48 hours with a power of 80% and a significance level of 
0.05. Therefore a fully powered trial would require at least 178 infants. During 
The VoluVent Trial nine infants did not reach the ‘success’ criteria and one 
infant was withdrawn after consent had been obtained. These 10 infants 
represent 8.8% of the 113 infants originally enrolled into The VoluVent Trial. To 
account for a similar proportion of censored data and withdrawals in a larger 
trial, a further 16 infants (8.8% of 178) would be required. Therefore, a fully 
powered trial would require a sample size of at least 194 infants. 
The sample size for The VoluVent Trial was not large enough to test statistically 
for treatment effect using the log-rank analyses. However, results of pilot trials 
are not definitive and should not be interpreted as such (Arnold et al., 2009; 
Lancaster et al., 2004). The results were therefore presented as summary 
statistics focusing on the descriptive analyses and, crucially, based on non-
parametric Kaplan-Meier time-to-event analyses. They were not used to test the 
original hypothesis and this is appropriate for a pilot trial (Lancaster et al, 2004).  
7.5.2 Single centre study  
This study was undertaken in one centre. Both inborn and outborn infants were 
included and only nine sets of parents (who were present at the trial site) were 
not approached to discuss the trial. These measures aimed to ensure that the 
trial data were as generalisable as possible. They also ensured that as many 
parents as possible had the chance to consider their infants’ participation in the 
trial. 
However, by its nature as a single centre study, this trial is limited in the 
generalisability of its findings to other centres. Ninety one per cent of the 
enrolled infants had mothers whose ethnic background was White British. This 
is slightly higher than the 86% reported for the Middlesbrough ward (Tees Joint 
Strategic Needs Assessment, Middlesbrough JSNA Ethnicity). It may reflect the 
fact that infants from all parts of the North East and North Cumbria, as well as 
 198 
other regions of the UK, were enrolled. Ethnicity is one characteristic used as a 
measure of generalisability. However other characteristics such as social 
deprivation could also be used and incorporated into the design of a larger trial. 
7.5.3 Unmasked interventions 
After randomisation the clinicians, researchers and parents were aware of the 
mode to which all infants had been allocated. It is currently not possible to mask 
a mode of ventilation whilst it is in use. To aim to minimise the risk of bias a 
detailed trial protocol was used and detailed instructions regarding the protocol 
and trial procedures were available at the cotside of each enrolled infants. 
However, despite this, the unmasked interventions may have led to both 
performance and detection bias (Higgins et al., 2011).   
7.5.4 Concomitant medications 
The use of concomitant therapies that can impact on the respiratory outcomes 
of infants were permitted in this trial. These included postnatal steroids (Doyle 
et al., 2017b), medical and surgical treatment for a PDA, inhaled nitric oxide, 
and sedatives (Donn et al., 2017a).  
The use of sedatives was specifically monitored with respect to the timing of the 
SBT. However, the protocol and SAP did not mandate that the use of sedation 
at other times, or the use of inhaled nitric oxide, should be recorded. These 
therapies are used infrequently in preterm infants at the trial site and therefore 
are unlikely to have had a large effect on the results. There may have been an 
imbalance in their use between the two arms that is not recorded. This may not 
have affected the results in this small trial but could have caused performance 
bias. Data on these therapies should be collected in a larger study so that their 
impact as covariates can be assessed.  
The use of medical or surgical treatments for PDA and the use of postnatal 
steroids were identified during trial design as being treatments that could impact 
on the enrolled infants’ respiratory outcomes. These treatments are used to 
improve a ventilator-dependent infant’s lung function and aim to facilitate 
extubation. It was thought that their use would improve the hazard risk of infants 
reaching the ‘success’ criteria. As such the case record forms were designed to 
record the use of these interventions. The SAP identified surgical ligation of a 
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PDA and the use of postnatal steroids a priori as potentially influential 
covariates that would be analysed by univariable and multivariable analyses.  
Univariable analyses appeared to show that these covariates led to a reduced 
hazard risk in the time to reach the ‘success’ criteria. This appeared to imply 
that they increased the duration of time taken for an infant to be ready for 
extubation. However, only six infants received a PDA ligation and only six 
received postnatal corticosteroids. These infants all required prolonged periods 
of ventilation. Given the small numbers of infants receiving either treatment, 
these results reflect the practice in this unit that these treatments were only 
considered for infants with severe lung disease. A larger trial may show different 
results. However, this also emphasises that the use of these treatments in a 
larger multi-centre trial would need to have clear, pre-defined specifications to 
minimise bias caused by differing practices. 
7.5.5 The challenges of analysing data on an intention-to-treat basis 
The challenges of defining an ‘intention-to-treat’ approach to data analysis was 
emphasised by this trial. The trial’s protocol and SAP stated that statistical 
analyses would be carried out on an intention-to-treat basis for all infants for 
whom consent was obtained. Specific ‘intention-to-treat’ scenarios identified a 
priori in the protocol or SAP included those listed below.  
• Infants for whom a protocol deviation occurred. 
• Ineligible infants. 
• Infants who received postnatal corticosteroids to facilitate extubation 
(allowed as a concomitant therapy and specified a priori as a 
potentially influential covariate). 
• Infants who underwent surgical PDA ligation to facilitate extubation 
(allowed as a concomitant therapy and specified a priori as a 
potentially influential covariate). This involved a treatment to facilitate 
extubation and also required transfer to a cardiothoracic centre for an 
operation during which different modes of ventilation were used. The 
periods during which they received other modes of ventilation were 
included in the time-to-event analyses for primary and secondary 
outcomes. 
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• Infants who had an unplanned extubation and remained extubated for 
at least 24 hours (specified a priori in the definition of the primary 
outcome measure). 
The points mentioned below were not specified a priori as those requiring 
intention-to-treat analysis but which were identified as such during the course of 
the trial. 
• Infants who were extubated at the discretion of the treating clinician 
before reaching the ‘success’ criteria, either to avoid hypocarbia or to 
avoid prolonged ventilation (not specified in the protocol but permitted 
during the trial to maintain patient safety as part of a pragmatic 
protocol).  
• Infants who received pressure-limited ventilation (PLV) at the discretion 
of the treating clinician. The use of ‘other non-trial modes of ventilation’ 
(which includes PLV) was included as a protocol deviation and 
monitored as part of compliance monitoring. 
Data on the above events were collected for every infant for whom they 
occurred. These data are presented in Chapter 4 Results in the sections on 
compliance (Section 4.9), serious adverse events (Section 4.15) and secondary 
outcome measures (Section 4.12) 
Only one infant was withdrawn from the trial after consent was obtained. The 
details of this are described in Section 4.2.6 of Chapter 4 Results. After 
randomisation had been undertaken and consent had been obtained, this infant 
was found to have an underlying congenital condition that intrinsically affected 
his/her respiratory system. This meant that (s)he was found, retrospectively, to 
meet the ineligibility criteria for the trial although this had not been known at the 
time of randomisation and consent. 
The research team discussed this carefully and decided to exclude this infant 
from all data analyses. This decision was made because this infant’s underlying 
condition made him/her inherently different from the rest of the trial population. 
The aim of this pilot trial was to evaluate the effect of VG and VCV on the 
primary outcome in a target population. The target population was preterm 
infants whose principal need for ventilation was RDS. Although this infant did 
have RDS after birth it is possible that the initial requirement for mechanical 
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ventilation was due to the underlying congenital condition. Certainly this infant’s 
ongoing need for mechanical ventilation was due to the underlying condition. 
Not only was the infant inherently different from the target population but his/her 
underlying condition influenced his/her interaction with the trial intervention and 
led to a prolonged course of ventilation. Had this infant’s data been included in 
the analysis, the effects of this interaction would have impacted on inferences 
drawn from the trial’s data. 
Therefore the decision to exclude this infant’s data from the analyses was a 
justified protocol deviation for this pilot trial (Giangregorio et al., 2015). The 
analysis undertaken was in keeping with a modified intention-to-treat analysis 
(Sianani, 2010; Gupta, 2011). 
7.5.5.1 Addressing intention-to-treat challenges  
In the strictest sense, undertaking intention-to-treat analyses involves analysing 
complete datasets from all participants randomised into a trial (Lamb et al., 
2015). Data are analysed according to the arm to which the participant was 
randomised, regardless of whether the participant received the intervention or 
not.  
There are several reasons for advocating a strict intention-to-treat approach to 
data analysis. These include aiming to: 
• maintain the balance of prognostic baseline characteristics achieved 
through randomisation (Gupta, 2011; Sedgewick, 2015),    
• minimise selection bias and manipulation of data (Gupta, 2011), 
• encourage transparency and accountability (Gupta, 2011; Fergusson 
et al., 2002), 
• reflect ‘real life’ events, in that patients who receive interventions 
outside a trial do not interact with these interventions in a protocolised 
manner (Gupta, 2011), 
• achieve statistical power by ensuring that the sample size is 
maintained (Wertz, 1995)   
As a result, a strict intention-to-treat approach minimises Type 1 errors and 
improves the validity and generalisability of the trial (Gupta, 2011, Fergusson et 
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al., 2002). Ideally, a strict intention-to-treat approach should be adhered to in all 
definitive trials (Sedgewick, 2015). 
However there are difficulties in interpreting the results of this approach in early 
phase trials (Fergusson et al., 2002). Datasets may not be complete and 
missing data may either positively or negatively affect the intervention’s impact 
on the outcome (Sainani, 2010). Some participants may not have received the 
intervention in full or even at all. Some participants may die or withdraw from 
the trial, meaning that their data are censored or incomplete. Factors that 
reduce compliance with the trial protocol can reduce the validity of the data 
ascribed to the interventions. Despite these challenges, it is considered good 
practice in a definitive trial to analyse data from all participants who have been 
formally randomised and enrolled (ICH Harmonised Tripartite Guideline E9, 
1988). 
A counter-argument to a strict intention-to-treat approach is that the analyses 
and results do not measure or reflect what they were intended to. Analysing all 
participants, regardless of the events that they encountered during a trial, has a 
dilutional influence on the effect of the interventions (Gupta, 2011). This can 
lead to Type 2 errors (Gupta, 2011; Fergusson et al., 2002). Different 
approaches have been described such as the modified intention-to-treat 
analysis (Gupta, 2011) and per protocol analysis (Sedgewick, 2015).  
There are limitations to the decision to exclude one infant’s data from The 
VoluVent Trial’s analysis. It could have introduced subjective bias, particularly 
as this was an unmasked trial. The impact of excluding one infant from a small 
trial population could introduce a proportionately greater bias than exclusion of 
one infant from a large trial. In a pilot trial such as this, a modified intention-to-
treat approach is acceptable because the aim of a pilot trial is to explore the 
effect of the interventions on a target population. In a larger definitive trial, a 
modified intention-to-treat analysis could lead to bias because exclusion of 
some participants’ data interferes with the prognostic balance achieved through 
randomisation (Gupta, 2011; Fergusson et al., 2002). 
The above challenges highlight the need to include a detailed definition of the 
intention-to-treat approach in a trial’s SAP prior to data analysis and, preferably, 
prior to any data collection. Version-controlled SAPs can then be updated to 
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reflect unexpected events that may challenge the definition of intention-to-treat. 
In a pilot trial, a modification to the definition of intention-to-treat may be 
justified. However, in a large definitive trial, the original intention-to-treat 
definition should be adhered to for the reasons listed above. Modification to a 
strict intention-to-treat analysis can cause subjective bias (Gupta, 2011). 
Modified intention-to-treat or per protocol analyses can be acceptable as pre-
defined secondary analyses within definitive trials.  
Despite the above points, a definition of ‘intention-to-treat’ as the analysis of 
data from all enrolled participants can be relatively straightforward for trials 
using prospective consent. In such trials, consent is obtained before 
participants are randomised. However, the use of deferred consent introduces 
new challenges regarding the definition and implementation of intention-to-treat 
analysis. The VoluVent Trial highlighted examples of these challenges. 
7.5.5.2 Effect of deferred consent on the definition of intention-to-treat 
The introduction of deferred consent in The VoluVent Trial emphasised the 
impact that a consent method can have on defining and implementing an 
intention-to-treat approach. Twenty-nine infants were randomised but not 
enrolled because consent was not obtained. In line with good practice, these 
infants are accounted for in the CONSORT diagram (Figure 4-1) (Schulz et al., 
2010; Fergusson et al., 2002). Obtaining written consent was one of the 
inclusion criteria for the trial. As consent had not been obtained from these 
infants’ parents no data were collected or analysed. These infants (described in 
Section 4.2.5 of Chapter 4 Results) included:  
• those whose parents declined consent, 
• those whose parents were not approached or were not present in the 
unit before the consent deadline, 
• those who were randomised but shortly afterwards found to have an 
anatomical congenital anomaly consistent with exclusion criteria, 
• those who were randomised in error when being intubated after 24 
hours of age (and therefore not meeting inclusion criteria).  
These infants were balanced between groups; 14 had been randomised to VG 
and 15 had been randomised to VCV. This minimised the prognostic imbalance 
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that could have affected the trial population. This is reassuring given the small 
sample size in this trial. Such a balance between groups would be expected in 
a large trial but in a small trial, it is possible that lack of deferred consent may 
cause unequal allocation of interventions to the enrolled population. 
As demonstrated above, a strict intention-to-treat approach (Lamb et al., 2015) 
is difficult to apply to trials using deferred consent. It is likely that there will 
always be some participants randomised but not enrolled. For example, the 
decision by parents to decline consent should never be overruled (General 
Medical Council, 2007) and data from those infants cannot be used. Infants who 
are randomised but then found, before consent is sought, to have diagnoses 
consistent with the exclusion criteria also cannot be enrolled. 
However there are strategies to optimise the intention-to-treat approach that 
could be used for other infants who are randomised but not enrolled.  
Seeking consent: Lack of consent because parents are not approached could 
be addressed by improving consent practices amongst the clinical or research 
teams. Lack of consent because parents have not arrived at the hospital before 
the consent deadline could be addressed by considering a different consent 
deadline. This may be possible in many trials but would have to be carefully 
considered. Extending a consent deadline too long may be perceived as 
withholding information from parents.  
Infants randomised in error: Two infants were randomised but not enrolled 
because they had been intubated after 24 hours of age. In both cases the 
infants were otherwise similar to the trial population and they both had RDS. In 
such cases, advice could be sought from the ethics committee about whether to 
enroll them and include their data in analyses, or whether to exclude them from 
analyses (Fergusson et al., 2002). However, the consent deadline may not 
leave enough time to seek this advice, again highlighting how deferred consent 
can impact on adherence to a particular intention-to-treat approach.    
Infants who died before consent was sought: Two infants were randomised 
appropriately but died before consent could be sought from parents. These 
parents were not approached with information about the trial and data on these 
infants were not collected. However, it is possible that bereaved parents can be 
offered the opportunity for their infants’ data to be used in analyses. Qualitative 
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research has revealed that some bereaved parents would want the opportunity 
to consider giving consent for their infants’ data to be used for analysis (Woolfall 
et al., 2014; Furyk et al., 2017). The approach and its timing would have to be 
carefully considered and individualised for each family.  
Harron et al. (Harron et al., 2015) reported the use of deferred consent in a trial 
comparing different types of central venous catheter in a paediatric intensive 
care unit (PICU) (Gilbert et al., 2016). They discuss the challenges in seeking 
consent from bereaved parents but describe how it can be achieved. They 
highlight the important point that exclusion of such children from data analysis 
can reduce the validity and generalisability of an emergency interventions trial. 
They suggest that ethics committees should consider approving the use of data 
from such children without seeking consent, a suggestion also made by Jansen 
and colleagues (Jansen et al., 2007; Jansen et al., 2010). However, opinions on 
such a suggestion should also be sought from other stakeholders, including 
parents, children, young people, journal editors, and funders.  
The above strategies may improve enrolment but it is likely that there will 
always be some infants who are randomised but not enrolled. The negative 
impact that this may have on the balance of prognostic covariates between 
groups would need to be accepted as a limitation in a trial using deferred 
consent. In a large trial, any imbalance is likely to be minimal. However, in a 
small trial the impact may be greater. One final strategy to address this would 
be the use of adaptive randomisation (Altman et al., 2005). With this strategy, 
as the trial proceeds, the overall balance of randomisation is maintained across 
treatment groups in eligible patients for whom consent is obtained. The original 
sample size would also need to be achieved in order to maintain power.  
Experience gained through The VoluVent Trial can be used to plan a larger trial 
and the above strategies could be included prospectively in the trial protocol 
and SAP. An imbalance in randomisation would need to be monitored at pre-
defined time points by a Data and Safety Monitoring Committee.  
7.6 Other challenges 
There were certain challenges encountered during the trial that were either 
unexpected or that could not be controlled for within the trial protocol. These 
challenges are described here. 
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7.6.1 Recruitment 
The recruitment graph shown in Figure 4-2 demonstrates that, during the entire 
recruitment period, there were fewer eligible infants than expected. This, 
combined with the unforeseen problems in obtaining prospective parental 
consent during the first four months of the trial, meant that recruitment took five 
months longer than anticipated. Part of the process evaluation for a pilot trial is 
to identify and explore these unanticipated challenges. However, in a larger 
definitive trial, robust site feasibility assessments would be required prior to 
recruitment to ensure that recruitment targets could achieved. 
7.6.1.1 Use of non-invasive ventilation 
The main reason for the reduction in the number of ventilated infants was due 
to the increase in the use of non-invasive ventilation (NIV) at the trial site in 
recent years. Such modes include CPAP and HHFNC. This reflects similar 
changes in practice in neonatal units throughout the world (Courtney, 2015). At 
the trial site itself, this change in practice may also have been influenced by the 
previous RCT run at the site that compared two modes of NIV in infants born 
between 28 and 31+6 weeks’ gestation (Wood et al., 2013). The clinical team 
was familiar with, and had expertise in, the use of NIV in such infants since 
2009. As such the use of NIV, and in particular the use of CPAP, in moderately 
and very preterm infants was embedded in routine care at the trial site. 
7.6.1.2 Consent declined  
Amongst those infants who were ventilated and therefore eligible, the lower 
than anticipated recruitment rate could be explained by a number of reasons. 
Figure 4-1 shows the CONSORT diagram for the trial, the numbers of infants 
not enrolled and the reasons for non-enrolment. Before the use of deferred 
consent, nine sets of parents declined prospective consent. After the 
introduction of deferred consent, 11 sets of parents declined deferred consent. 
Parents were not asked for their reasons for declining participation as this was 
felt to be inappropriate at such a stressful time in their lives. However, seeking 
information on such parental decisions is vital to improve the design of future 
trials. Consent being declined is likely in all research studies. Understanding 
parental reasons for declining consent may enable researchers to improve 
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parental experiences of being approached about research studies. Recent 
qualitative research has studied various aspects of consent for emergency 
research (Woolfall et al., 2014; Furyk et al., 2017) but information on the 
reasons for declining parental consent is lacking. A qualitative study exploring 
this aspect of recruitment could be undertaken as an individual study or as a 
nested study within the design of a definitive RCT. 
7.6.1.3 Availability of parents to discuss the trial  
Sixteen sets of parents were not present at the trial site in time to discuss the 
trial before the consent deadline. All of these infants were outborn infants. Eight 
were admitted to the trial site before the introduction of deferred consent. At that 
time the protocol stated that prospective consent had to be given within 12 
hours of intubation. The other eight infants were admitted after the introduction 
of deferred consent at which point consent had to be given within 36 hours of 
intubation.  
There were other outborn infants whose parents had arrived at the unit within a 
few hours before the consent deadline. Some of these parents were 
approached by senior clinicians or researchers experienced in seeking consent, 
if it was considered to be appropriate. However, some of these parents declined 
trial information on the basis that they did not have enough time to consider it 
before the consent deadline.  
Along with the difficulties in seeking informed consent appropriately and 
sensitively in a trial of emergency interventions, these data highlight another 
challenge in recruiting to such trials. Recruiting outborn infants can be more 
difficult than recruiting inborn infants due to logistical challenges. One such 
challenge is the length of time taken to transfer the infant and the parents to the 
trial site. Another includes the fact that outborn infants may receive treatments 
outwith the trial protocol before randomisation. In this trial, outborn infants 
received other modes of ventilation before reaching the trial site. This can make 
data more difficult to analyse as certain covariates, to which inborn infants have 
not been exposed, need to be accounted for.  
However outborn infants must not be excluded from research studies just 
because of difficulties in recruitment. It is just as important to improve their 
clinical care and outcomes through research as it is in inborn infants. Including 
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outborn infants in a research study creates a more heterogeneous study 
population. This ensures that the trial population’s generalisability. Prior to the 
introduction of deferred consent, the 33% of parents of ventilated infants could 
not be approached because they had not arrived at the trial site. After the 
introduction of deferred consent only 5% of parents could not be approached for 
this reason. 
The change in consent method was a major strength of this study for several 
reasons. It enabled a longer time frame in which to seek consent which 
increased the number of parents of outborn infants who could be approached. 
Randomisation of eligible infants at the time of admission or intubation ensured 
that infants could start their allocated trial mode of ventilation immediately. In 
recruiting more outborn infants, we improved the generalisability of the trial 
population and the results. 
7.6.2 Radiological criteria used for the definition of respiratory distress 
syndrome 
The trial protocol gave a clear description of the clinical, radiological and 
biochemical criteria with which a diagnosis of RDS could be made prior to 
randomisation. However, during the trial it became clear that some of these 
criteria could not be confirmed before randomisation.  
The majority of infants (63%) was intubated and received surfactant in the 
delivery room. Initially, the opinion of an independent Paediatric Radiologist was 
sought to provide baseline assessments of the radiological features of RDS on 
the infants’ initial chest x-rays. The Radiologist was blinded to treatment 
allocation. However, the prior administration of surfactant to infants who were 
intubated before receiving their first chest x-ray meant that the radiological 
features of RDS were minimal in most chest x-rays. Therefore this procedure 
was abandoned as very few chest x-rays provided meaningful baseline 
information on the initial severity of RDS. This also meant that the radiological 
criteria specified in the protocol’s definition of RDS could not be reliably used in 
many of the trial infants. 
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7.6.3 Missing maternal data 
Table 4-2 demonstrates that some of the data about maternal characteristics 
were missing. This particular part of the data collection was most affected by 
missing data. Data were deemed to be missing if they had not been recorded in 
the infants’ medical records. These data were likely to have been recorded in 
the maternal medical records and should have been recorded in the infants’ 
records as part of standard care. However the trial consent forms only permitted 
the Principal Investigator access to infants’ records and therefore data in 
maternal records could not be accessed.   
A recent neonatal trial used consent forms that included a statement giving 
maternal consent for researchers to access maternal medical records (McGuire, 
2016). Therefore, in this trial, mothers’ signatures were always required on the 
consent forms even if married fathers have also provided consent for their 
infants to participate. This enabled the research teams to seek relevant 
information in the maternal records that was missing from the infants’ notes.  
In designing a larger definitive trial on VTV, use of consent forms that permit the 
research team access to maternal records would substantially reduce missing 
data. This would improve the generalisability of the trial and give greater validity 
to the data on prognostic factors.  
7.6.4 Use of sedation 
Administration of sedation to enrolled infants was permitted as part of 
concomitant medications although it had to be stopped prior to extubation. 
Sedative medications often reduce respiratory drive, thereby potentially 
decreasing the likelihood of successful extubation. Therefore, the research 
team specified that infants must not have a SBT if they had received any 
sedation within the previous six hours. The clinical team adhered to this 
instruction. The use of sedatives in ventilated infants is not routine practice at 
the trial site. They were only used in a small number of infants at the discretion 
of the clinical team if deemed necessary for individual patients.  
7.7 Summary and future directions 
The VoluVent Trial demonstrated that there is a potential difference between 
VCV and VG in preterm infants, with those receiving VG being ready for 
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extubation sooner than those receiving VCV. The data from this trial are 
clinically relevant. As an example of a complex interventions study, The 
VoluVent Trial highlighted many methodological, procedural and clinical 
challenges that arise when undertaking research in an intensive care setting. 
The data and experiences gained from this trial can be used to plan a larger, 
definitive study. Recommendations for planning such a study are discussed in 
Chapter 8.   
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Chapter 8 Conclusion 
This thesis described the use of a complex interventions trial to compare two 
emergency interventions in a neonatal intensive care setting. This was a 
randomised controlled trial called The VoluVent Trial (ISRCTN 04448562.) 
Volume-targeted ventilation (VTV) is used in neonatology with the aim of limiting 
volutrauma and ventilator-associated lung injury (VALI) in ventilated newborn 
infants. It is associated with improved outcomes in newborn infants when 
compared with pressure-limited ventilation (PVL) (Klingenberg et al., 2017). 
Many of these outcomes are clinical manifestations of VALI, such as 
bronchopulmonary dysplasia (BPD) and pulmonary air leak. Others are indirect 
measures of the likelihood of VALI, such as duration of ventilation. The recently 
updated Cochrane review (Klingenberg et al., 2017) reported that the evidence 
favouring the use of VTV over PLV is now even stronger. The authors reiterated 
their recommendation that future research should include comparisons of 
different modes. The VoluVent Trial (ISRCTN 04448562) is the first and, to 
date, the only trial to compare two modes of VTV in ventilated preterm infants 
with respiratory distress syndrome. 
The VoluVent Trial was a complex interventions trial comparing two emergency 
interventions within a neonatal intensive care setting. These interventions, 
volume-controlled ventilation (VCV) and volume guarantee (VG), are already in 
clinical use and this was, therefore, a comparative effectiveness trial. This pilot 
trial showed that infants receiving VG were ready for extubation faster than 
infants in the VCV group with a median difference of 13 hours. This clinically 
relevant result shows that a larger trial is required to provide a definitive result.  
The VoluVent Trial also showed that future research should focus on 
ascertaining whether particular VTV modes benefit particular sub-groups of 
infants. The longer an infant is ventilated, the more their underlying lung 
condition changes and the more likely it is that their ventilation requirements will 
change (Keszler et al., 2009; Hunt et al., 2018). Therefore one remaining gap in 
knowledge is how to choose a VTV mode depending on the infant’s gestational 
age and underlying pathology. In this trial, there was a marked difference in the 
duration of time taken to be ready for extubation in infants born at 28 – 33+6 
weeks’ gestation compared with those born at <28 weeks’ gestation. Those 
 212 
born at 28 – 33+6 weeks’ gestation were ready for extubation much earlier than 
those born <28 weeks’ gestation. The use of VG appeared to benefit infants in 
the more mature group. The use of VCV appeared to favour the more extremely 
preterm infants. These results provide useful data with which to plan a larger 
trial in order to answer these questions.  
A process evaluation is essential when undertaking a pilot trial (Craig P. et al., 
2008) and the ancillary study formed part of this process evaluation. Analysis of 
continuous airway pressure data sampled with every breath and at 100Hz 
closely matched the manual recordings of mean airway pressure values 
documented once every hour by neonatal nurses. This validated the primary 
outcome for this trial. It also provides unique data that validate the use of 
manual hourly recordings of mean airway pressure in neonatal intensive care.   
The VoluVent Trial also demonstrated the challenges that can arise when 
investigating complex interventions in a complex environment. These included 
challenges with recruitment, obtaining informed consent, co-enrolment, 
statistical analysis considerations and clarifying an intention-to-treat definition. 
The strategies used to respond to these challenges included the use of deferred 
consent, a detailed SAP and a trial oversight review. These strategies provided 
useful information on how best to plan a larger, definitive trial. 
The experience and data gained from The VoluVent Trial provide a set of 
recommendations that can be used when planning a larger neonatal trial on 
VTV. These recommendations are listed below.  
Recommendations for a larger trial 
1. Use the data from this pilot trial to determine a sample size that would 
provide definitive results for the whole population. Using statistical 
expertise, consider the feasibility of aiming for sample size that would 
provide significant results for sub-groups of infants, such as those of 
different gestational age groups.  
2. Consider using a ‘censor-point’ for the primary outcome, after which all 
data would be censored. For example, data on only the first 96 hours 
could be analysed for the primary outcome. Data from infants who had 
not yet met the ‘success’ criteria by that point would be censored. This 
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would then enable analysis of the primary outcome to focus on infants 
with acute surfactant deficiency. Analysis of data beyond 96 hours could 
form part of the secondary outcome data but would provide a useful sub-
group for analysis as infants ventilated longer than 96 hours tend to have 
changing lung pathology. 
3. Include a request on the consent form that would permit researchers 
trial-specific access to maternal medical records. 
4. Use deferred consent and include a nested qualitative study to obtain 
data on parents’ experiences of this method of consent in the neonatal 
intensive care setting. 
5. Consider a qualitative research study prior to undertaking a larger trial to 
ascertain the views of parents, ethics committee members, clinicians, 
researchers and other stakeholders on deferred consent and, in 
particular, on how and whether to seek consent for infants who die 
before consent is sought. 
6. In the context of deferred consent, include a clear definition of the 
intention-to-treat approach in the protocol and SAP. Use the experiences 
from this trial to aim to ensure that as few randomised infants as possible 
are excluded from analysis. Data from infants whose parents do not give 
consent cannot be used. However, data from infants randomised in error 
or from those with congenital anomalies could potentially be used. These 
circumstances could be prospectively agreed with the ethics committee 
prior to starting the trial. Alternatively, it might be possible to include 
these infants in analysis if a strategy for seeking urgent advice from the 
ethics committee could be agreed upon.  
7. Ensure that a Data Safety Monitoring Committee monitors the impact of 
deferred consent on the balance of randomisation for enrolled infants to 
ensure that a significant imbalance does not occur.  
8. Clearly express strategies for co-enrolment in order to ensure that all 
parents are offered the choice of participation in multiple trials but are not 
burdened by it. 
9. If a multi-centre trial is undertaken aim to ensure that the same devices 
are used in as many centres as possible. This may not be feasible in 
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which case a pragmatic approach could be considered in which different 
devices are used as long as the same modes are used. 
10. Consider specifying clear criteria for the use of postnatal corticosteroids 
and surgical ligation of patent ductus arterioses. These criteria would 
standardise secondary outcomes. However, obtaining agreement on 
such criteria might be difficult in a multi-centre trial and a pragmatic 
approach may have to be considered. This could include analysing these 
variables as potentially influential covariates, as was done in this trial. 
11. Use software such as the VOXP Research Data Collector to obtain 
mechanistic data on how the delivered tidal volumes differ between VCV 
and VG. Such data would be important in ascertaining the actual tidal 
volumes, and the stability of the tidal volumes, that are delivered to 
ventilated infants.   
The VoluVent Trial has shown a clinically relevant difference between VCV and 
VG that appears to favour VG in preterm infants and, potentially, in the sub-
group of infants born at 28 – 33+6 weeks’ gestation. The recommendations 
above can be used to plan a larger trial to provide definitive results. 
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Chapter 9 Appendices 
Appendix 9.1 Ethical approval from the North East-York Ethics Committee 
 
 216 
 
  
 217 
Appendix 9.2 Approval from The South Tees Hospitals NHS Foundation 
Trust’s Research and Development Department (trial sponsor) 
 
 218 
 
 
  
 219 
Appendix 9.3 Statistical Analysis Plan 
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Appendix 9.4 Spontaneous breathing test data collection form 
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Appendix 9.5 Caring for an infant randomised to VCV 
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Appendix 9.6 Caring for an infant randomised to VG 
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Appendix 9.7 Example of a case record form 
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